<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Electroconvulsive therapy for treatment‐resistant schizophrenia - Sinclair, DJM - 2019 | Cochrane Library</title> <meta content="Electroconvulsive therapy for treatment‐resistant schizophrenia - Sinclair, DJM - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011847.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Electroconvulsive therapy for treatment‐resistant schizophrenia - Sinclair, DJM - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011847.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011847.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Electroconvulsive therapy for treatment‐resistant schizophrenia" name="citation_title"/> <meta content="Diarmid JM Sinclair" name="citation_author"/> <meta content="Nottinghamshire Healthcare NHS Trust" name="citation_author_institution"/> <meta content="diarmid.sinclair@nhs.net" name="citation_author_email"/> <meta content="Sai Zhao" name="citation_author"/> <meta content="The Ingenuity Centre, The University of Nottingham" name="citation_author_institution"/> <meta content="Fang Qi" name="citation_author"/> <meta content="The Ingenuity Centre, The University of Nottingham" name="citation_author_institution"/> <meta content="Kazare Nyakyoma" name="citation_author"/> <meta content="Derbyshire Healthcare Foundation NHS Trust" name="citation_author_institution"/> <meta content="Joey SW Kwong" name="citation_author"/> <meta content="National Center for Child Health and Development" name="citation_author_institution"/> <meta content="Clive E Adams" name="citation_author"/> <meta content="The University of Nottingham" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD011847.pub2" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/03/19" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011847.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011847.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011847.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antipsychotic Agents [therapeutic use]; Brief Psychiatric Rating Scale; Electroconvulsive Therapy [*adverse effects, methods]; Flupenthixol [therapeutic use]; Memory Disorders [*etiology]; Patient Readmission [statistics &amp; numerical data]; Piperazines [therapeutic use]; Randomized Controlled Trials as Topic; Schizophrenia [*therapy]; Standard of Care; Thiazoles [therapeutic use]; Treatment Outcome" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011847.pub2&amp;doi=10.1002/14651858.CD011847.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011847.pub2&amp;doi=10.1002/14651858.CD011847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011847.pub2&amp;doi=10.1002/14651858.CD011847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011847.pub2&amp;doi=10.1002/14651858.CD011847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011847.pub2&amp;doi=10.1002/14651858.CD011847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011847.pub2&amp;doi=10.1002/14651858.CD011847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011847.pub2&amp;doi=10.1002/14651858.CD011847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011847.pub2&amp;doi=10.1002/14651858.CD011847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011847.pub2&amp;doi=10.1002/14651858.CD011847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011847.pub2&amp;doi=10.1002/14651858.CD011847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011847.pub2&amp;doi=10.1002/14651858.CD011847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011847.pub2&amp;doi=10.1002/14651858.CD011847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011847.pub2&amp;doi=10.1002/14651858.CD011847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011847.pub2&amp;doi=10.1002/14651858.CD011847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011847.pub2&amp;doi=10.1002/14651858.CD011847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011847.pub2&amp;doi=10.1002/14651858.CD011847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011847.pub2&amp;doi=10.1002/14651858.CD011847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011847.pub2&amp;doi=10.1002/14651858.CD011847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011847.pub2&amp;doi=10.1002/14651858.CD011847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011847.pub2&amp;doi=10.1002/14651858.CD011847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011847.pub2&amp;doi=10.1002/14651858.CD011847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011847.pub2&amp;doi=10.1002/14651858.CD011847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011847.pub2&amp;doi=10.1002/14651858.CD011847.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="mV7VuqgF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011847\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011847\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011847\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011847\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ms","ja","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011847.pub2",title:"Electroconvulsive therapy for treatment\\u2010resistant schizophrenia",firstPublishedDate:"Mar 19, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mV7VuqgF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011847.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011847.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011847.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011847.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011847.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011847.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011847.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011847.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011847.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011847.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>17424 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011847.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011847.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011847.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011847.pub2/full#CD011847-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011847.pub2/full#CD011847-sec-0325"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011847.pub2/full#CD011847-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011847.pub2/full#CD011847-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011847.pub2/full#CD011847-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011847.pub2/full#CD011847-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011847.pub2/full#CD011847-sec-0119"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011847.pub2/full#CD011847-sec-0315"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/table_n/CD011847StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/table_n/CD011847StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011847.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011847.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011847.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011847.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011847.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011847.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Electroconvulsive therapy for treatment‐resistant schizophrenia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011847.pub2/information#CD011847-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Diarmid JM Sinclair</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011847.pub2/information#CD011847-cr-0003">Sai Zhao</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011847.pub2/information#CD011847-cr-0004">Fang Qi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011847.pub2/information#CD011847-cr-0005">Kazare Nyakyoma</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011847.pub2/information#CD011847-cr-0006">Joey SW Kwong</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011847.pub2/information#CD011847-cr-0007">Clive E Adams</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/information/en#CD011847-sec-0336">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 19 March 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011847.pub2">https://doi.org/10.1002/14651858.CD011847.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011847-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011847-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011847-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011847-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011847-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011847-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011847-abs-0001" lang="en"> <section id="CD011847-sec-0001"> <h3 class="title" id="CD011847-sec-0001">Background</h3> <p>Electroconvulsive therapy (ECT) involves the induction of a seizure by the administration of an electrical stimulus via electrodes usually placed bilaterally on the scalp and was introduced as a treatment for schizophrenia in 1938. However, ECT is a controversial treatment with concerns about long‐term side effects such a memory loss. Therefore, it is important to determine its clinical efficacy and safety for people with schizophrenia who are not responding to their treatment. </p> </section> <section id="CD011847-sec-0002"> <h3 class="title" id="CD011847-sec-0002">Objectives</h3> <p>Our primary objective was to assess the effects (benefits and harms) of ECT for people with treatment‐resistant schizophrenia. </p> <p>Our secondary objectives were to determine whether ECT produces a differential response in people: who are treated with unilateral compared to bilateral ECT; who have had a long (more than 12 sessions) or a short course of ECT; who are given continuation or maintenance ECT; who are diagnosed with well‐defined treatment‐resistant schizophrenia as opposed to less rigorously defined treatment‐resistant schizophrenia (who would be expected to have a greater affective component to their illness). </p> </section> <section id="CD011847-sec-0003"> <h3 class="title" id="CD011847-sec-0003">Search methods</h3> <p>We searched the Cochrane Schizophrenia Group's Study‐Based Register of Trials including clinical trial registries on 9 September 2015 and 4 August 2017. There were no limitations on language, date, document type, or publication status for the inclusion of records in the register. We also inspected references of all the included records to identify further relevant studies. </p> </section> <section id="CD011847-sec-0004"> <h3 class="title" id="CD011847-sec-0004">Selection criteria</h3> <p>Randomised controlled trials investigating the effects of ECT in people with treatment‐resistant schizophrenia. </p> </section> <section id="CD011847-sec-0005"> <h3 class="title" id="CD011847-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data. For binary outcomes, we calculated the risk ratio (RR) and its 95% confidence intervals (CIs), on an intention‐to‐treat basis. For continuous data, we estimated the mean difference (MD) between the groups and its 95% CIs. We employed the fixed‐effect model for all analyses. We assessed risk of bias for the included studies and created 'Summary of findings' tables using the GRADE framework. </p> </section> <section id="CD011847-sec-0006"> <h3 class="title" id="CD011847-sec-0006">Main results</h3> <p>We included 15 studies involving 1285 participants (1264 completers with an average age of 18 to 46 years) with treatment‐resistant schizophrenia. We rated most studies (14/15, 93.3%) as at high risk of bias due to issues related to the blinding of participants and personnel. Our main outcomes of interest were: (i) clinically important response to treatment; (ii) clinically important change in cognitive functioning; (iii) leaving the study early; (iv) clinically important change in general mental state; (v) clinically important change in general functioning; (vi) number hospitalised; and (vii) death. No trial reported data on death. </p> <p>The included trials reported useable data for four comparisons: ECT plus standard care compared with sham‐ECT added to standard care; ECT plus standard care compared with antipsychotic added to standard care; ECT plus standard care compared with standard care; and ECT alone compared with antipsychotic alone. </p> <p>For the comparison ECT plus standard care versus sham‐ECT plus standard care, only average endpoint BPRS (Brief Psychiatric Rating Scale) scores from one study were available for mental state; no clear difference between groups was observed (short term; MD 3.60, 95% CI ‐3.69 to 10.89; participants = 25; studies = 1; <i>very low‐quality evidence</i> ). One study reported data for service use, measured as number readmitted; there was a clear difference favouring the ECT group (short term; RR 0.29, 95% CI 0.10 to 0.85; participants = 25; studies = 1; <i>low‐quality evidence</i>). </p> <p>When ECT plus standard care was compared with antipsychotics (clozapine) plus standard care, data from one study showed no clear difference for clinically important response to treatment (medium term; RR 1.23, 95% CI 0.95 to 1.58; participants = 162; studies = 1; <i>low‐quality evidence</i> ). Clinically important change in mental state data were not available, but average endpoint BPRS scores were reported. A positive effect for the ECT group was found (short‐term BPRS; MD ‐5.20, 95% CI ‐7.93 to ‐2.47; participants = 162; studies = 1; <i>very low‐quality evidence</i>). </p> <p>When ECT plus standard care was compared with standard care, more participants in the ECT group had a clinically important response (medium term; RR 2.06, 95% CI 1.75 to 2.42; participants = 819; studies = 9; <i>moderate‐quality evidence</i> ). Data on clinically important change in cognitive functioning were not available, but data for memory deterioration were reported. Results showed that adding ECT to standard care may increase the risk of memory deterioration (short term; RR 27.00, 95% CI 1.67 to 437.68; participants = 72; studies = 1; <i>very low‐quality evidence</i> ). There were no clear differences between groups in satisfaction and acceptability of treatment, measured as leaving the study early (medium term; RR 1.18, 95% CI 0.38 to 3.63; participants = 354; studies = 3; <i>very low‐quality evidence</i> ). Only average endpoint scale scores were available for mental state (BPRS) and general functioning (Global Assessment of Functioning). There were clear differences in scores, favouring ECT group for mental state (medium term; MD ‐11.18, 95% CI ‐12.61 to ‐9.76; participants = 345; studies = 2; <i>low‐quality evidence</i> ) and general functioning (medium term; MD 10.66, 95% CI 6.98 to 14.34; participants = 97; studies = 2; <i>very low‐quality evidence</i>). </p> <p>For the comparison ECT alone versus antipsychotics (flupenthixol) alone, only average endpoint scale scores were available for mental state and general functioning. Mental state scores were similar between groups (medium‐term BPRS; MD ‐0.93, 95% CI ‐6.95 to 5.09; participants = 30; studies = 1; <i>very low‐quality evidence</i> ); general functioning scores were also similar between groups (medium‐term Global Assessment of Functioning; MD ‐0.66, 95% CI ‐3.60 to 2.28; participants = 30; studies = 1; <i>very low‐quality evidence</i>). </p> </section> <section id="CD011847-sec-0007"> <h3 class="title" id="CD011847-sec-0007">Authors' conclusions</h3> <p>Moderate‐quality evidence indicates that relative to standard care, ECT has a positive effect on medium‐term clinical response for people with treatment‐resistant schizophrenia. However, there is no clear and convincing advantage or disadvantage for adding ECT to standard care for other outcomes. The available evidence was also too weak to indicate whether adding ECT to standard care is superior or inferior to adding sham‐ECT or other antipsychotics to standard care, and there was insufficient evidence to support or refute the use of ECT alone. More good‐quality evidence is needed before firm conclusions can be made. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011847-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011847-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011847-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011847-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011847-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011847-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD011847-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011847-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011847-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011847-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011847-abs-0005" lang="en"> <h3>Electroconvulsive therapy for treatment‐resistant schizophrenia</h3> <p><b>Review question</b> </p> <p>Is electroconvulsive therapy (ECT) a safe and effective treatment for people with schizophrenia who have not responded to their previous treatment? </p> <p><b>Background</b> </p> <p>Electroconvulsive therapy involves the induction of a seizure by the administration of an electrical stimulus via electrodes usually placed bilaterally on the scalp. Electroconvulsive therapy was once widely used as a treatment for people with schizophrenia, but its use in now reduced due to the development of antipsychotic medications and concerns regarding possible long‐term adverse effects of ECT. </p> <p><b>Methods and results</b> </p> <p>Searches for randomised clinical trials (a type of study in which participants are assigned to one of two or more treatment groups using a random method) were conducted in 2015 and updated in 2017. We included 15 studies involving 1285 people with treatment‐resistant schizophrenia. The age range of participants was 18 to 46 years. One study compared adding ECT to standard care with adding sham‐ECT (non‐active ECT); one study compared adding ECT to standard care with adding additional antipsychotic to standard care; and 12 studies compared adding ECT to standard care with standard care. One study compared ECT as the sole treatment with antipsychotics as the sole treatment. </p> <p>Our main outcomes of interest were clinically important response to treatment, cognitive functioning, leaving the study early, mental state, general functioning, number hospitalised, and death. None of the included studies reported data for death. The quality of the evidence for each main outcome was mostly very low or low, with the quality of the evidence rated as moderate for only one outcome. This was mostly due to issues with the way the studies were conducted (e.g. participants were not blinded to treatment) and small sample sizes. </p> <p>For the comparison of adding ECT to standard care versus standard care, moderate‐quality evidence indicates that adding ECT to standard care may have some beneficial effect on clinical response to treatment. Very low‐quality evidence indicates that adding ECT to standard care may increase the risk of short‐term memory problems and could have a positive effect on Global Assessment of Functioning scores. Low‐quality evidence indicates that adding ECT to standard care may have a positive effect on Brief Psychiatric Rating Scale scores. </p> <p>The evidence for the other comparisons was also of low or very low quality, and overall no clear differences between the treatment groups were found. </p> <p><b>Conclusions</b> </p> <p>We found moderate‐quality evidence that adding ECT to standard care has a positive effect on clinical response when compared with standard care. The currently available evidence was too weak to clearly demonstrate that adding ECT to standard treatment is associated with benefits or harm for our other outcomes. There is also a lack of evidence on the effects and safety of adding ECT to standard care compared with sham‐ECT or additional antipsychotics and inadequate evidence regarding the use of ECT alone. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011847-sec-0325" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011847-sec-0325">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011847-sec-0446">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011847-sec-0325"></div> <h3 class="title" id="CD011847-sec-0326">Implications for practice</h3> <section id="CD011847-sec-0326"> <section id="CD011847-sec-0327"> <h5 class="title">For people with treatment‐resistant schizophrenia</h5> <p>When ECT plus standard care was compared with standard care, moderate‐quality evidence showed medium‐term benefits of ECT in terms of response to treatment. There was some advantage of ECT on mental state and general functioning. However, ECT may also induce memory deterioration. The quality of this evidence was very low or low, indicating limited confidence in the effect estimate. This may change with future research. There was also a lack of evidence evaluating ECT versus other controls (sham‐ECT or other antipsychotics). Additionally, there is insufficient evidence regarding the long‐term effects or safety parameters of ECT to enable a more comprehensive evaluation. </p> </section> <section id="CD011847-sec-0328"> <h5 class="title">For clinicians</h5> <p>When combined with standard care, ECT may improve patients' clinical response, mental state, and general functioning when compared with antipsychotics alone. However, the current evidence is too weak to indicate whether ECT is superior or inferior to other controls for the management of people with treatment‐resistant schizophrenia. </p> </section> <section id="CD011847-sec-0329"> <h5 class="title">For policymakers and funders</h5> <p>Very low‐ to moderate‐quality evidence indicates that there are some benefits of adding ECT to standard care for treatment‐resistant schizophrenia. However, very low‐quality evidence shows that ECT may cause specific adverse events (such as memory deterioration). In summary, there is a lack of evidence from this review to either support or discourage the use of ECT as an add‐on treatment. There is a need for further rigorous, well‐designed, and large trials in more countries. </p> </section> </section> <h3 class="title" id="CD011847-sec-0330">Implications for research</h3> <section id="CD011847-sec-0330"> <section id="CD011847-sec-0331"> <h5 class="title">General</h5> <p>Strict adherence to the CONSORT recommendations for reporting of trials is suggested (<a href="./references#CD011847-bbs2-0120" title="PandisN , ChungB , SchererRW , ElbourneD , AltmanDG . CONSORT 2010 statement: extension checklist for reporting within person randomised trials. BMJ2017;357:j2835. ">Pandis 2017</a>). Generation of the allocation sequence, allocation concealment, and blinding are important parts of methodology and should be well‐reported. We also suggest that the availability of all data should be expanded (not only shown in figures or transformed for skewed data). This would prevent valuable data or trials from being excluded in a meta‐analysis, and would avoid redundancy (multiple publications) and facilitate the production of clearer results. </p> </section> <section id="CD011847-sec-0332"> <h5 class="title">Specific</h5> <p>Further studies with high‐quality methodology should address the following areas:</p> <p> <ul id="CD011847-list-0013"> <li> <p>ensuring blinding of participants, personnel, and outcome assessor;</p> </li> <li> <p>ensuring an 80% statistical power for primary outcome (sufficient sample size);</p> </li> <li> <p>exploring the use of ECT, or the different forms of ECT (unilateral versus bilateral, long course versus short course, continuation versus maintenance); </p> </li> <li> <p>focusing on key outcomes in this review;</p> </li> <li> <p>extending the follow‐up duration to longer than six months.</p> </li> </ul> </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011847-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011847-sec-0029"></div> <div class="table" id="CD011847-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">ECT plus standard care versus sham‐ECT plus standard care for treatment‐resistant schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>ECT plus standard care versus sham‐ECT plus standard care for treatment‐resistant schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with treatment‐resistant schizophrenia<br/> <b>Settings:</b> hospital<br/> <b>Intervention:</b> ECT plus standard care </p> <p><b>Comparison:</b> sham‐ECT plus standard care </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with sham‐ECT</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ECT (add‐on)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response to treatment</b> </p> <p>Clinically important response to treatment as defined by each study</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive functioning</b> </p> <p>Clinically important change in cognitive functioning as defined by each study</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction and acceptability of treatment</b> ‐ leaving the study early </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state (short term)</b> ‐ total scores (BPRS, high = poor) </p> <p>Follow‐up: 4 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state ‐ average scores (BPRS, high = poor, short term) was <b>40.4</b>. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 3.60 higher</b> (3.69 lower to 10.89 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for predefined outcome 'clinically important change' not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>General functioning</b><br/> Clinically important change in general functioning as defined by each study </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Service use (short term)</b> ‐ hospitalisation (number readmitted) </p> <p>Follow‐up: 4 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.29</b> </p> <p>(0.10 to 0.85)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>25</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>700 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>203 per 1000</b> </p> <p>(70 to 595)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse event/effect(s) ‐</b> death </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>BPRS:</b> Brief Psychiatric Rating Scale; <b>CI:</b> confidence interval; <b>ECT:</b> electroconvulsive therapy; <b>MD:</b> mean difference; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to indirectness: scores from scale were employed as a surrogate index of the intended outcome.<br/> <sup>2</sup>Downgraded by two levels due to imprecision: very small sample size. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011847-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">ECT plus standard care versus antipsychotics plus standard care for treatment‐resistant schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>ECT plus standard care versus antipsychotics plus standard care for treatment‐resistant schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with treatment‐resistant schizophrenia<br/> <b>Settings:</b> hospital<br/> <b>Intervention:</b> ECT plus ziprasidone </p> <p><b>Comparison:</b> clozapine plus ziprasidone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with antipsychotics (clozapine)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ECT (add‐on)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Response to treatment (medium term)</b><br/> Clinically important response to treatment as defined by each study<br/> Follow‐up: 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.23</b> <br/> (0.95 to 1.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>162<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>543 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>668 per 1000</b><br/> (516 to 858) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive functioning</b> </p> <p>Clinically important change in cognitive functioning as defined by each study</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction and acceptability of treatment</b> ‐ leaving the study early </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state (short term)</b> ‐ total scores (BPRS, high = poor) </p> <p>Follow‐up: 4 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state ‐ average scores (BPRS, high = poor, short term) was <b>44.7</b>. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 5.20 lower</b> (7.93 to 2.47 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for predefined outcome 'clinically important change' not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>General functioning</b><br/> Clinically important change in general functioning as defined by each study </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service use</b> ‐ hospitalisation </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse event/effect(s)</b> ‐ death </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>BPRS:</b> Brief Psychiatric Rating Scale; <b>CI:</b> confidence interval; <b>ECT:</b> electroconvulsive therapy; <b>MD:</b> mean difference; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to risk of bias: <a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a> had high risk of bias for blinding of participants and personnel.<br/> <sup>2</sup>Downgraded by one level due to indirectness: scores from scale were employed as a surrogate index of the intended outcome.<br/> <sup>3</sup>Downgraded by one level due to imprecision: small sample size and wide confidence interval. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011847-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">ECT plus standard care versus standard care for treatment‐resistant schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>ECT plus standard care versus standard care for treatment‐resistant schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with treatment‐resistant schizophrenia<br/> <b>Settings:</b> hospital<br/> <b>Intervention:</b> ECT plus standard care </p> <p><b>Comparison:</b> standard care </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo (no treatment)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ECT (add‐on)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response to treatment (medium term)</b> </p> <p>Clinically important response to treatment as defined by each study<br/> Follow‐up: 8 to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>308 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>635 per 1000</b><br/> (539 to 746) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.06</b> <br/> (1.75 to 2.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>819<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive functioning (short term)</b> ‐ memory deterioration </p> <p>Follow‐up: 3 to 4 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> <p>(1 to 219)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 27</b> </p> <p>(1.67 to 437.68)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for predefined outcome 'clinically important change' not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction and acceptability of treatment (medium term)</b> ‐ leaving the study early<br/> Follow‐up: 8 to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>27 per 1000</b><br/> (9 to 82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.18</b> <br/> (0.38 to 3.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>354<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state (medium term)</b> ‐ total scores (BPRS, high = poor) </p> <p>Follow‐up: 8 to 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state ‐ average scores (BPRS, high = poor, medium term) was <b>33.4</b>. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 11.18 lower</b> (12.61 to 9.76 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>345<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for predefined outcome 'clinically important change' not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>General functioning (medium term)</b> ‐ average scores (GAF, high = good) </p> <p>Follow‐up: 12 weeks to 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state ‐ average scores (GAF, high = good, medium term) was <b>47.3</b>. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 10.66 higher</b> (6.98 to 14.34 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for predefined outcome 'clinically important change' not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service use</b> ‐ hospitalisation </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse event/effect(s)</b> ‐ death </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>BPRS:</b> Brief Psychiatric Rating Scale; <b>CI:</b> confidence interval; <b>ECT:</b> electroconvulsive therapy; <b>GAF:</b> Global Assessment of Functioning; <b>MD:</b> mean difference; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to risk of bias: high risk of bias with blinding of participants and personnel.<br/> <sup>2</sup>Downgraded by one level due to indirectness: scores from scale were employed as a surrogate index of the intended outcome.<br/> <sup>3</sup>Downgraded by one level due to heterogeneity.<br/> <sup>4</sup>Downgraded by two levels due to imprecision: low event rate.<br/> <sup>5</sup>Downgraded by one level due to imprecision: small sample size. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011847-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">ECT alone versus antipsychotics for treatment‐resistant schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>ECT alone versus antipsychotics for treatment‐resistant schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with treatment‐resistant schizophrenia<br/> <b>Settings:</b> hospital<br/> <b>Intervention:</b> ECT </p> <p><b>Comparison:</b> Flupenthixol </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with antipsychotics (flupenthixol)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ECT (alone)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response to treatment</b> </p> <p>Clinically significant response to treatment as defined by each study</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive functioning</b> </p> <p>Clinically important change in cognitive functioning as defined by each study</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction and acceptability of treatment</b> ‐ leaving the study early </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state (medium term)</b> ‐ total scores (BPRS, high = poor) </p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state ‐ average scores (BPRS, high = poor, medium term) was <b>44.3</b>. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.93 lower</b> (6.95 lower to 5.09 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for predefined outcome 'clinically important change' not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>General functioning (medium term)</b> ‐ average scores (GAF, high = good) </p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean general functioning ‐ average scores (GAF, high = good, medium term) was <b>30.1</b>. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.66 lower</b> (3.6 lower to 2.28 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for predefined outcome 'clinically important change' not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service use</b> ‐ hospitalisation </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse event/effect(s)</b> ‐ death </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>BPRS:</b> Brief Psychiatric Rating Scale; <b>CI:</b> confidence interval; <b>ECT:</b> electroconvulsive therapy; <b>GAF:</b> Global Assessment of Functioning; <b>MD:</b> mean difference; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to risk of bias: <a href="./references#CD011847-bbs2-0002" title="ChanpattanaW . ECT in schizophrenia. Journal of the Psychiatric Association of Thailand1999;44(2):156‐70. [CSzG: Ref8163] ChanpattanaW , ChakrabhandML , KitaroonchaiW , ChoovanichvongS , PrasertsukY . Effects of twice‐ versus thrice‐weekly electroconvulsive therapy in schizophrenia. Journal of the Medical Association of Thailand1999;82(5):477‐82. ChanpattanaW , ChakrabhandML , SackeimHA , KitaroonchaiW , KongsakonR , TechakasemP , et al. Continuation ECT in treatment resistant schizophrenia: a controlled study. Journal of ECT1999;15(3):178‐92. [CSzG: Ref4913; MEDLINE: 10492856] ">Chanpattana 1999</a> had high risk of bias for blinding of participants and personnel.<br/> <sup>2</sup>Downgraded by one level due to indirectness: scores from scale were employed as a surrogate index of the intended outcome.<br/> <sup>3</sup>Downgraded by two levels due to imprecision: small sample size and wide confidence interval. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011847-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011847-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011847-sec-0347">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD011847-sec-0030"></div> <section id="CD011847-sec-0031"> <h3 class="title" id="CD011847-sec-0031">Description of the condition</h3> <p>Schizophrenia is a common mental health condition with an incidence of 15.2 cases per 100,000 per year and a lifetime prevalence of 7.2 cases per 100,000 globally (<a href="./references#CD011847-bbs2-0111" title="McGrathJ , SahaS , ChantD , WelhamJ . Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiologic Reviews2008;30:67‐76. [PUBMED: 18480098] ">McGrath 2008</a>). It is a psychotic condition with symptoms that are comprised of fixed beliefs held on unreasonable grounds (delusions), perceptions without a cause (hallucinations), and disorganised thinking (thought disorder). The course of the illness is variable, with a minority of people fully recovering from an initial episode, and most individuals experience a relapsing‐remitting course (<a href="./references#CD011847-bbs2-0094" title="HarrisonG , HopperK , CraigT , LaskaE , SiegelC , WanderlingJ , et al. Recovery from psychotic illness: a 15‐ and 25‐year international follow‐up study. British Journal of Psychiatry2001;178:506‐17. ">Harrison 2001</a>). The degree of disability is high, with 80% to 90% unemployment (<a href="./references#CD011847-bbs2-0110" title="MarwahaS , JohnsonS . Schizophrenia and employment ‐ a review. Social Psychiatry and Psychiatric Epidemiology2004;39(5):337‐49. [PUBMED: 15133589] ">Marwaha 2004</a>). Up to 60% of people with schizophrenia will respond to treatment, but it is well‐recognised that approximately 1 in 3 people have an illness that is 'treatment‐resistant' (<a href="./references#CD011847-bbs2-0112" title="MeltzerHY . Treatment‐resistant schizophrenia ‐ the role of clozapine. Current Medical Research and Opinion1997;14(1):1‐20. ">Meltzer 1997</a>). </p> <p>Treatment‐resistant schizophrenia has not been consistently defined in the literature (<a href="./references#CD011847-bbs2-0127" title="SuzukiT , RemingtonG , MulsantBH , UchidaH , RajjiTK , Graff‐GuerreroA , et al. Defining treatment‐resistant schizophrenia and response to antipsychotics: a review and recommendation. Psychiatry Research2012;197(1‐2):1‐6. ">Suzuki 2012</a>). In a landmark randomised trial, Kane and colleagues investigated the effects of clozapine compared with chlorpromazine for people with defined treatment‐resistant illnesses (<a href="./references#CD011847-bbs2-0099" title="KaneJ , HonigfeldG , SingerJ , MeltzerH . Clozapine for the treatment‐resistant schizophrenic. A double‐blind comparison with chlorpromazine. Archives of General Psychiatry1988;45(9):789‐96. ">Kane 1988</a>). In this study treatment‐resistant schizophrenia was defined as "at least three periods of treatment with antipsychotics from at least two different classes at adequate doses for an adequate period time with no relief and no period of good functioning over the previous five years". The criteria used to define treatment resistance in this study remain some of the most cited in randomised trials evaluating people with treatment‐resistant schizophrenia (<a href="./references#CD011847-bbs2-0081" title="ConleyRR , BuchananRW . Evaluation of treatment‐resistant schizophrenia. Schizophrenia Bulletin1997;23(4):663‐74. ">Conley 1997</a>), although there is still heterogeneity in the criteria used. </p> </section> <section id="CD011847-sec-0032"> <h3 class="title" id="CD011847-sec-0032">Description of the intervention</h3> <p>Electroconvulsive therapy (ECT) was introduced as a treatment for schizophrenia in 1938 as a replacement for chemically induced seizures (<a href="./references#CD011847-bbs2-0090" title="EndlerNS . The origins of electroconvulsive therapy (ECT). Convulsive Therapy1988;4(1):5‐23. ">Endler 1988</a>). It involves the induction of a seizure ('fit') by administering an electrical stimulus via electrodes usually placed bilaterally on the scalp. </p> <p>Electroconvulsive therapy can be modified by the use of anaesthetic agents and muscle relaxants to reduce apprehension and the likelihood of adverse outcomes such as spinal and limb fractures that result from the convulsions. In the industrialised world most ECT treatment administered is modified ECT. Unmodified ECT is still used in some parts of the world, especially in areas that do not have ready access to anaesthetic equipment. There is evidence that the use of ECT in less industrialised countries is higher than in higher‐income countries (<a href="./references#CD011847-bbs2-0074" title="AgarwalAK , AndradeC , ReddyMV . The practice of ECT in India: issue relating to the administration of ECT. Indian Journal of Psychiatry1992;34(4):285‐97. ">Agarwal 1992</a>; <a href="./references#CD011847-bbs2-0118" title="OdejideAO , OhaeriJU , IkuesanBA . Electroconvulsive therapy in Nigeria. Journal of ECT1987;3(1):31‐9. ">Odejide 1987</a>), and that there is also greater use of unmodified ECT. Possible explanations for this may be that ECT has a perceived greater speed of response and can also be administered inexpensively when compared with drug treatments. </p> <p>Electroconvulsive therapy has been recognised as an effective treatment for mood disorders, and its use for the treatment of schizophrenia has declined in higher‐income countries with most individuals receiving ECT for depressive disorders (<a href="./references#CD011847-bbs2-0102" title="LeiknesKA , Jarosh‐von SchwederL , HøieB . Contemporary use and practice of electroconvulsive therapy worldwide. Brain and Behavior2012;2(3):283‐344. ">Leiknes 2012</a>). Electroconvulsive therapy also pre‐dates the introduction of neuroleptic and antidepressant medications by more than a decade, and there is evidence that its use has declined over time (<a href="./references#CD011847-bbs2-0128" title="ThompsonJW , WeinerRD , MyersCP . Use of ECT in the United States in 1975, 1980, and 1986. American Journal of Psychiatry1994;151(11):1657‐61. ">Thompson 1994</a>). This may be due to concerns about long‐term side effects such as memory loss (<a href="./references#CD011847-bbs2-0121" title="RoseD , FleischmannP , WykesT , LeeseM , BindmanJ . Patients' perspectives on electroconvulsive therapy: systematic review. BMJ2003;326(7403):1363. [PUBMED: 12816822] ">Rose 2003</a>). However, there is no conclusive evidence that ECT results in brain damage (<a href="./references#CD011847-bbs2-0083" title="DevanandDP , DworkAJ , HutchinsonER , BolwigTG , SackeimHA . Does ECT alter brain structure?. American Journal of Psychiatry1994;151(7):957‐70. ">Devanand 1994</a>; <a href="./references#CD011847-bbs2-0086" title="DworkAJ , ArangoV , UnderwoodM , IlievskiB , RosoklijaG , SackeimHA , et al. Absence of histological lesions in primate models of ECT and magnetic seizure therapy. American Journal of Psychiatry2004;161(3):576‐8. [PUBMED: 14992989] ">Dwork 2004</a>; <a href="./references#CD011847-bbs2-0089" title="EndeG , BrausDF , WalterS , Weber‐FahrW , HennFA . The hippocampus in patients treated with electroconvulsive therapy: a proton magnetic resonance spectroscopic imaging study. Archives of General Psychiatry2000;57(10):937‐43. ">Ende 2000</a>; <a href="./references#CD011847-bbs2-0130" title="WeinerRD , RogersHJ , DavidsonJRT , SquireLR . Effects of stimulus parameters on cognitive side effects. Annals of the New York Academy of Sciences1986;462(1):315‐25. ">Weiner 1986</a>). To reduce the risk of cognitive side effects, ECT is sometimes given unilaterally to the non‐dominant hemisphere, although there is evidence that a large dose of electrical stimulus must be used and that the efficacy is less than with bilateral electrode placement (<a href="./references#CD011847-bbs2-0123" title="SackeimHA , PrudicJ , DevanandDP , KierskyJE , FitzsimonsL , MoodyBJ , et al. Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. New England Journal of Medicine1993;328(12):839‐46. ">Sackeim 1993</a>; <a href="./references#CD011847-bbs2-0124" title="SackeimHA , PrudicJ , DevanandDP , NoblerMS , LisanbySH , PeyserS , et al. A prospective, randomized, double‐blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Archives of General Psychiatry2000;57(5):425‐34. ">Sackeim 2000a</a>). </p> <p>There is inconsistency among expert groups about the use of ECT and its indications. The American Psychiatric Association recommends the use of ECT in schizophrenia in the following circumstances: when psychotic symptoms in the present episode have an abrupt or recent onset, when schizophrenia is of the catatonic type, or when there is a history of a favourable response to ECT (<a href="./references#CD011847-bbs2-0076" title="American Psychiatric Association. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging (A Task Force Report of the American Psychiatric Association). Arlington, VA: American Psychiatric Association Publishing, 2008. ">APA 2008</a>). The Royal College of Psychiatrists states that 1) while the treatment of choice for schizophrenia is drug therapy, ECT may be considered for treatment‐resistant cases and catatonia, and 2) although there is some evidence supporting the short‐term effectiveness of ECT, evidence for sustained medium‐ and long‐term benefits is lacking (<a href="./references#CD011847-bbs2-0126" title="ScottA . The ECT Handbook: The Third Report of the Royal College of Psychiatrists' Special Committee of ECT. London: RCPsych Publications, 2005. ">Scott 2005</a>). The National Institute for Health and Care Excellence (NICE) only recommends ECT for severe depressive illness, a prolonged or severe episode of mania, or catatonia (which may also occur in other disorders such as depression) (<a href="./references#CD011847-bbs2-0116" title="National Institute for Health and Care Excellence. Guidance on the use of electroconvulsive therapy. NICE technology appraisal guidance [TA59]. Published date: April 2003. www.nice.org.uk/guidance/ta59 (accessed prior to 5 February 2019). ">NICE 2003</a>). </p> <p>Electroconvulsive therapy dosing schedules vary from country to country, with treatments often being delivered three times per week in the USA compared to twice a week in the UK (<a href="./references#CD011847-bbs2-0126" title="ScottA . The ECT Handbook: The Third Report of the Royal College of Psychiatrists' Special Committee of ECT. London: RCPsych Publications, 2005. ">Scott 2005</a>). There is also considerable variation in practice, with small numbers of clinicians in different parts of the world administering ECT daily or many times a day until a state of regression is achieved (regressive ECT) (<a href="./references#CD011847-bbs2-0074" title="AgarwalAK , AndradeC , ReddyMV . The practice of ECT in India: issue relating to the administration of ECT. Indian Journal of Psychiatry1992;34(4):285‐97. ">Agarwal 1992</a>). The number of sessions in a course typically varies from four to 12 (<a href="./references#CD011847-bbs2-0131" title="WeinerRD . Treatment optimization with ECT. Psychopharmacology Bulletin1994;30(3):313‐20. ">Weiner 1994</a>). It has been suggested that individuals with schizophrenia may need 12 to 20 sessions (<a href="./references#CD011847-bbs2-0101" title="KendellRE . The present status of electroconvulsive therapy. British Journal of Psychiatry1981;139:265‐83. ">Kendell 1981</a>). Rarely, some patients are also prescribed ECT fortnightly or monthly as 'continuation ECT' or 'maintenance ECT' to prevent relapse (<a href="./references#CD011847-bbs2-0113" title="MonroeRRJ . Maintenance electroconvulsive therapy. Psychiatric Clinics of North America1991;14(4):947‐60. ">Monroe 1991</a>; <a href="./references#CD011847-bbs2-0125" title="ScottAI , WeeksDJ , McDonaldCF . Continuation electroconvulsive therapy: preliminary guidelines and an illustrative case report. British Journal of Psychiatry1991;159:867‐70. ">Scott 1991</a>). There is evidence that the frequency of ECT influences the speed of response as well as the adverse effects on cognition (<a href="./references#CD011847-bbs2-0092" title="GangadharBN , ThirthalliJ . Frequency of electroconvulsive therapy sessions in a course. Journal of ECT2010;26(3):181‐5. ">Gangadhar 2010</a>). </p> <p>In addition, there is evidence that the dose of the electrical stimulus also affects the outcome of the treatment, with higher doses of electricity being associated with greater efficacy but more cognitive side effects (<a href="./references#CD011847-bbs2-0123" title="SackeimHA , PrudicJ , DevanandDP , KierskyJE , FitzsimonsL , MoodyBJ , et al. Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. New England Journal of Medicine1993;328(12):839‐46. ">Sackeim 1993</a>). </p> <p>Due to the controversial nature of ECT, there are legal restrictions on its administration when compared with other treatments in many jurisdictions (<a href="./references#CD011847-bbs2-0098" title="KalaA . Time to face new realities; mental health care bill ‐ 2013. Indian Journal of Psychiatry2013;55(3):216‐9. ">Kala 2013</a>; <a href="./references#CD011847-bbs2-0107" title="LooC , TrollorJ , AlonzoA , RendinaN , KavessR . Mental health legislation and psychiatric treatments in NSW: electroconvulsive therapy and deep brain stimulation. Australasian Psychiatry2010;18(5):417‐25. [PUBMED: 20863180] ">Loo 2010</a>). In the UK, for example, a patient who has the capacity to consent to a medication but is refusing it may be administered that medication if they are subject to the Mental Health Act. Comparatively, a patient who has the capacity to consent to ECT but is refusing it may not be administered ECT under the Mental Health Act (<a href="./references#CD011847-bbs2-0114" title="MughalF , MenezesSB . Severe depression with Cotard’s phenomenon: treatment of a capacitated patient within the United Kingdom’s Mental Health Act 2007. Mental Illness2013;5(1):e3. [PUBMED: 25478127] ">Mughal 2013</a>). </p> <p>The ethics of research in schizophrenia are also debated given that it is a condition that can affect decision making. Individuals with treatment‐resistant schizophrenia may be expected to have a severe and enduring illness and considered to be more likely to have impairments in their decision‐making capacity. However, there is evidence that, with the appropriate interventions in place, individuals with schizophrenia are able to perform as well as non‐ill controls in assessments of decisional capacity (<a href="./references#CD011847-bbs2-0080" title="CarpenterWTJr , GoldJM , LahtiAC , QueernCA , ConleyRR , BartkoJJ , et al. Decisional capacity for informed consent in schizophrenia research. Archives of General Psychiatry2000;57(6):533‐8. ">Carpenter 2000</a>). </p> </section> <section id="CD011847-sec-0033"> <h3 class="title" id="CD011847-sec-0033">How the intervention might work</h3> <p>How ECT works is not well understood. Despite concerns about brain damage and cognitive side effects, there is empirical evidence from animal models that ECT causes neurogenesis (<a href="./references#CD011847-bbs2-0108" title="MadsenTM , TreschowA , BengzonJ , BolwigTG , LindvallO , TingströmA . Increased neurogenesis in a model of electroconvulsive therapy. Biological Psychiatry2000;47(12):1043‐9. ">Madsen 2000</a>). Studies from depressed individuals have shown that ECT causes an increase in brain‐derived neurotrophic factor (<a href="./references#CD011847-bbs2-0078" title="Bocchio‐ChiavettoL , ZanardiniR , BortolomasiM , AbateM , SegalaM , GiacopuzziM , et al. Electroconvulsive therapy (ECT) increases serum brain derived neurotrophic factor (BDNF) in drug resistant depressed patients. European Neuropsychopharmacology2006;16(8):620‐4. ">Bocchio‐Chiavetto 2006</a>). However, studies have also shown that brain‐derived neurotrophic factor may play a potential role in the development of schizophrenia (<a href="./references#CD011847-bbs2-0115" title="MugliaP , VicenteAM , VergaM , KingN , MacciardiF , KennedyJL . Association between the BDNF gene and schizophrenia. Molecular Psychiatry2003;8(2):146‐7. ">Muglia 2003</a>; <a href="./references#CD011847-bbs2-0117" title="NietoR , KukuljanM , SilvaH . BDNF and schizophrenia: from neurodevelopment to neuronal plasticity, learning, and memory. Frontiers in Psychiatry2013;4:45. ">Nieto 2013</a>). Other putative mechanisms include influences on dopamine and serotonin neurotransmitter activity and immune system modulation (<a href="./references#CD011847-bbs2-0122" title="RosenquistPB , MillerB , PillaiA . The antipsychotic effects of ECT: a review of possible mechanisms. Journal of ECT2014;30(2):125‐31. ">Rosenquist 2014</a>). </p> </section> <section id="CD011847-sec-0034"> <h3 class="title" id="CD011847-sec-0034">Why it is important to do this review</h3> <p>Previous Cochrane Reviews of ECT for the treatment of schizophrenia have not looked specifically at the evidence for ECT in people with treatment‐resistant schizophrenia, despite this being a clinical dilemma that is a consensus priority for research (<a href="./references#CD011847-bbs2-0106" title="LloydK , WhiteJ . Democratizing clinical research. Nature2011;474(7351):277‐8. ">Lloyd 2011</a>; <a href="./references#CD011847-bbs2-0134" title="TharyanP , AdamsCE . Electroconvulsive therapy for schizophrenia. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD000076.pub2; PUBMED: 15846598] ">Tharyan 2005</a>). Given that ECT remains a controversial treatment, it is essential to determine its efficacy. This review attempted to assess the current evidence for ECT specifically for the group of people whose illness has been designated as resistant to treatment. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011847-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011847-sec-0035">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011847-sec-0352">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011847-sec-0035"></div> <p>Our primary objective was to assess the effects (benefits and harms) of ECT for people with treatment‐resistant schizophrenia. </p> <p>Our secondary objectives were to determine whether ECT produces a differential response in people: </p> <p> <ul id="CD011847-list-0001"> <li> <p>who are treated with unilateral compared with bilateral ECT;</p> </li> <li> <p>who have had a long (more than 12 sessions) or a short course of ECT;</p> </li> <li> <p>who are given continuation or maintenance ECT;</p> </li> <li> <p>who are diagnosed with well‐defined treatment‐resistant schizophrenia as opposed to less rigorously defined treatment‐resistant schizophrenia (who would be expected to have a greater affective component to their illness). </p> </li> </ul> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011847-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011847-sec-0036">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011847-sec-0353">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011847-sec-0036"></div> <section id="CD011847-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011847-sec-0038"> <h4 class="title">Types of studies</h4> <p>We considered all relevant randomised controlled trials. If a trial was described as 'double blind' but implied randomisation, we planned to include such trials in a sensitivity analysis (<a href="#CD011847-sec-0112">Sensitivity analysis</a>). We excluded quasi‐randomised studies such as those allocating by alternate days of the week. For cases in which people were given additional treatments to ECT, we only included data if the adjunct treatment was evenly distributed between the groups, and only the ECT was randomised. </p> </section> <section id="CD011847-sec-0039"> <h4 class="title">Types of participants</h4> <p>We included people of both sexes, aged 18 years or more, with a diagnosis of treatment‐resistant schizophrenia or related disorders (e.g. schizoaffective disorder, schizophreniform disorder), regardless of how it was diagnosed. We planned to conduct a sensitivity analysis by only including people with strictly diagnosed schizophrenia by international standards (International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD‐10), Diagnostic and Statistical Manual of Mental Disorders (DSM) (DSM‐III, DSM‐IV, DSM‐5), Chinese Classification of Mental Disorders (CCMD) (CCMD‐1, CCMD‐2, CCMD‐3). </p> </section> <section id="CD011847-sec-0040"> <h4 class="title">Types of interventions</h4> <section id="CD011847-sec-0041"> <h5 class="title">1. ECT</h5> <p>Electroconvulsive therapy is a procedure that involves passing an electrical stimulus through the brain to produce a seizure. It is a practice in many countries to administer 'modified' ECT, which entails administering a general anaesthetic and muscle relaxant as well as the electrical stimulus. Electroconvulsive therapy can normally be delivered as a course over several sessions. We did not exclude studies based on the number and frequency of ECT sessions or whether the ECT was modified or unmodified. We also did not exclude studies in which the participants were receiving concurrent pharmacological interventions and other interventions, provided that only ECT was being randomised. </p> <section id="CD011847-sec-0042"> <h6 class="title">Standard care</h6> <p>For this review we have defined standard care as the treatment the participants received alongside the trial intervention as part of their ongoing care for their illness. </p> <p>We planned to compare ECT therapy with the following.</p> </section> <section id="CD011847-sec-0043"> <h6 class="title">'Sham‐ECT' or 'simulated‐ECT'</h6> <p>'Sham‐ECT' or 'simulated‐ECT' is a situation in which a patient undergoes all the preparations for ECT, often including receiving a general anaesthetic and muscle relaxant, but does not receive the electrical stimulus. </p> </section> <section id="CD011847-sec-0044"> <h6 class="title">Treatment with antipsychotics</h6> <p>Antipsychotic drugs are medications designed to treat psychosis; they are thought to act in part by their dopamine‐blocking action, although other chemical pathways have also been identified. </p> </section> <section id="CD011847-sec-0045"> <h6 class="title">Non‐pharmacological forms of treatment</h6> <p>Non‐pharmacological management of schizophrenia includes but is not limited to interventions such as occupational therapy and psychotherapy. </p> </section> <section id="CD011847-sec-0046"> <h6 class="title">Placebo</h6> <p>Any intervention that is not thought to be an active treatment for schizophrenia.</p> </section> <section id="CD011847-sec-0047"> <h6 class="title">Standard care</h6> <p>For this review we have defined standard care as the treatment the participants received alongside the trial intervention as part of their ongoing care for their illness. </p> </section> </section> <section id="CD011847-sec-0048"> <h5 class="title">2. ECT alone</h5> <p>Electroconvulsive therapy may be the sole treatment that is prescribed for a patient. For this comparison, we excluded studies in which the participants were prescribed concurrent interventions, whether pharmacological or non‐pharmacological, except when these interventions were part of the process of ECT. We also planned to include studies in which participants received alternative interventions, provided these studies were randomised comparisons with ECT. We did not identify any study of this type in the review. </p> <p>We planned to compare ECT alone with the following:</p> <p> <ul id="CD011847-list-0002"> <li> <p>sham‐ECT or simulated‐ECT;</p> </li> <li> <p>treatment with antipsychotics;</p> </li> <li> <p>non‐pharmacological forms of treatment;</p> </li> <li> <p>placebo</p> </li> <li> <p>standard care</p> </li> </ul> </p> <p>However, we did not identify any relevant studies comparing ECT alone with the following therapies: sham‐ECT or simulated‐ECT, non‐pharmacological forms of treatment, placebo or standard care </p> </section> <section id="CD011847-sec-0049"> <h5 class="title">3. Electrode placement</h5> <section id="CD011847-sec-0050"> <h6 class="title">Bilateral ECT versus unilateral ECT</h6> <p>In bilateral ECT, the electrical stimulus is administered across both hemispheres of the brain. The placement is usually bi‐temporal. In unilateral ECT, the electrical stimulus is administered to the non‐dominant hemisphere of the brain, and the placement is usually temporoparietal. We did not identify any studies with this comparison for inclusion in the review. </p> </section> </section> <section id="CD011847-sec-0051"> <h5 class="title">4. Duration of course</h5> <section id="CD011847-sec-0052"> <h6 class="title">Course of 6 to 12 ECT sessions versus course of 12 to 30 sessions</h6> <p>A session of ECT is a session in which an electrical stimulus is delivered to the brain. A repeat stimulus may be administered in the same session if the seizure was inadequate. A typical course of ECT for depression is 6 to 12 sessions, but this is not well‐defined for schizophrenia. We planned to determine if there was evidence that people with schizophrenia required a longer course of ECT than that given for people with depression. We did not identify any studies with this comparison for inclusion in the review. </p> </section> </section> <section id="CD011847-sec-0053"> <h5 class="title">5. Frequency of treatment</h5> <section id="CD011847-sec-0054"> <h6 class="title">ECT administered fortnightly or monthly versus any other treatment</h6> <p>Electroconvulsive therapy is normally administered at least weekly. In some situations, it is given less often and may be called 'maintenance' ECT. We defined 'maintenance' ECT as ECT that is delivered either fortnightly or monthly for at least six sessions. We planned to compare maintenance ECT with any other pharmacological or non‐pharmacological treatment strategies. We did not identify any studies with this comparison for inclusion in the review. </p> </section> </section> </section> <section id="CD011847-sec-0055"> <h4 class="title">Types of outcome measures</h4> <p>If possible, we divided all outcomes into short term (less than six weeks), medium term (six weeks to six months), and long term (over six months). </p> <section id="CD011847-sec-0056"> <h5 class="title">Primary outcomes</h5> <section id="CD011847-sec-0057"> <h6 class="title">1. Response to treatment</h6> <p>Clinically important response to treatment ‐ as defined by the original studies</p> </section> <section id="CD011847-sec-0058"> <h6 class="title">2. Cognitive functioning</h6> <p>Clinically important change in cognitive functioning ‐ as defined by individual studies</p> </section> </section> <section id="CD011847-sec-0059"> <h5 class="title">Secondary outcomes</h5> <section id="CD011847-sec-0060"> <h6 class="title">1. Satisfaction and acceptability of treatment</h6> <p>1.1. Leaving the study early<br/> 1.2. Participants reporting adverse events, e.g. post‐ECT headache </p> </section> <section id="CD011847-sec-0061"> <h6 class="title">2. Mental state</h6> <p>2.1. Clinically important change in general mental state at short, medium, and long term<br/> 2.2. Average endpoint general mental state score<br/> 2.3. Average change in general mental state scores<br/> 2.4. Clinically important change in specific symptoms (positive symptoms of schizophrenia, negative symptoms of schizophrenia) at short, medium, and long term<br/> 2.5. Average endpoint specific symptom score<br/> 2.6. Average change in specific symptom scores </p> </section> <section id="CD011847-sec-0062"> <h6 class="title">3. General functioning</h6> <p>3.1. Clinically important change in general functioning at short and medium term<br/> 3.2. Average endpoint general functioning score<br/> 3.3. Average change in general functioning scores </p> </section> <section id="CD011847-sec-0063"> <h6 class="title">4. Service use</h6> <p>4.1. Number hospitalised<br/> 4.2. Number discharged or readmitted (as defined in individual trials) </p> </section> <section id="CD011847-sec-0064"> <h6 class="title">5. Adverse event/effect(s)</h6> <section id="CD011847-sec-0065"> <p><b>5.1 General</b></p> <p>5.1.1. Any major adverse event<br/> 5.1.2. Any reported adverse event<br/> 5.1.3. Average endpoint in general adverse event score<br/> 5.1.4. Average change in general adverse event score </p> </section> <section id="CD011847-sec-0066"> <p><b>5.2 Specific</b></p> <p>5.2.1. Any major adverse event<br/> 5.2.2. Any reported adverse event<br/> 5.2.3. Average endpoint in specific adverse event score (e.g. cognitive function)<br/> 5.2.4. Average change in specific adverse event score<br/> 5.2.5. Death </p> </section> </section> <section id="CD011847-sec-0067"> <h6 class="title">'Summary of findings' table</h6> <p>We used <a href="https://community.cochrane.org/help/tools-and-software/gradepro-gdt" target="_blank">GRADEpro GDT</a> to import data from Cochrane's statistical software Review Manager 5 to create the 'Summary of findings' tables (<a href="http://www.ims.cochrane.org/revman" target="_blank">Review Manager</a>). These tables provide outcome‐specific information concerning the overall quality of the evidence from each included study in the comparison, the magnitude of the effect of the interventions examined, and the sum of available data on all outcomes that we rated as important to patient care and decision making. </p> <p>We selected the following main outcomes for inclusion in the 'Summary of findings' table. </p> <p> <ul id="CD011847-list-0003"> <li> <p>Response to treatment: clinically important response ‐ as defined by each of the studies.</p> </li> <li> <p>Cognitive functioning: clinically important change in cognitive functioning ‐ as defined by each of the studies. </p> </li> <li> <p>Acceptability of treatment: leaving the study early.</p> </li> <li> <p>Mental state: clinically important change in general mental state ‐ as defined by each of the studies. </p> </li> <li> <p>General functioning: clinically important change in general functioning ‐ as defined by each of the studies. </p> </li> <li> <p>Service use: number hospitalised</p> </li> <li> <p>Adverse events/effects: death.</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD011847-sec-0068"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011847-sec-0069"> <h4 class="title">Electronic searches</h4> <section id="CD011847-sec-0070"> <h5 class="title">Cochrane Schizophrenia Group's Study‐Based Register of Trials</h5> <p>On 9 September 2015 and 4 August 2017, the Cochrane Schizophrenia Group Information Specialist searched the register using the following search strategy: </p> <p> <ul id="CD011847-list-0004"> <li> <p>(*Electroconvulsive Therapy* in Intervention Field) AND (*Treatment Resistant* in Healthcare Condition Field) of STUDY </p> </li> </ul> </p> <p>In such a study‐based register, searching the major concept retrieves all the synonyms and relevant studies because all the studies have already been organised based on their interventions and have been linked to the relevant topics. </p> <p>This register was compiled by systematic searches of major resources (including AMED (Allied and Complementary Medicine), BIOSIS, CINAHL (Cumulative Index to Nursing and Allied Health Literature), Embase, MEDLINE, PsycINFO, PubMed, and registries of clinical trials) and their monthly updates, handsearches, grey literature, and conference proceedings (see <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html" target="_blank">Group's Module</a>). There were no limitations on language, date, document type, or publication status for the inclusion of records into the register. </p> </section> </section> <section id="CD011847-sec-0071"> <h4 class="title">Searching other resources</h4> <p>We inspected the references of all included records to identify further relevant studies. Contact information was available for five included studies (<a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>; <a href="./references#CD011847-bbs2-0009" title="BragaRJ , MendelowitzAJ , FinkM , SchoolerNR , BailineSH , MalurC , et al. A randomized controlled trial of ECT in clozapine‐refractory schizophrenia. Biological Psychiatry2009;65(8):212S‐3S. [CSzG: Ref19511] PetridesG . ECT augmentation in clozapine‐resistant schizophrenia: acute efficacy and maintance data. Schizophrenia Bulletin2015;41:S328. [CSzG: Ref29626] PetridesG . Electroconvulsive therapy (ECT) for medication resistant schizophrenia. Schizophrenia Research2012;136:S22. [CSzG: Ref29625] PetridesG , GoldbergT , JohnM , BragaR , MalurC , MalhotraA , et al. Electroconvulsive therapy for clozapine‐resistant schizophrenia: cognitive effects. Neuropsychopharmacology2016;41:S257. [CSzG: Ref35678] PetridesG , MalurC , BragaRJ , BailineSH , SchoolerNR , MalhotraAK , et al. Electroconvulsive therapy augmentation in clozapine‐resistant schizophrenia: a prospective, randomized study. American Journal of Psychiatry2015;172(1):52‐8. [CSzG: Ref29366] ">Petrides 2015</a>; <a href="./references#CD011847-bbs2-0010" title="WangBH , ZengDZ , FanXW , HuaSG . Efficacy of modified electroconvulsive therapy in treatment‐refractory schizophrenia [无抽搐电休克对难治性精神分裂症的增效作用]. 临床精神医学杂志 [Journal of Clinical Psychiatry]2008;18(6):415‐7. [CSzG: Ref17865] ">Wang 2008</a>; <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a>; <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a>). We contacted the first author of these studies for information regarding unpublished trials. We noted the outcome of this contact in the 'Characteristics of included studies' or 'Characteristics of studies awaiting classification' tables of the review. </p> </section> </section> <section id="CD011847-sec-0072"> <h3 class="title" id="CD011847-sec-0072">Data collection and analysis</h3> <section id="CD011847-sec-0073"> <h4 class="title">Selection of studies</h4> <p>Two review authors (DS, FQ) independently inspected all of the citations from the searches and identified relevant abstracts. When disputes arose, we retrieved the full‐text report for further assessment. We obtained the full reports of the records that met the review criteria, and the two review authors (DS, FQ) independently inspected these. In cases of disagreement, we consulted a third review author (SZ). Where doubt still remained, we added these trials to the list of those studies awaiting classification and attempted to contact the study authors for clarification. </p> </section> <section id="CD011847-sec-0074"> <h4 class="title">Data extraction and management</h4> <section id="CD011847-sec-0075"> <h5 class="title">1. Extraction</h5> <p>Two review authors (DS, FQ) independently extracted data from all the included studies. Again, any disagreements were discussed, decisions documented, and, if necessary, attempts made to contact the authors of the studies for clarification. If there were any remaining issues, we consulted a third review author (SZ) for clarification and documented these final decisions. We extracted data presented only in graphs and figures whenever possible, but only included data for which the two review authors had independently extracted the same results. We attempted to contact authors through an open‐ended request in order to obtain missing information or for clarification whenever necessary. For multicentre studies, we planned whenever possible to extract data relevant to each component centre separately. However, data were not available for each centre in the relevant studies. </p> </section> <section id="CD011847-sec-0076"> <h5 class="title">2. Management</h5> <section id="CD011847-sec-0077"> <h6 class="title">2.1. Data collection forms</h6> <p>We extracted data onto pre‐standardised data extraction forms.</p> </section> <section id="CD011847-sec-0078"> <h6 class="title">2.2. Scale‐derived data</h6> <p>We included continuous data from rating scales only if:</p> <p> <ul id="CD011847-list-0005"> <li> <p>the psychometric properties of the measuring instrument had been described in a peer‐reviewed journal (<a href="./references#CD011847-bbs2-0109" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249‐52. ">Marshall 2000</a>); and </p> </li> <li> <p>the measuring instrument had not been written or modified by one of the trialists for that particular trial. </p> </li> </ul> </p> <p>Ideally, the measuring instrument should either be a self report tool or one that was completed by an independent rater or a relative (not the therapist). We realise that this is often not reported clearly, therefore we made a note of the description of the measuring instrument in the <a href="#CD011847-sec-0120">Description of studies</a> section. </p> </section> <section id="CD011847-sec-0079"> <h6 class="title">2.3. Endpoint versus change data</h6> <p>There are advantages to both endpoint and change data. Change data can remove a component of between‐person variability from the analysis. On the other hand, a calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and hard‐to‐measure conditions such as schizophrenia. We decided to primarily use endpoint data and to only use change data if the former were not available. We planned to combine endpoint and change data in the analysis because we preferred to use mean differences (MDs) rather than standardised mean differences (SMDs) throughout (<a href="./references#CD011847-bbs2-0096" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). Ultimately, the endpoint data were available in all the included studies. </p> </section> <section id="CD011847-sec-0080"> <h6 class="title">2.4. Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we applied the following standards to all the data before inclusion. </p> <p> <ul id="CD011847-list-0006"> <li> <p>For change data, we planned to enter relevant useable change data into the analyses. For instance, when continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether the data are skewed or not. However, no change data were identified. </p> </li> <li> <p>For endpoint data from small trials (n &lt; 200):</p> <ul id="CD011847-list-0007"> <li> <p>when a scale started from the finite number 0, we subtracted the lowest possible value from the mean, and divided this by the standard deviation (SD). If this value was lower than 1, it strongly suggested a skew, and we excluded the study data. If this ratio was higher than 1 but below 2, there was a suggestion of skew. We entered the study data and tested whether inclusion or exclusion changed the results substantially. Finally, if the ratio was larger than 2, we included the study data, because a skew was less likely (<a href="./references#CD011847-bbs2-0075" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313(7066):1200. ">Altman 1996</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1506231229092750134863197782982%26format=REVMAN#REF-Higgins-2011" target="_blank">Higgins 2011</a>); </p> </li> <li> <p>if a scale started from a positive value (such as the Positive and Negative Syndrome Scale (PANSS), which has values from 30 to 210) (<a href="https://archie.cochrane.org/sections/documents/view?version=z1506231229092750134863197782982%26format=REVMAN#REF-Kay-1986" target="_blank">Kay 1986</a>), we modified the calculation described above to take into account the scale starting point. In such cases, a skew was present if 2 SD &gt; (S ‐ S min), where S was the mean score and S min was the minimum score. </p> </li> </ul> </li> <li> <p>For endpoint data from larger trials (n &gt; 200), we entered the relevant endpoint data from studies of at least 200 participants in the analyses irrespective of the above rules because skewed data poses less of a problem in large studies. </p> </li> </ul> </p> </section> <section id="CD011847-sec-0081"> <h6 class="title">2.5. Common measures</h6> <p>To facilitate comparisons between trials, we planned to convert variables that could be reported in different metrics, such as days in hospital (mean days per year, per week, or per month) to a common metric (e.g. mean days per month). </p> </section> <section id="CD011847-sec-0082"> <h6 class="title">2.6. Conversion of continuous to binary data</h6> <p>Whenever possible, we made efforts to convert outcome measures to dichotomous data. This could be done by identifying cut‐off points in rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It was generally assumed that if there was a 50% reduction in a scale‐derived score such as the Brief Psychiatric Rating Scale (BPRS) or the PANSS (<a href="./references#CD011847-bbs2-0100" title="KaySR , FiszbeinA , OpferLA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>; <a href="./references#CD011847-bbs2-0119" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>), this could be considered a clinically significant response (<a href="./references#CD011847-bbs2-0104" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . What does the PANSS mean?. Schizophrenia Research2005;79(2‐3):231‐8. ">Leucht 2005</a>; <a href="./references#CD011847-bbs2-0105" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of Brief Psychiatric Rating Scale scores. British Journal of Psychiatry2005;187:366‐71. ">Leucht 2005a</a>). If data based on these thresholds were not available, we used the primary cut‐off presented by the original authors. </p> </section> <section id="CD011847-sec-0083"> <h6 class="title">2.7. Direction of graphs</h6> <p>Whenever possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for ECT. In cases where keeping to this made it impossible to avoid outcome titles with clumsy double‐negatives (e.g. 'Not un‐improved'), we reported data where the left of the line indicated an unfavourable outcome and noted this in the relevant graphs. </p> </section> </section> </section> <section id="CD011847-sec-0084"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (DS, FQ) independently assessed risk of bias using the criteria described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011847-bbs2-0096" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). This set of criteria is based on evidence of associations between an overestimate of effect and a high risk of bias for the article related to sequence generation, allocation concealment, blinding, incomplete outcome data, and selective reporting. </p> <p>In case of disagreement, the final rating was made by consensus with the involvement of a third review author (SZ). When inadequate details of randomisation and other characteristics of trials were provided, we attempted to contact the authors of the studies to obtain further information. However, we did not receive any reply from the authors we contacted. We reported non‐concurrence in the quality assessment, but if disputes arose as to which category a trial should be allocated to, we again resolved the issue by discussion. </p> <p>We noted the level of risk of bias in both the text of the review and in the 'Summary of findings' table. </p> </section> <section id="CD011847-sec-0085"> <h4 class="title">Measures of treatment effect</h4> <section id="CD011847-sec-0086"> <h5 class="title">1. Binary data</h5> <p>For binary outcomes, we calculated the standard estimation of risk ratios (RRs) and their 95% confidence intervals (CIs). It has been shown that RRs are more intuitive than odds ratios (ORs), and that ORs tend to be interpreted as RRs by clinicians (<a href="./references#CD011847-bbs2-0079" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie1999;54(4):405‐11. [PUBMED: 10667106] ">Boissel 1999</a>; <a href="./references#CD011847-bbs2-0082" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. Proceedings of the 8th International Cochrane Colloquium. Cape Town. The Cochrane Collaboration, 25‐28 Oct 2000. ">Deeks 2000</a>). The number needed to treat for an additional beneficial outcome/harmful outcome (NNTB/H) statistics with 95% CIs are intuitively attractive to clinicians but can be problematic both in terms of accurate calculation in meta‐analyses and interpretation (<a href="./references#CD011847-bbs2-0097" title="HuttonJL . Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology2009;146(1):27‐30. ">Hutton 2009</a>). For binary data presented in the 'Summary of findings' tables, we calculated illustrative comparative risks where possible. </p> </section> <section id="CD011847-sec-0087"> <h5 class="title">2. Continuous data</h5> <p>For continuous outcomes, we estimated MDs between the groups. We preferred not to calculate measures of effect size (i.e. using SMDs). However, if scales of very considerable similarity were used, we planned to presume there was a small difference in measurement. We also planned to calculate effect size and transform the effect back to the units of one or more of the specific instruments. We reported the outcomes measured by different scales separately in the review. </p> </section> </section> <section id="CD011847-sec-0088"> <h4 class="title">Unit of analysis issues</h4> <section id="CD011847-sec-0089"> <h5 class="title">1. Cluster trials</h5> <p>Though studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice), the analysis and pooling of clustered data pose problems. First, authors often fail to account for intraclass correlations in clustered studies, leading to a 'unit of analysis' error (<a href="./references#CD011847-bbs2-0084" title="DivineGW , BrownJT , FrazierLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7(6):623‐9. ">Divine 1992</a>), whereby P values are spuriously low, CIs unduly narrow, and statistical significance overestimated. This causes type I errors (<a href="./references#CD011847-bbs2-0077" title="BlandJM , KerrySM . Statistics notes: trials randomised in clusters. BMJ1997;315(7108):600. ">Bland 1997</a>; <a href="./references#CD011847-bbs2-0093" title="GullifordMC , UkoumunneOC , ChinnS . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149(9):876‐83. ">Gulliford 1999</a>). </p> <p>For cases where clustering was not accounted for in the primary studies, we planned to present data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. We planned to attempt to contact the first authors of these studies to obtain intraclass correlation coefficients (ICCs) for their clustered data and adjust for this by using accepted methods (<a href="./references#CD011847-bbs2-0093" title="GullifordMC , UkoumunneOC , ChinnS . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149(9):876‐83. ">Gulliford 1999</a>). For cases where clustering had been incorporated into the analysis of primary studies, we planned to present these data as if from a non‐cluster‐randomised study, but adjust for the clustering effect. </p> <p>We sought statistical advice and were advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the ICC (design effect = 1 + (m ‐ 1)*ICC) (<a href="./references#CD011847-bbs2-0085" title="DonnerA , KlarN . Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine2002;21:2971‐80. ">Donner 2002</a>). If the ICC was not reported, we would assume it to be 0.1 (<a href="./references#CD011847-bbs2-0129" title="UkoumunneOC , GullifordMC , ChinnS , SterneJA , BurneyPG . Methods for evaluating area‐wide and organisation‐based interventions in health and health care: a systematic review. Health Technology Assessment1999;3(5):iii‐92. ">Ukoumunne 1999</a>). </p> <p>If cluster studies were appropriately analysed taking into account ICCs and relevant data documented in the report, synthesis with other studies would be possible using the generic inverse‐variance technique. </p> <p>However, we did not identify any study with a cluster‐randomised design for inclusion in the review. </p> </section> <section id="CD011847-sec-0090"> <h5 class="title">2. Cross‐over trials</h5> <p>A major concern of cross‐over trials is the carry‐over effect. This occurs if an effect (e.g. pharmacological, physiological, or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, upon entry to the second phase participants can differ systematically from their initial state despite a wash‐out phase. For the same reason cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD011847-bbs2-0088" title="ElbourneD , AltmanDG , HigginsJPT , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). As both effects are very likely in cases of severe mental illness, we planned to only use data from the first phase of cross‐over studies. However, we did not identify any study with a cross‐over design for inclusion in the review. </p> </section> <section id="CD011847-sec-0091"> <h5 class="title">3. Studies with multiple treatment groups</h5> <p>When a study involved more than two treatment arms, if relevant, we presented the additional treatment arms in the comparisons. For binary data, we planned to simply add them together and combine them within the two‐by‐two table. For continuous data, we planned to combine data following the formula in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011847-bbs2-0096" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). When the additional treatment arms were not relevant, we planned not to use these data. </p> </section> </section> <section id="CD011847-sec-0092"> <h4 class="title">Dealing with missing data</h4> <section id="CD011847-sec-0093"> <h5 class="title">1. Overall loss of credibility</h5> <p>At some degree of loss of follow‐up data there is a loss of credibility (<a href="./references#CD011847-bbs2-0132" title="XiaJ , AdamsC , BhagatN , BhagatV , BhoopathiP , El‐SayehH , et al. Losing participants before the trial ends erodes credibility of findings. Psychiatric Bulletin2009;33(7):254‐7. ">Xia 2009</a>). If for any particular outcome more than 50% of the data were unaccounted for, we planned not to reproduce these data or use them in the analyses. If, however, more than 50% of the data in one arm of a study were lost, but the total loss was less than 50%, we planned to address this within the 'Summary of findings' tables by down‐rating quality. Finally, we also planned to downgrade quality within the 'Summary of findings' tables should the loss of data be between 25% and 50% in total. However, we did not identify any studies with the above‐stated issues for inclusion in the review. </p> </section> <section id="CD011847-sec-0094"> <h5 class="title">2. Binary</h5> <p>For cases where attrition for a binary outcome was between 0 and 50%, and these data were not clearly described, we presented data on a 'once‐randomised‐always‐analyse' basis (an intention‐to‐treat (ITT) analysis). We assumed that all participants who left the study early had the same rate of negative outcomes as those who completed the study, with the exception of the outcomes of death and adverse effects. For these outcomes, the rate of negative outcomes for those who stayed in the study ‐ in that particular arm of the trial ‐ was used for those who left the study. We undertook a sensitivity analysis to test how prone the primary outcomes were to change when data from only people who completed the study up to that point were compared with the ITT analysis using the above assumptions. </p> </section> <section id="CD011847-sec-0095"> <h5 class="title">3. Continuous</h5> <section id="CD011847-sec-0096"> <h6 class="title">3.1 Attrition</h6> <p>For cases where attrition for a continuous outcome was between 0 and 50%, and data from only people who completed the study up to that point were reported, we used these data. </p> </section> <section id="CD011847-sec-0097"> <h6 class="title">3.2 Standard deviations</h6> <p>If standard deviations (SDs) were not reported, we first planned to attempt to obtain the missing values from the authors. If this information was not available, when there were missing measures of variance for continuous data, but an exact standard error (SE) and CIs were available for group means, and either P or T values were available for differences in the mean, we planned to calculate them according to the rules described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011847-bbs2-0096" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>): when only the SE was reported, we planned to calculate SDs using the formula SD = SE * square root (n). The <i>Cochrane Handbook for Systematic Reviews of Interventions</i> provides detailed formulae for estimating SDs from P, T, or F values, CIs, ranges, or other statistics (<a href="./references#CD011847-bbs2-0096" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). If these formulae did not apply, we planned to calculate the SDs according to a validated imputation method based on the SDs of the other included studies (<a href="./references#CD011847-bbs2-0091" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(7):7‐10. ">Furukawa 2006</a>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study's outcome and thus lose information. We nevertheless planned to examine the validity of the imputations in a sensitivity analysis excluding the imputed values. However, we did not perform any imputations on missing SDs in this review. </p> </section> <section id="CD011847-sec-0098"> <h6 class="title">3.3 Assumptions about participants who left the trials early or were lost to follow‐up</h6> <p>Various methods are available to account for participants who leave the trials early or are lost to follow‐up. Some trials just present the results of study completers, while others use the method of 'last observation carried forward' (LOCF). More recently methods such as multiple imputation or mixed‐effects models for repeated measurements have become more of a standard. While the latter methods seem to be somewhat better than LOCF (<a href="./references#CD011847-bbs2-0103" title="LeonAC , MallinckrodtCH , Chuang‐SteinC , ArchibaldDG , ArcherGE , ChartierK . Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry2006;59(11):1001‐5. [PUBMED: 16905632] ">Leon 2006</a>), we felt that the high percentage of participants leaving the studies early and the differences in their reasons for leaving early between groups were often the core problem in randomised trials evaluating schizophrenia. We therefore did not exclude studies based on the statistical approach used. However, we preferred to use the more sophisticated approaches, for example mixed‐effects models for repeated measurements or multiple imputation instead of LOCF. In addition, we only presented completer analyses if some kind of ITT data were completely unavailable. Moreover, we addressed this issue in the incomplete outcome data domain of the 'Risk of bias' tool. </p> </section> </section> </section> <section id="CD011847-sec-0099"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD011847-sec-0100"> <h5 class="title">1. Clinical heterogeneity</h5> <p>To judge clinical heterogeneity, we considered all the included studies initially without looking at the comparison data. We simply inspected all studies for clearly outlying people or situations that we had not predicted would arise. When such situations or participant groups arose, we discussed these in detail. </p> </section> <section id="CD011847-sec-0101"> <h5 class="title">2. Methodological heterogeneity</h5> <p>To judge methodological heterogeneity, we considered all the included studies initially without looking at the comparison data. We simply inspected all studies for clearly outlying methods that we had not predicted would arise. When such methodological outliers arose, we discussed these in detail. </p> </section> <section id="CD011847-sec-0102"> <h5 class="title">3. Statistical heterogeneity</h5> <section id="CD011847-sec-0103"> <h6 class="title">3.1 Visual inspection</h6> <p>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD011847-sec-0104"> <h6 class="title">3.2 Employing the I<sup>2</sup> statistic </h6> <p>We investigated statistical heterogeneity between studies by considering the I<sup>2</sup> statistic alongside the P value of the Chi<sup>2</sup> test. The I<sup>2</sup> statistic provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD011847-bbs2-0095" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). The importance of the observed value of I<sup>2</sup> depends on both the magnitude and direction of the effects and the strength of evidence for heterogeneity (e.g. P value from Chi<sup>2</sup> test or CIs for I<sup>2</sup>). We considered an I<sup>2</sup> statistic estimate of greater than or equal to approximately 50% accompanied by a statistically significant Chi<sup>2</sup> test (P &lt; 0.1) as evidence of substantial levels of heterogeneity (<a href="./references#CD011847-bbs2-0096" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). When we found substantial levels of heterogeneity, we explored reasons for the heterogeneity (<a href="#CD011847-sec-0109">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> </section> <section id="CD011847-sec-0105"> <h4 class="title">Assessment of reporting biases</h4> <section id="CD011847-sec-0106"> <h5 class="title">1. Protocol versus full study</h5> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of the results (<a href="./references#CD011847-bbs2-0096" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We attempted to locate the protocols of the included randomised trials. We planned that if the protocol was available, we would compare the outcomes in the protocol and with those in the published report. If the protocol was not available, we compared the outcomes listed in the methods section of the trial report with the actual reported results. </p> </section> <section id="CD011847-sec-0107"> <h5 class="title">2. Funnel plots</h5> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of the results (<a href="./references#CD011847-bbs2-0087" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. ">Egger 1997</a>; <a href="./references#CD011847-bbs2-0096" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We are aware that funnel plots may be useful in investigating reporting biases, but are of limited power to detect small‐study effects. We did not use funnel plots for outcomes when there were 10 or fewer studies, or when all studies were of a similar size. In other cases, when funnel plots were possible, we planned to seek statistical advice for their interpretation. However, there were no outcomes for which there were more than 10 studies. </p> </section> </section> <section id="CD011847-sec-0108"> <h4 class="title">Data synthesis</h4> <p>We understand that there is no definitive argument that supports a preference for use of the fixed‐effect or the random‐effects model. The random‐effects method incorporates an assumption that the different studies are estimating different yet related intervention effects. This seems often to be true to us. Furthermore, the random‐effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random‐effects model, in that it gives added weight to small studies, which are often the most biased. Depending on the direction of the effect, these studies can either inflate or deflate the effect size. We chose the fixed‐effect model for all analyses. However, the reader can choose to inspect the data using the random‐effects model. </p> </section> <section id="CD011847-sec-0109"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD011847-sec-0110"> <h5 class="title">1. Secondary objectives</h5> <p>Our secondary objectives were to determine whether ECT produced a differential response in the following subgroups: </p> <p> <ul id="CD011847-list-0008"> <li> <p>people who were treated with unilateral compared with bilateral ECT;</p> </li> <li> <p>people who had a long (more than 12 months) versus a short course of ECT;</p> </li> <li> <p>people who were given continuation or maintenance ECT;</p> </li> <li> <p>people who were diagnosed with well‐defined treatment‐resistant schizophrenia as opposed to those with less rigorously defined treatment‐resistant schizophrenia. </p> </li> </ul> </p> <p>If the trials directly compared the techniques (e.g. people were randomised to unilateral or bilateral ECT), then we would present these data within the relevant comparison. We did not identify any study that directly compared techniques for inclusion in the review. However, if, within a comparison, data were reported on subgroups of people (e.g. within the unilateral‐versus‐bilateral comparison, data were presented for those who had a long course compared with those who had a shorter course), then we reported these subgroups. We did this only for the primary outcomes. </p> </section> <section id="CD011847-sec-0111"> <h5 class="title">2. Investigation of heterogeneity</h5> <p>If data were clearly heterogeneous, we checked that they had been extracted and entered correctly, and that no unit of analysis errors had occurred. If high levels of heterogeneity remained, we did not undertake a meta‐analysis at this point, as if there is considerable variation in results, and particularly inconsistency in the direction of effect, it may be misleading to quote an average value for the intervention effect. </p> <p>When unanticipated clinical or methodological heterogeneity was obvious, we would simply state hypotheses regarding this for future reviews or versions of this review. We did not anticipate undertaking future analyses related to this. </p> </section> </section> <section id="CD011847-sec-0112"> <h4 class="title">Sensitivity analysis</h4> <section id="CD011847-sec-0113"> <h5 class="title">1. Implication of randomisation</h5> <p>We planned to include trials in a sensitivity analysis if they were described in a way that implied randomisation. For the primary outcomes, we planned to include these studies. If there was no substantive difference when the implied randomised studies were added to those with a better description of randomisation, then we would use any relevant data from these studies. However, we did not identify any study with the above‐stated issues for inclusion in the review. </p> </section> <section id="CD011847-sec-0114"> <h5 class="title">2. Assumptions for lost binary data</h5> <p>For cases where assumptions had to be made regarding people lost to follow‐up (see <a href="#CD011847-sec-0092">Dealing with missing data</a>), we compared the findings of the primary outcomes when we used our assumptions and when we used data only from people who completed the study up to that point. If there was a substantial difference, we would report the results and discuss them but would continue to use our assumption. </p> <p>For cases where assumptions had to be made regarding missing SDs (see <a href="#CD011847-sec-0092">Dealing with missing data</a>), we planned to compare the findings of the primary outcomes when we used our assumptions and when we used data only from people who had completed the study up to that point. We planned to undertake a sensitivity analysis to test how prone the results were to change when only completer‐only data were compared with the imputed data using the above assumption. If there was a substantial difference, we would report results and discuss them, but would continue to use our assumption. However, we did not make any assumptions regarding missing SDs. </p> </section> <section id="CD011847-sec-0115"> <h5 class="title">3. Risk of bias</h5> <p>For the meta‐analysis of the primary outcome, we planned to analyse the effects of excluding trials that were judged to be at high risk of bias across one or more of the domains of randomisation (implied as randomised with no further details available) including allocation concealment, blinding, and outcome reporting. If the exclusion of trials at high risk of bias did not substantially alter the direction of the effect or the precision of the effect estimates, then we would include data from these trials in the analysis. This sensitivity analysis was not available because all the included studies were at high risk of bias in at least one domain. </p> </section> <section id="CD011847-sec-0116"> <h5 class="title">4. Imputed values</h5> <p>We also planned to undertake a sensitivity analysis to assess the effects of including data from trials for which we had used imputed values for ICC to calculate the design effect in cluster‐randomised trials. </p> <p>If we noted substantial differences in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we would not pool data from the excluded trials with the other trials contributing to the outcome, but would present them separately. </p> <p>However, we did not identify any studies with a cluster‐randomised design for inclusion in the review. </p> </section> <section id="CD011847-sec-0117"> <h5 class="title">5. Fixed‐effect versus random‐effects model</h5> <p>We analysed all the data using a fixed‐effect model; however, we also synthesised data for the primary outcome using a random‐effects model to evaluate whether this altered the significance of the result. </p> </section> <section id="CD011847-sec-0118"> <h5 class="title">6. Diagnostic criteria</h5> <p>We planned to undertake a sensitivity analysis to assess the effects of excluding trials in which participants did not have strictly diagnosed schizophrenia by international standards (ICD‐10, DSM‐III, DSM‐IV, DSM‐5, CCMD‐1, CCMD‐2, or CCMD‐3). If there was a substantial difference in our results, then we would report these differences and discuss them. The sensitivity analysis was not available because all included studies enrolled participants with strictly diagnosed schizophrenia by international standards. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011847-sec-0119" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011847-sec-0119"></div> <section id="CD011847-sec-0120"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD011847-sec-0343" title="">Characteristics of included studies</a>; <a href="./references#CD011847-sec-0344" title="">Characteristics of excluded studies</a>; <a href="./references#CD011847-sec-0345" title="">Characteristics of studies awaiting classification</a>; <a href="./references#CD011847-sec-0346" title="">Characteristics of ongoing studies</a>. </p> <section id="CD011847-sec-0121"> <h4 class="title">Results of the search</h4> <p>The initial search resulted in a total of 255 references that were identified from databases. We identified no additional references through other sources. After de‐duplication, 252 unique references remained. We excluded an additional 154 references upon inspection of the titles and abstracts. We read the remaining 73 studies (with 98 references) in full and subsequently excluded 49 studies (with 65 references) with reasons (further details are provided in <a href="#CD011847-fig-0001">Figure 1</a>). Six studies (with 8 references) are awaiting assessment, and three studies are ongoing. We included 15 studies (with 22 references) in the review. </p> <div class="figure" id="CD011847-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011847-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD011847-sec-0122"> <h4 class="title">Included studies</h4> <p>A total of 15 randomised controlled trials involving 1285 participants (1264 completers) met the inclusion criteria for this review. The sample sizes ranged from 31 to 246 (see <a href="./references#CD011847-sec-0343" title="">Characteristics of included studies</a>). </p> <section id="CD011847-sec-0123"> <h5 class="title">Participants</h5> <p>Most of the participants (n = 1164) were recruited from China (<a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a>; <a href="./references#CD011847-bbs2-0003" title="ChenDR . Controlled study on MECT for treatment‐resistant schizophrenia [无抽搐电休克治疗难治性精神分裂症的对照分析]. 新疆医学 [Xinjiang Medical Journal]2012;9:57‐60. [CSzG: Ref32661] ">Chen 2012</a>; <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>; <a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a>; <a href="./references#CD011847-bbs2-0007" title="LinK , ChenXM . Clinical effect on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果刍议]. Yiayao Qianyan [医药前沿]2014;19:202‐3. ">Lin 2014</a>; <a href="./references#CD011847-bbs2-0008" title="LiuFQ , GongGQ . The effect of MECT for treatment‐resistant schizophrenic patients [精神分裂症患者无抽搐电休克的效果]. China Modern Doctor [中国现代医生]2010;48(1):29, 36. [CSzG: Ref22012] ">Liu 2010</a>; <a href="./references#CD011847-bbs2-0010" title="WangBH , ZengDZ , FanXW , HuaSG . Efficacy of modified electroconvulsive therapy in treatment‐refractory schizophrenia [无抽搐电休克对难治性精神分裂症的增效作用]. 临床精神医学杂志 [Journal of Clinical Psychiatry]2008;18(6):415‐7. [CSzG: Ref17865] ">Wang 2008</a>; <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a>; <a href="./references#CD011847-bbs2-0012" title="WangF , GuoDW . The effect on olanzapine combined with modified electroconvulsive therapy in refractory schizophrenia [奥氮平联合改良电休克治疗难治性精神分裂症的疗效观察]. Clinical Rational Drug Use [临床合理用药杂志]2013;24:99. [CSzG: Ref27406] ">Wang 2013</a>; <a href="./references#CD011847-bbs2-0013" title="YangKJ , LiuTB , YangHC . The effect of clozapine combining MECT for the resistant schizophrenics with agitation and aggressive behavior. Medical Journal of Chinese People's Health [中国民康医学]2005;17(9):485‐6. [CSzG: Ref12755] ">Yang 2005</a>; <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a>; <a href="./references#CD011847-bbs2-0015" title="ZhangSR , ZhangJL , LiXZ , YangYP , LangSY . The effect of MECT combined with olanzapine for refractory schizophrenia [无抽搐电休克联合奥氮平治疗难治性精神分裂症疗效观察]. People's Military Surgeon [人民军医]2012;2:141‐3. [CSzG: Ref27071] ">Zhang 2012</a>). The remaining participants were recruited from India (n = 31; <a href="./references#CD011847-bbs2-0004" title="GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia syndrome: a double‐blind study. Indian Journal of Psychiatry2001; Vol. 43. [CSzG: Ref14832] GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia: a double‐blind study. Indian Journal of Psychiatry2003;45(1):26‐9. [CSzG: Ref14826] ">Goswami 2003</a>), Thailand (n = 51; <a href="./references#CD011847-bbs2-0002" title="ChanpattanaW . ECT in schizophrenia. Journal of the Psychiatric Association of Thailand1999;44(2):156‐70. [CSzG: Ref8163] ChanpattanaW , ChakrabhandML , KitaroonchaiW , ChoovanichvongS , PrasertsukY . Effects of twice‐ versus thrice‐weekly electroconvulsive therapy in schizophrenia. Journal of the Medical Association of Thailand1999;82(5):477‐82. ChanpattanaW , ChakrabhandML , SackeimHA , KitaroonchaiW , KongsakonR , TechakasemP , et al. Continuation ECT in treatment resistant schizophrenia: a controlled study. Journal of ECT1999;15(3):178‐92. [CSzG: Ref4913; MEDLINE: 10492856] ">Chanpattana 1999</a>), and the USA (n = 39; <a href="./references#CD011847-bbs2-0009" title="BragaRJ , MendelowitzAJ , FinkM , SchoolerNR , BailineSH , MalurC , et al. A randomized controlled trial of ECT in clozapine‐refractory schizophrenia. Biological Psychiatry2009;65(8):212S‐3S. [CSzG: Ref19511] PetridesG . ECT augmentation in clozapine‐resistant schizophrenia: acute efficacy and maintance data. Schizophrenia Bulletin2015;41:S328. [CSzG: Ref29626] PetridesG . Electroconvulsive therapy (ECT) for medication resistant schizophrenia. Schizophrenia Research2012;136:S22. [CSzG: Ref29625] PetridesG , GoldbergT , JohnM , BragaR , MalurC , MalhotraA , et al. Electroconvulsive therapy for clozapine‐resistant schizophrenia: cognitive effects. Neuropsychopharmacology2016;41:S257. [CSzG: Ref35678] PetridesG , MalurC , BragaRJ , BailineSH , SchoolerNR , MalhotraAK , et al. Electroconvulsive therapy augmentation in clozapine‐resistant schizophrenia: a prospective, randomized study. American Journal of Psychiatry2015;172(1):52‐8. [CSzG: Ref29366] ">Petrides 2015</a>). </p> <p>The age of the included participants ranged from 18 to 46 years; there were 704 males and 567 females. Three studies did not report the age and sex of the 14 participants who left early (<a href="./references#CD011847-bbs2-0002" title="ChanpattanaW . ECT in schizophrenia. Journal of the Psychiatric Association of Thailand1999;44(2):156‐70. [CSzG: Ref8163] ChanpattanaW , ChakrabhandML , KitaroonchaiW , ChoovanichvongS , PrasertsukY . Effects of twice‐ versus thrice‐weekly electroconvulsive therapy in schizophrenia. Journal of the Medical Association of Thailand1999;82(5):477‐82. ChanpattanaW , ChakrabhandML , SackeimHA , KitaroonchaiW , KongsakonR , TechakasemP , et al. Continuation ECT in treatment resistant schizophrenia: a controlled study. Journal of ECT1999;15(3):178‐92. [CSzG: Ref4913; MEDLINE: 10492856] ">Chanpattana 1999</a>; <a href="./references#CD011847-bbs2-0004" title="GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia syndrome: a double‐blind study. Indian Journal of Psychiatry2001; Vol. 43. [CSzG: Ref14832] GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia: a double‐blind study. Indian Journal of Psychiatry2003;45(1):26‐9. [CSzG: Ref14826] ">Goswami 2003</a>; <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>). The included participants were all diagnosed with treatment‐resistant schizophrenia by international standards, including CCMD‐2‐R, CCMD‐3, DSM‐IV, and ICD‐10. The average length of illness ranged from 6.3 to 18.6 years, while four studies (n = 287) did not report the average length of the illness (<a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a>; <a href="./references#CD011847-bbs2-0008" title="LiuFQ , GongGQ . The effect of MECT for treatment‐resistant schizophrenic patients [精神分裂症患者无抽搐电休克的效果]. China Modern Doctor [中国现代医生]2010;48(1):29, 36. [CSzG: Ref22012] ">Liu 2010</a>; <a href="./references#CD011847-bbs2-0009" title="BragaRJ , MendelowitzAJ , FinkM , SchoolerNR , BailineSH , MalurC , et al. A randomized controlled trial of ECT in clozapine‐refractory schizophrenia. Biological Psychiatry2009;65(8):212S‐3S. [CSzG: Ref19511] PetridesG . ECT augmentation in clozapine‐resistant schizophrenia: acute efficacy and maintance data. Schizophrenia Bulletin2015;41:S328. [CSzG: Ref29626] PetridesG . Electroconvulsive therapy (ECT) for medication resistant schizophrenia. Schizophrenia Research2012;136:S22. [CSzG: Ref29625] PetridesG , GoldbergT , JohnM , BragaR , MalurC , MalhotraA , et al. Electroconvulsive therapy for clozapine‐resistant schizophrenia: cognitive effects. Neuropsychopharmacology2016;41:S257. [CSzG: Ref35678] PetridesG , MalurC , BragaRJ , BailineSH , SchoolerNR , MalhotraAK , et al. Electroconvulsive therapy augmentation in clozapine‐resistant schizophrenia: a prospective, randomized study. American Journal of Psychiatry2015;172(1):52‐8. [CSzG: Ref29366] ">Petrides 2015</a>; <a href="./references#CD011847-bbs2-0010" title="WangBH , ZengDZ , FanXW , HuaSG . Efficacy of modified electroconvulsive therapy in treatment‐refractory schizophrenia [无抽搐电休克对难治性精神分裂症的增效作用]. 临床精神医学杂志 [Journal of Clinical Psychiatry]2008;18(6):415‐7. [CSzG: Ref17865] ">Wang 2008</a>). </p> </section> <section id="CD011847-sec-0124"> <h5 class="title">Interventions</h5> <p>In all 15 studies participants in the ECT group were given ECT or modified ECT (MECT) in addition to standard care (where standard care was an active intervention such as an antipsychotic given to all participants in both treatment groups). One of the studies, <a href="./references#CD011847-bbs2-0002" title="ChanpattanaW . ECT in schizophrenia. Journal of the Psychiatric Association of Thailand1999;44(2):156‐70. [CSzG: Ref8163] ChanpattanaW , ChakrabhandML , KitaroonchaiW , ChoovanichvongS , PrasertsukY . Effects of twice‐ versus thrice‐weekly electroconvulsive therapy in schizophrenia. Journal of the Medical Association of Thailand1999;82(5):477‐82. ChanpattanaW , ChakrabhandML , SackeimHA , KitaroonchaiW , KongsakonR , TechakasemP , et al. Continuation ECT in treatment resistant schizophrenia: a controlled study. Journal of ECT1999;15(3):178‐92. [CSzG: Ref4913; MEDLINE: 10492856] ">Chanpattana 1999</a>, had three treatment arms where in addition to the ECT arm, the study also had another treatment arm (n = 15) where ECT was given alone. Five studies (n = 439) reported the use of bilateral electrode placement (<a href="./references#CD011847-bbs2-0002" title="ChanpattanaW . ECT in schizophrenia. Journal of the Psychiatric Association of Thailand1999;44(2):156‐70. [CSzG: Ref8163] ChanpattanaW , ChakrabhandML , KitaroonchaiW , ChoovanichvongS , PrasertsukY . Effects of twice‐ versus thrice‐weekly electroconvulsive therapy in schizophrenia. Journal of the Medical Association of Thailand1999;82(5):477‐82. ChanpattanaW , ChakrabhandML , SackeimHA , KitaroonchaiW , KongsakonR , TechakasemP , et al. Continuation ECT in treatment resistant schizophrenia: a controlled study. Journal of ECT1999;15(3):178‐92. [CSzG: Ref4913; MEDLINE: 10492856] ">Chanpattana 1999</a>; <a href="./references#CD011847-bbs2-0004" title="GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia syndrome: a double‐blind study. Indian Journal of Psychiatry2001; Vol. 43. [CSzG: Ref14832] GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia: a double‐blind study. Indian Journal of Psychiatry2003;45(1):26‐9. [CSzG: Ref14826] ">Goswami 2003</a>; <a href="./references#CD011847-bbs2-0009" title="BragaRJ , MendelowitzAJ , FinkM , SchoolerNR , BailineSH , MalurC , et al. A randomized controlled trial of ECT in clozapine‐refractory schizophrenia. Biological Psychiatry2009;65(8):212S‐3S. [CSzG: Ref19511] PetridesG . ECT augmentation in clozapine‐resistant schizophrenia: acute efficacy and maintance data. Schizophrenia Bulletin2015;41:S328. [CSzG: Ref29626] PetridesG . Electroconvulsive therapy (ECT) for medication resistant schizophrenia. Schizophrenia Research2012;136:S22. [CSzG: Ref29625] PetridesG , GoldbergT , JohnM , BragaR , MalurC , MalhotraA , et al. Electroconvulsive therapy for clozapine‐resistant schizophrenia: cognitive effects. Neuropsychopharmacology2016;41:S257. [CSzG: Ref35678] PetridesG , MalurC , BragaRJ , BailineSH , SchoolerNR , MalhotraAK , et al. Electroconvulsive therapy augmentation in clozapine‐resistant schizophrenia: a prospective, randomized study. American Journal of Psychiatry2015;172(1):52‐8. [CSzG: Ref29366] ">Petrides 2015</a>; <a href="./references#CD011847-bbs2-0012" title="WangF , GuoDW . The effect on olanzapine combined with modified electroconvulsive therapy in refractory schizophrenia [奥氮平联合改良电休克治疗难治性精神分裂症的疗效观察]. Clinical Rational Drug Use [临床合理用药杂志]2013;24:99. [CSzG: Ref27406] ">Wang 2013</a>; <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a>), while the placement was unclear in the remaining studies. Ten studies (n = 787) used a short course (6 to 12 ECT sessions) of ECT (<a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a>; <a href="./references#CD011847-bbs2-0003" title="ChenDR . Controlled study on MECT for treatment‐resistant schizophrenia [无抽搐电休克治疗难治性精神分裂症的对照分析]. 新疆医学 [Xinjiang Medical Journal]2012;9:57‐60. [CSzG: Ref32661] ">Chen 2012</a>; <a href="./references#CD011847-bbs2-0004" title="GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia syndrome: a double‐blind study. Indian Journal of Psychiatry2001; Vol. 43. [CSzG: Ref14832] GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia: a double‐blind study. Indian Journal of Psychiatry2003;45(1):26‐9. [CSzG: Ref14826] ">Goswami 2003</a>; <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>; <a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a>; <a href="./references#CD011847-bbs2-0008" title="LiuFQ , GongGQ . The effect of MECT for treatment‐resistant schizophrenic patients [精神分裂症患者无抽搐电休克的效果]. China Modern Doctor [中国现代医生]2010;48(1):29, 36. [CSzG: Ref22012] ">Liu 2010</a>; <a href="./references#CD011847-bbs2-0010" title="WangBH , ZengDZ , FanXW , HuaSG . Efficacy of modified electroconvulsive therapy in treatment‐refractory schizophrenia [无抽搐电休克对难治性精神分裂症的增效作用]. 临床精神医学杂志 [Journal of Clinical Psychiatry]2008;18(6):415‐7. [CSzG: Ref17865] ">Wang 2008</a>; <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a>; <a href="./references#CD011847-bbs2-0012" title="WangF , GuoDW . The effect on olanzapine combined with modified electroconvulsive therapy in refractory schizophrenia [奥氮平联合改良电休克治疗难治性精神分裂症的疗效观察]. Clinical Rational Drug Use [临床合理用药杂志]2013;24:99. [CSzG: Ref27406] ">Wang 2013</a>; <a href="./references#CD011847-bbs2-0013" title="YangKJ , LiuTB , YangHC . The effect of clozapine combining MECT for the resistant schizophrenics with agitation and aggressive behavior. Medical Journal of Chinese People's Health [中国民康医学]2005;17(9):485‐6. [CSzG: Ref12755] ">Yang 2005</a>); four studies (n = 420) used a long course (14 to 20 sessions) (<a href="./references#CD011847-bbs2-0002" title="ChanpattanaW . ECT in schizophrenia. Journal of the Psychiatric Association of Thailand1999;44(2):156‐70. [CSzG: Ref8163] ChanpattanaW , ChakrabhandML , KitaroonchaiW , ChoovanichvongS , PrasertsukY . Effects of twice‐ versus thrice‐weekly electroconvulsive therapy in schizophrenia. Journal of the Medical Association of Thailand1999;82(5):477‐82. ChanpattanaW , ChakrabhandML , SackeimHA , KitaroonchaiW , KongsakonR , TechakasemP , et al. Continuation ECT in treatment resistant schizophrenia: a controlled study. Journal of ECT1999;15(3):178‐92. [CSzG: Ref4913; MEDLINE: 10492856] ">Chanpattana 1999</a>; <a href="./references#CD011847-bbs2-0009" title="BragaRJ , MendelowitzAJ , FinkM , SchoolerNR , BailineSH , MalurC , et al. A randomized controlled trial of ECT in clozapine‐refractory schizophrenia. Biological Psychiatry2009;65(8):212S‐3S. [CSzG: Ref19511] PetridesG . ECT augmentation in clozapine‐resistant schizophrenia: acute efficacy and maintance data. Schizophrenia Bulletin2015;41:S328. [CSzG: Ref29626] PetridesG . Electroconvulsive therapy (ECT) for medication resistant schizophrenia. Schizophrenia Research2012;136:S22. [CSzG: Ref29625] PetridesG , GoldbergT , JohnM , BragaR , MalurC , MalhotraA , et al. Electroconvulsive therapy for clozapine‐resistant schizophrenia: cognitive effects. Neuropsychopharmacology2016;41:S257. [CSzG: Ref35678] PetridesG , MalurC , BragaRJ , BailineSH , SchoolerNR , MalhotraAK , et al. Electroconvulsive therapy augmentation in clozapine‐resistant schizophrenia: a prospective, randomized study. American Journal of Psychiatry2015;172(1):52‐8. [CSzG: Ref29366] ">Petrides 2015</a>; <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a>; <a href="./references#CD011847-bbs2-0015" title="ZhangSR , ZhangJL , LiXZ , YangYP , LangSY . The effect of MECT combined with olanzapine for refractory schizophrenia [无抽搐电休克联合奥氮平治疗难治性精神分裂症疗效观察]. People's Military Surgeon [人民军医]2012;2:141‐3. [CSzG: Ref27071] ">Zhang 2012</a>), while <a href="./references#CD011847-bbs2-0007" title="LinK , ChenXM . Clinical effect on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果刍议]. Yiayao Qianyan [医药前沿]2014;19:202‐3. ">Lin 2014</a> (n = 78) did not report the course of ECT. Five studies (n = 335) used ECT three times a week (<a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a>; <a href="./references#CD011847-bbs2-0004" title="GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia syndrome: a double‐blind study. Indian Journal of Psychiatry2001; Vol. 43. [CSzG: Ref14832] GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia: a double‐blind study. Indian Journal of Psychiatry2003;45(1):26‐9. [CSzG: Ref14826] ">Goswami 2003</a>; <a href="./references#CD011847-bbs2-0008" title="LiuFQ , GongGQ . The effect of MECT for treatment‐resistant schizophrenic patients [精神分裂症患者无抽搐电休克的效果]. China Modern Doctor [中国现代医生]2010;48(1):29, 36. [CSzG: Ref22012] ">Liu 2010</a>; <a href="./references#CD011847-bbs2-0012" title="WangF , GuoDW . The effect on olanzapine combined with modified electroconvulsive therapy in refractory schizophrenia [奥氮平联合改良电休克治疗难治性精神分裂症的疗效观察]. Clinical Rational Drug Use [临床合理用药杂志]2013;24:99. [CSzG: Ref27406] ">Wang 2013</a>; <a href="./references#CD011847-bbs2-0013" title="YangKJ , LiuTB , YangHC . The effect of clozapine combining MECT for the resistant schizophrenics with agitation and aggressive behavior. Medical Journal of Chinese People's Health [中国民康医学]2005;17(9):485‐6. [CSzG: Ref12755] ">Yang 2005</a>), and one study (n = 76) used ECT once every other day (<a href="./references#CD011847-bbs2-0010" title="WangBH , ZengDZ , FanXW , HuaSG . Efficacy of modified electroconvulsive therapy in treatment‐refractory schizophrenia [无抽搐电休克对难治性精神分裂症的增效作用]. 临床精神医学杂志 [Journal of Clinical Psychiatry]2008;18(6):415‐7. [CSzG: Ref17865] ">Wang 2008</a>). Eight studies (n = 796) did not use ECT with a unique frequency within the treatment period (<a href="./references#CD011847-bbs2-0002" title="ChanpattanaW . ECT in schizophrenia. Journal of the Psychiatric Association of Thailand1999;44(2):156‐70. [CSzG: Ref8163] ChanpattanaW , ChakrabhandML , KitaroonchaiW , ChoovanichvongS , PrasertsukY . Effects of twice‐ versus thrice‐weekly electroconvulsive therapy in schizophrenia. Journal of the Medical Association of Thailand1999;82(5):477‐82. ChanpattanaW , ChakrabhandML , SackeimHA , KitaroonchaiW , KongsakonR , TechakasemP , et al. Continuation ECT in treatment resistant schizophrenia: a controlled study. Journal of ECT1999;15(3):178‐92. [CSzG: Ref4913; MEDLINE: 10492856] ">Chanpattana 1999</a>; <a href="./references#CD011847-bbs2-0003" title="ChenDR . Controlled study on MECT for treatment‐resistant schizophrenia [无抽搐电休克治疗难治性精神分裂症的对照分析]. 新疆医学 [Xinjiang Medical Journal]2012;9:57‐60. [CSzG: Ref32661] ">Chen 2012</a>; <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>; <a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a>; <a href="./references#CD011847-bbs2-0009" title="BragaRJ , MendelowitzAJ , FinkM , SchoolerNR , BailineSH , MalurC , et al. A randomized controlled trial of ECT in clozapine‐refractory schizophrenia. Biological Psychiatry2009;65(8):212S‐3S. [CSzG: Ref19511] PetridesG . ECT augmentation in clozapine‐resistant schizophrenia: acute efficacy and maintance data. Schizophrenia Bulletin2015;41:S328. [CSzG: Ref29626] PetridesG . Electroconvulsive therapy (ECT) for medication resistant schizophrenia. Schizophrenia Research2012;136:S22. [CSzG: Ref29625] PetridesG , GoldbergT , JohnM , BragaR , MalurC , MalhotraA , et al. Electroconvulsive therapy for clozapine‐resistant schizophrenia: cognitive effects. Neuropsychopharmacology2016;41:S257. [CSzG: Ref35678] PetridesG , MalurC , BragaRJ , BailineSH , SchoolerNR , MalhotraAK , et al. Electroconvulsive therapy augmentation in clozapine‐resistant schizophrenia: a prospective, randomized study. American Journal of Psychiatry2015;172(1):52‐8. [CSzG: Ref29366] ">Petrides 2015</a>; <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a>; <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a>; <a href="./references#CD011847-bbs2-0015" title="ZhangSR , ZhangJL , LiXZ , YangYP , LangSY . The effect of MECT combined with olanzapine for refractory schizophrenia [无抽搐电休克联合奥氮平治疗难治性精神分裂症疗效观察]. People's Military Surgeon [人民军医]2012;2:141‐3. [CSzG: Ref27071] ">Zhang 2012</a>); of these, most studies used ECT three times a week for two to four weeks, then once or twice a week for the subsequent weeks. The remaining study (n = 78) did not report information on frequency (<a href="./references#CD011847-bbs2-0007" title="LinK , ChenXM . Clinical effect on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果刍议]. Yiayao Qianyan [医药前沿]2014;19:202‐3. ">Lin 2014</a>). </p> <p>The included studies did not cover all predefined comparisons in our protocol; only the following comparisons were involved: </p> <p> <ul id="CD011847-list-0009"> <li> <p>ECT plus standard care versus sham‐ECT plus standard care (one study, <a href="./references#CD011847-bbs2-0004" title="GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia syndrome: a double‐blind study. Indian Journal of Psychiatry2001; Vol. 43. [CSzG: Ref14832] GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia: a double‐blind study. Indian Journal of Psychiatry2003;45(1):26‐9. [CSzG: Ref14826] ">Goswami 2003</a>; chlorpromazine used as the standard care); </p> </li> <li> <p>ECT plus standard care versus clozapine plus standard care (one study, <a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a>; ziprasidone used as the standard care); </p> </li> <li> <p>ECT plus standard care versus standard care (13 studies, <a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a>; <a href="./references#CD011847-bbs2-0002" title="ChanpattanaW . ECT in schizophrenia. Journal of the Psychiatric Association of Thailand1999;44(2):156‐70. [CSzG: Ref8163] ChanpattanaW , ChakrabhandML , KitaroonchaiW , ChoovanichvongS , PrasertsukY . Effects of twice‐ versus thrice‐weekly electroconvulsive therapy in schizophrenia. Journal of the Medical Association of Thailand1999;82(5):477‐82. ChanpattanaW , ChakrabhandML , SackeimHA , KitaroonchaiW , KongsakonR , TechakasemP , et al. Continuation ECT in treatment resistant schizophrenia: a controlled study. Journal of ECT1999;15(3):178‐92. [CSzG: Ref4913; MEDLINE: 10492856] ">Chanpattana 1999</a>; <a href="./references#CD011847-bbs2-0003" title="ChenDR . Controlled study on MECT for treatment‐resistant schizophrenia [无抽搐电休克治疗难治性精神分裂症的对照分析]. 新疆医学 [Xinjiang Medical Journal]2012;9:57‐60. [CSzG: Ref32661] ">Chen 2012</a>; <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>; <a href="./references#CD011847-bbs2-0007" title="LinK , ChenXM . Clinical effect on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果刍议]. Yiayao Qianyan [医药前沿]2014;19:202‐3. ">Lin 2014</a>; <a href="./references#CD011847-bbs2-0008" title="LiuFQ , GongGQ . The effect of MECT for treatment‐resistant schizophrenic patients [精神分裂症患者无抽搐电休克的效果]. China Modern Doctor [中国现代医生]2010;48(1):29, 36. [CSzG: Ref22012] ">Liu 2010</a>; <a href="./references#CD011847-bbs2-0009" title="BragaRJ , MendelowitzAJ , FinkM , SchoolerNR , BailineSH , MalurC , et al. A randomized controlled trial of ECT in clozapine‐refractory schizophrenia. Biological Psychiatry2009;65(8):212S‐3S. [CSzG: Ref19511] PetridesG . ECT augmentation in clozapine‐resistant schizophrenia: acute efficacy and maintance data. Schizophrenia Bulletin2015;41:S328. [CSzG: Ref29626] PetridesG . Electroconvulsive therapy (ECT) for medication resistant schizophrenia. Schizophrenia Research2012;136:S22. [CSzG: Ref29625] PetridesG , GoldbergT , JohnM , BragaR , MalurC , MalhotraA , et al. Electroconvulsive therapy for clozapine‐resistant schizophrenia: cognitive effects. Neuropsychopharmacology2016;41:S257. [CSzG: Ref35678] PetridesG , MalurC , BragaRJ , BailineSH , SchoolerNR , MalhotraAK , et al. Electroconvulsive therapy augmentation in clozapine‐resistant schizophrenia: a prospective, randomized study. American Journal of Psychiatry2015;172(1):52‐8. [CSzG: Ref29366] ">Petrides 2015</a>; <a href="./references#CD011847-bbs2-0010" title="WangBH , ZengDZ , FanXW , HuaSG . Efficacy of modified electroconvulsive therapy in treatment‐refractory schizophrenia [无抽搐电休克对难治性精神分裂症的增效作用]. 临床精神医学杂志 [Journal of Clinical Psychiatry]2008;18(6):415‐7. [CSzG: Ref17865] ">Wang 2008</a>; <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a>; <a href="./references#CD011847-bbs2-0012" title="WangF , GuoDW . The effect on olanzapine combined with modified electroconvulsive therapy in refractory schizophrenia [奥氮平联合改良电休克治疗难治性精神分裂症的疗效观察]. Clinical Rational Drug Use [临床合理用药杂志]2013;24:99. [CSzG: Ref27406] ">Wang 2013</a>; <a href="./references#CD011847-bbs2-0013" title="YangKJ , LiuTB , YangHC . The effect of clozapine combining MECT for the resistant schizophrenics with agitation and aggressive behavior. Medical Journal of Chinese People's Health [中国民康医学]2005;17(9):485‐6. [CSzG: Ref12755] ">Yang 2005</a>; <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a>; <a href="./references#CD011847-bbs2-0015" title="ZhangSR , ZhangJL , LiXZ , YangYP , LangSY . The effect of MECT combined with olanzapine for refractory schizophrenia [无抽搐电休克联合奥氮平治疗难治性精神分裂症疗效观察]. People's Military Surgeon [人民军医]2012;2:141‐3. [CSzG: Ref27071] ">Zhang 2012</a>; various antipsychotics used as the standard care across treatment groups, including clozapine, olanzapine, risperidone, chlorpromazine, perphenazine, flupenthixol, and ziprasidone); </p> </li> <li> <p>ECT alone versus flupenthixol alone (one study, <a href="./references#CD011847-bbs2-0002" title="ChanpattanaW . ECT in schizophrenia. Journal of the Psychiatric Association of Thailand1999;44(2):156‐70. [CSzG: Ref8163] ChanpattanaW , ChakrabhandML , KitaroonchaiW , ChoovanichvongS , PrasertsukY . Effects of twice‐ versus thrice‐weekly electroconvulsive therapy in schizophrenia. Journal of the Medical Association of Thailand1999;82(5):477‐82. ChanpattanaW , ChakrabhandML , SackeimHA , KitaroonchaiW , KongsakonR , TechakasemP , et al. Continuation ECT in treatment resistant schizophrenia: a controlled study. Journal of ECT1999;15(3):178‐92. [CSzG: Ref4913; MEDLINE: 10492856] ">Chanpattana 1999</a>). </p> </li> </ul> </p> <p>The treatment duration of the included studies ranged from 2 weeks, in <a href="./references#CD011847-bbs2-0004" title="GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia syndrome: a double‐blind study. Indian Journal of Psychiatry2001; Vol. 43. [CSzG: Ref14832] GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia: a double‐blind study. Indian Journal of Psychiatry2003;45(1):26‐9. [CSzG: Ref14826] ">Goswami 2003</a>, to 24 weeks, in <a href="./references#CD011847-bbs2-0002" title="ChanpattanaW . ECT in schizophrenia. Journal of the Psychiatric Association of Thailand1999;44(2):156‐70. [CSzG: Ref8163] ChanpattanaW , ChakrabhandML , KitaroonchaiW , ChoovanichvongS , PrasertsukY . Effects of twice‐ versus thrice‐weekly electroconvulsive therapy in schizophrenia. Journal of the Medical Association of Thailand1999;82(5):477‐82. ChanpattanaW , ChakrabhandML , SackeimHA , KitaroonchaiW , KongsakonR , TechakasemP , et al. Continuation ECT in treatment resistant schizophrenia: a controlled study. Journal of ECT1999;15(3):178‐92. [CSzG: Ref4913; MEDLINE: 10492856] ">Chanpattana 1999</a>. The treatment duration in the other studies was 4 weeks (<a href="./references#CD011847-bbs2-0008" title="LiuFQ , GongGQ . The effect of MECT for treatment‐resistant schizophrenic patients [精神分裂症患者无抽搐电休克的效果]. China Modern Doctor [中国现代医生]2010;48(1):29, 36. [CSzG: Ref22012] ">Liu 2010</a>; <a href="./references#CD011847-bbs2-0012" title="WangF , GuoDW . The effect on olanzapine combined with modified electroconvulsive therapy in refractory schizophrenia [奥氮平联合改良电休克治疗难治性精神分裂症的疗效观察]. Clinical Rational Drug Use [临床合理用药杂志]2013;24:99. [CSzG: Ref27406] ">Wang 2013</a>), 8 weeks (<a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a>; <a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a>; <a href="./references#CD011847-bbs2-0007" title="LinK , ChenXM . Clinical effect on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果刍议]. Yiayao Qianyan [医药前沿]2014;19:202‐3. ">Lin 2014</a>; <a href="./references#CD011847-bbs2-0009" title="BragaRJ , MendelowitzAJ , FinkM , SchoolerNR , BailineSH , MalurC , et al. A randomized controlled trial of ECT in clozapine‐refractory schizophrenia. Biological Psychiatry2009;65(8):212S‐3S. [CSzG: Ref19511] PetridesG . ECT augmentation in clozapine‐resistant schizophrenia: acute efficacy and maintance data. Schizophrenia Bulletin2015;41:S328. [CSzG: Ref29626] PetridesG . Electroconvulsive therapy (ECT) for medication resistant schizophrenia. Schizophrenia Research2012;136:S22. [CSzG: Ref29625] PetridesG , GoldbergT , JohnM , BragaR , MalurC , MalhotraA , et al. Electroconvulsive therapy for clozapine‐resistant schizophrenia: cognitive effects. Neuropsychopharmacology2016;41:S257. [CSzG: Ref35678] PetridesG , MalurC , BragaRJ , BailineSH , SchoolerNR , MalhotraAK , et al. Electroconvulsive therapy augmentation in clozapine‐resistant schizophrenia: a prospective, randomized study. American Journal of Psychiatry2015;172(1):52‐8. [CSzG: Ref29366] ">Petrides 2015</a>; <a href="./references#CD011847-bbs2-0013" title="YangKJ , LiuTB , YangHC . The effect of clozapine combining MECT for the resistant schizophrenics with agitation and aggressive behavior. Medical Journal of Chinese People's Health [中国民康医学]2005;17(9):485‐6. [CSzG: Ref12755] ">Yang 2005</a>; <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a>; <a href="./references#CD011847-bbs2-0015" title="ZhangSR , ZhangJL , LiXZ , YangYP , LangSY . The effect of MECT combined with olanzapine for refractory schizophrenia [无抽搐电休克联合奥氮平治疗难治性精神分裂症疗效观察]. People's Military Surgeon [人民军医]2012;2:141‐3. [CSzG: Ref27071] ">Zhang 2012</a>), or 12 weeks (<a href="./references#CD011847-bbs2-0003" title="ChenDR . Controlled study on MECT for treatment‐resistant schizophrenia [无抽搐电休克治疗难治性精神分裂症的对照分析]. 新疆医学 [Xinjiang Medical Journal]2012;9:57‐60. [CSzG: Ref32661] ">Chen 2012</a>; <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>; <a href="./references#CD011847-bbs2-0010" title="WangBH , ZengDZ , FanXW , HuaSG . Efficacy of modified electroconvulsive therapy in treatment‐refractory schizophrenia [无抽搐电休克对难治性精神分裂症的增效作用]. 临床精神医学杂志 [Journal of Clinical Psychiatry]2008;18(6):415‐7. [CSzG: Ref17865] ">Wang 2008</a>; <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a>). </p> </section> <section id="CD011847-sec-0125"> <h5 class="title">Primary outcomes</h5> <section id="CD011847-sec-0126"> <h6 class="title">1. Response to treatment</h6> <p>Eleven studies reported the response to treatment. One study reported the short‐term outcome (<a href="./references#CD011847-bbs2-0012" title="WangF , GuoDW . The effect on olanzapine combined with modified electroconvulsive therapy in refractory schizophrenia [奥氮平联合改良电休克治疗难治性精神分裂症的疗效观察]. Clinical Rational Drug Use [临床合理用药杂志]2013;24:99. [CSzG: Ref27406] ">Wang 2013</a>), while the other studies reported the medium‐term outcome (<a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a>; <a href="./references#CD011847-bbs2-0003" title="ChenDR . Controlled study on MECT for treatment‐resistant schizophrenia [无抽搐电休克治疗难治性精神分裂症的对照分析]. 新疆医学 [Xinjiang Medical Journal]2012;9:57‐60. [CSzG: Ref32661] ">Chen 2012</a>; <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>; <a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a>; <a href="./references#CD011847-bbs2-0009" title="BragaRJ , MendelowitzAJ , FinkM , SchoolerNR , BailineSH , MalurC , et al. A randomized controlled trial of ECT in clozapine‐refractory schizophrenia. Biological Psychiatry2009;65(8):212S‐3S. [CSzG: Ref19511] PetridesG . ECT augmentation in clozapine‐resistant schizophrenia: acute efficacy and maintance data. Schizophrenia Bulletin2015;41:S328. [CSzG: Ref29626] PetridesG . Electroconvulsive therapy (ECT) for medication resistant schizophrenia. Schizophrenia Research2012;136:S22. [CSzG: Ref29625] PetridesG , GoldbergT , JohnM , BragaR , MalurC , MalhotraA , et al. Electroconvulsive therapy for clozapine‐resistant schizophrenia: cognitive effects. Neuropsychopharmacology2016;41:S257. [CSzG: Ref35678] PetridesG , MalurC , BragaRJ , BailineSH , SchoolerNR , MalhotraAK , et al. Electroconvulsive therapy augmentation in clozapine‐resistant schizophrenia: a prospective, randomized study. American Journal of Psychiatry2015;172(1):52‐8. [CSzG: Ref29366] ">Petrides 2015</a>; <a href="./references#CD011847-bbs2-0010" title="WangBH , ZengDZ , FanXW , HuaSG . Efficacy of modified electroconvulsive therapy in treatment‐refractory schizophrenia [无抽搐电休克对难治性精神分裂症的增效作用]. 临床精神医学杂志 [Journal of Clinical Psychiatry]2008;18(6):415‐7. [CSzG: Ref17865] ">Wang 2008</a>; <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a>; <a href="./references#CD011847-bbs2-0013" title="YangKJ , LiuTB , YangHC . The effect of clozapine combining MECT for the resistant schizophrenics with agitation and aggressive behavior. Medical Journal of Chinese People's Health [中国民康医学]2005;17(9):485‐6. [CSzG: Ref12755] ">Yang 2005</a>; <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a>; <a href="./references#CD011847-bbs2-0015" title="ZhangSR , ZhangJL , LiXZ , YangYP , LangSY . The effect of MECT combined with olanzapine for refractory schizophrenia [无抽搐电休克联合奥氮平治疗难治性精神分裂症疗效观察]. People's Military Surgeon [人民军医]2012;2:141‐3. [CSzG: Ref27071] ">Zhang 2012</a>). The clinically significant response in all studies (except for <a href="./references#CD011847-bbs2-0009" title="BragaRJ , MendelowitzAJ , FinkM , SchoolerNR , BailineSH , MalurC , et al. A randomized controlled trial of ECT in clozapine‐refractory schizophrenia. Biological Psychiatry2009;65(8):212S‐3S. [CSzG: Ref19511] PetridesG . ECT augmentation in clozapine‐resistant schizophrenia: acute efficacy and maintance data. Schizophrenia Bulletin2015;41:S328. [CSzG: Ref29626] PetridesG . Electroconvulsive therapy (ECT) for medication resistant schizophrenia. Schizophrenia Research2012;136:S22. [CSzG: Ref29625] PetridesG , GoldbergT , JohnM , BragaR , MalurC , MalhotraA , et al. Electroconvulsive therapy for clozapine‐resistant schizophrenia: cognitive effects. Neuropsychopharmacology2016;41:S257. [CSzG: Ref35678] PetridesG , MalurC , BragaRJ , BailineSH , SchoolerNR , MalhotraAK , et al. Electroconvulsive therapy augmentation in clozapine‐resistant schizophrenia: a prospective, randomized study. American Journal of Psychiatry2015;172(1):52‐8. [CSzG: Ref29366] ">Petrides 2015</a>) was defined as a 50% reduction in the BPRS or PANSS scores. The response criterion in <a href="./references#CD011847-bbs2-0009" title="BragaRJ , MendelowitzAJ , FinkM , SchoolerNR , BailineSH , MalurC , et al. A randomized controlled trial of ECT in clozapine‐refractory schizophrenia. Biological Psychiatry2009;65(8):212S‐3S. [CSzG: Ref19511] PetridesG . ECT augmentation in clozapine‐resistant schizophrenia: acute efficacy and maintance data. Schizophrenia Bulletin2015;41:S328. [CSzG: Ref29626] PetridesG . Electroconvulsive therapy (ECT) for medication resistant schizophrenia. Schizophrenia Research2012;136:S22. [CSzG: Ref29625] PetridesG , GoldbergT , JohnM , BragaR , MalurC , MalhotraA , et al. Electroconvulsive therapy for clozapine‐resistant schizophrenia: cognitive effects. Neuropsychopharmacology2016;41:S257. [CSzG: Ref35678] PetridesG , MalurC , BragaRJ , BailineSH , SchoolerNR , MalhotraAK , et al. Electroconvulsive therapy augmentation in clozapine‐resistant schizophrenia: a prospective, randomized study. American Journal of Psychiatry2015;172(1):52‐8. [CSzG: Ref29366] ">Petrides 2015</a> was defined as ≥ 40% improvement based on the psychotic symptom sub scale (PSYRATS), a Clinical Global Impression (CGI)‐severity rating of mild or less (&lt; 3), and a CGI‐improvement rating of much improved (≤ 2). </p> </section> <section id="CD011847-sec-0127"> <h6 class="title">2. Cognitive functioning</h6> <p>No study reported a clinically important change in participants' cognitive functioning. One study reported the incidence of short‐term memory deterioration (<a href="./references#CD011847-bbs2-0012" title="WangF , GuoDW . The effect on olanzapine combined with modified electroconvulsive therapy in refractory schizophrenia [奥氮平联合改良电休克治疗难治性精神分裂症的疗效观察]. Clinical Rational Drug Use [临床合理用药杂志]2013;24:99. [CSzG: Ref27406] ">Wang 2013</a>). Two studies reported the average endpoint cognitive functioning scores (<a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>; <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a>). The following scales were used in this review. </p> <p> <ul id="CD011847-list-0010"> <li> <p>Wechsler Memory Scale (WMS): a neuropsychological test designed to measure different memory functions. Higher scores indicate better memory. </p> </li> <li> <p>Wisconsin Card Sorting Test (WCST): a neuropsychological test of the ability to display flexibility in the face of changing schedules of reinforcement. </p> </li> </ul> </p> </section> </section> <section id="CD011847-sec-0128"> <h5 class="title">Secondary outcomes</h5> <section id="CD011847-sec-0129"> <h6 class="title">1. Satisfaction and acceptability of treatment</h6> <p>Three studies reported the number of participants who left the study early (<a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>; <a href="./references#CD011847-bbs2-0009" title="BragaRJ , MendelowitzAJ , FinkM , SchoolerNR , BailineSH , MalurC , et al. A randomized controlled trial of ECT in clozapine‐refractory schizophrenia. Biological Psychiatry2009;65(8):212S‐3S. [CSzG: Ref19511] PetridesG . ECT augmentation in clozapine‐resistant schizophrenia: acute efficacy and maintance data. Schizophrenia Bulletin2015;41:S328. [CSzG: Ref29626] PetridesG . Electroconvulsive therapy (ECT) for medication resistant schizophrenia. Schizophrenia Research2012;136:S22. [CSzG: Ref29625] PetridesG , GoldbergT , JohnM , BragaR , MalurC , MalhotraA , et al. Electroconvulsive therapy for clozapine‐resistant schizophrenia: cognitive effects. Neuropsychopharmacology2016;41:S257. [CSzG: Ref35678] PetridesG , MalurC , BragaRJ , BailineSH , SchoolerNR , MalhotraAK , et al. Electroconvulsive therapy augmentation in clozapine‐resistant schizophrenia: a prospective, randomized study. American Journal of Psychiatry2015;172(1):52‐8. [CSzG: Ref29366] ">Petrides 2015</a>; <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a>). </p> </section> <section id="CD011847-sec-0130"> <h6 class="title">2. Mental state</h6> <p>No study reported a clinically important change in participants' general mental state. Twelve studies reported the average endpoint general mental state scores (<a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a>; <a href="./references#CD011847-bbs2-0002" title="ChanpattanaW . ECT in schizophrenia. Journal of the Psychiatric Association of Thailand1999;44(2):156‐70. [CSzG: Ref8163] ChanpattanaW , ChakrabhandML , KitaroonchaiW , ChoovanichvongS , PrasertsukY . Effects of twice‐ versus thrice‐weekly electroconvulsive therapy in schizophrenia. Journal of the Medical Association of Thailand1999;82(5):477‐82. ChanpattanaW , ChakrabhandML , SackeimHA , KitaroonchaiW , KongsakonR , TechakasemP , et al. Continuation ECT in treatment resistant schizophrenia: a controlled study. Journal of ECT1999;15(3):178‐92. [CSzG: Ref4913; MEDLINE: 10492856] ">Chanpattana 1999</a>; <a href="./references#CD011847-bbs2-0003" title="ChenDR . Controlled study on MECT for treatment‐resistant schizophrenia [无抽搐电休克治疗难治性精神分裂症的对照分析]. 新疆医学 [Xinjiang Medical Journal]2012;9:57‐60. [CSzG: Ref32661] ">Chen 2012</a>; <a href="./references#CD011847-bbs2-0004" title="GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia syndrome: a double‐blind study. Indian Journal of Psychiatry2001; Vol. 43. [CSzG: Ref14832] GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia: a double‐blind study. Indian Journal of Psychiatry2003;45(1):26‐9. [CSzG: Ref14826] ">Goswami 2003</a>; <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>; <a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a>; <a href="./references#CD011847-bbs2-0009" title="BragaRJ , MendelowitzAJ , FinkM , SchoolerNR , BailineSH , MalurC , et al. A randomized controlled trial of ECT in clozapine‐refractory schizophrenia. Biological Psychiatry2009;65(8):212S‐3S. [CSzG: Ref19511] PetridesG . ECT augmentation in clozapine‐resistant schizophrenia: acute efficacy and maintance data. Schizophrenia Bulletin2015;41:S328. [CSzG: Ref29626] PetridesG . Electroconvulsive therapy (ECT) for medication resistant schizophrenia. Schizophrenia Research2012;136:S22. [CSzG: Ref29625] PetridesG , GoldbergT , JohnM , BragaR , MalurC , MalhotraA , et al. Electroconvulsive therapy for clozapine‐resistant schizophrenia: cognitive effects. Neuropsychopharmacology2016;41:S257. [CSzG: Ref35678] PetridesG , MalurC , BragaRJ , BailineSH , SchoolerNR , MalhotraAK , et al. Electroconvulsive therapy augmentation in clozapine‐resistant schizophrenia: a prospective, randomized study. American Journal of Psychiatry2015;172(1):52‐8. [CSzG: Ref29366] ">Petrides 2015</a>; <a href="./references#CD011847-bbs2-0010" title="WangBH , ZengDZ , FanXW , HuaSG . Efficacy of modified electroconvulsive therapy in treatment‐refractory schizophrenia [无抽搐电休克对难治性精神分裂症的增效作用]. 临床精神医学杂志 [Journal of Clinical Psychiatry]2008;18(6):415‐7. [CSzG: Ref17865] ">Wang 2008</a>; <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a>; <a href="./references#CD011847-bbs2-0013" title="YangKJ , LiuTB , YangHC . The effect of clozapine combining MECT for the resistant schizophrenics with agitation and aggressive behavior. Medical Journal of Chinese People's Health [中国民康医学]2005;17(9):485‐6. [CSzG: Ref12755] ">Yang 2005</a>; <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a>; <a href="./references#CD011847-bbs2-0015" title="ZhangSR , ZhangJL , LiXZ , YangYP , LangSY . The effect of MECT combined with olanzapine for refractory schizophrenia [无抽搐电休克联合奥氮平治疗难治性精神分裂症疗效观察]. People's Military Surgeon [人民军医]2012;2:141‐3. [CSzG: Ref27071] ">Zhang 2012</a>), and 13 studies reported average endpoint specific symptom scores (<a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a>; <a href="./references#CD011847-bbs2-0003" title="ChenDR . Controlled study on MECT for treatment‐resistant schizophrenia [无抽搐电休克治疗难治性精神分裂症的对照分析]. 新疆医学 [Xinjiang Medical Journal]2012;9:57‐60. [CSzG: Ref32661] ">Chen 2012</a>; <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>; <a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a>; <a href="./references#CD011847-bbs2-0007" title="LinK , ChenXM . Clinical effect on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果刍议]. Yiayao Qianyan [医药前沿]2014;19:202‐3. ">Lin 2014</a>; <a href="./references#CD011847-bbs2-0008" title="LiuFQ , GongGQ . The effect of MECT for treatment‐resistant schizophrenic patients [精神分裂症患者无抽搐电休克的效果]. China Modern Doctor [中国现代医生]2010;48(1):29, 36. [CSzG: Ref22012] ">Liu 2010</a>; <a href="./references#CD011847-bbs2-0009" title="BragaRJ , MendelowitzAJ , FinkM , SchoolerNR , BailineSH , MalurC , et al. A randomized controlled trial of ECT in clozapine‐refractory schizophrenia. Biological Psychiatry2009;65(8):212S‐3S. [CSzG: Ref19511] PetridesG . ECT augmentation in clozapine‐resistant schizophrenia: acute efficacy and maintance data. Schizophrenia Bulletin2015;41:S328. [CSzG: Ref29626] PetridesG . Electroconvulsive therapy (ECT) for medication resistant schizophrenia. Schizophrenia Research2012;136:S22. [CSzG: Ref29625] PetridesG , GoldbergT , JohnM , BragaR , MalurC , MalhotraA , et al. Electroconvulsive therapy for clozapine‐resistant schizophrenia: cognitive effects. Neuropsychopharmacology2016;41:S257. [CSzG: Ref35678] PetridesG , MalurC , BragaRJ , BailineSH , SchoolerNR , MalhotraAK , et al. Electroconvulsive therapy augmentation in clozapine‐resistant schizophrenia: a prospective, randomized study. American Journal of Psychiatry2015;172(1):52‐8. [CSzG: Ref29366] ">Petrides 2015</a>; <a href="./references#CD011847-bbs2-0010" title="WangBH , ZengDZ , FanXW , HuaSG . Efficacy of modified electroconvulsive therapy in treatment‐refractory schizophrenia [无抽搐电休克对难治性精神分裂症的增效作用]. 临床精神医学杂志 [Journal of Clinical Psychiatry]2008;18(6):415‐7. [CSzG: Ref17865] ">Wang 2008</a>; <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a>; <a href="./references#CD011847-bbs2-0013" title="YangKJ , LiuTB , YangHC . The effect of clozapine combining MECT for the resistant schizophrenics with agitation and aggressive behavior. Medical Journal of Chinese People's Health [中国民康医学]2005;17(9):485‐6. [CSzG: Ref12755] ">Yang 2005</a>; <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a>; <a href="./references#CD011847-bbs2-0015" title="ZhangSR , ZhangJL , LiXZ , YangYP , LangSY . The effect of MECT combined with olanzapine for refractory schizophrenia [无抽搐电休克联合奥氮平治疗难治性精神分裂症疗效观察]. People's Military Surgeon [人民军医]2012;2:141‐3. [CSzG: Ref27071] ">Zhang 2012</a>). The following scales were used in this review. </p> <p> <ul id="CD011847-list-0011"> <li> <p>Brief Psychiatric Rating Scale (BPRS): an 18‐item scale measuring positive symptoms, general psychopathology, and affective symptoms. Each item is rated on a 7‐point scale ranging from 'not present' to 'extremely severe'. The possible scores range from 18 to 126, with high scores indicating more severe symptoms. </p> </li> <li> <p>Mini‐Mental State Examination (MMSE): a 30‐point questionnaire that is used extensively in clinical and research settings to measure cognitive impairment. Lower scores indicate more severe cognitive impairment. </p> </li> <li> <p>Positive and Negative Syndrome Scale (PANSS): a 30‐item scale including three sub scales for measuring the severity of positive symptoms, negative symptoms, and general psychopathology. Each item is rated on a 7‐point scale. The possible scores range from 21 to 210, with higher scores indicating a worse outcome. </p> </li> <li> <p>Scale for the Assessment of Negative Symptoms (SANS): a valid instrument to assess the negative symptoms of schizophrenia. Each item is based on a 6‐point scale. Higher scores indicate more severe symptoms. </p> </li> <li> <p>Scale for Assessment of Positive Symptoms (SAPS): a valid instrument to assess the positive symptoms of schizophrenia. Each item is based on a 6‐point scale. Higher scores indicate more severe symptoms. </p> </li> </ul> </p> </section> <section id="CD011847-sec-0131"> <h6 class="title">3. General functioning</h6> <p>No study reported a clinically important change in participants' general functioning. Two studies reported the average endpoint general functioning scores assessed by the Global Assessment of Functioning (GAF) scale (<a href="./references#CD011847-bbs2-0002" title="ChanpattanaW . ECT in schizophrenia. Journal of the Psychiatric Association of Thailand1999;44(2):156‐70. [CSzG: Ref8163] ChanpattanaW , ChakrabhandML , KitaroonchaiW , ChoovanichvongS , PrasertsukY . Effects of twice‐ versus thrice‐weekly electroconvulsive therapy in schizophrenia. Journal of the Medical Association of Thailand1999;82(5):477‐82. ChanpattanaW , ChakrabhandML , SackeimHA , KitaroonchaiW , KongsakonR , TechakasemP , et al. Continuation ECT in treatment resistant schizophrenia: a controlled study. Journal of ECT1999;15(3):178‐92. [CSzG: Ref4913; MEDLINE: 10492856] ">Chanpattana 1999</a>; <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>). The GAF is a 90‐point rating scale that assesses psychological, social, and occupational functioning. The possible score ranges from 0 to 100, with higher scores indicating better functioning. </p> </section> <section id="CD011847-sec-0132"> <h6 class="title">4. Service use</h6> <p>One study reported the number of participants who were readmitted (<a href="./references#CD011847-bbs2-0004" title="GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia syndrome: a double‐blind study. Indian Journal of Psychiatry2001; Vol. 43. [CSzG: Ref14832] GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia: a double‐blind study. Indian Journal of Psychiatry2003;45(1):26‐9. [CSzG: Ref14826] ">Goswami 2003</a>). </p> </section> <section id="CD011847-sec-0133"> <h6 class="title">5. Adverse events</h6> <p>Only one study reported the number of general adverse events (<a href="./references#CD011847-bbs2-0015" title="ZhangSR , ZhangJL , LiXZ , YangYP , LangSY . The effect of MECT combined with olanzapine for refractory schizophrenia [无抽搐电休克联合奥氮平治疗难治性精神分裂症疗效观察]. People's Military Surgeon [人民军医]2012;2:141‐3. [CSzG: Ref27071] ">Zhang 2012</a>), and five studies reported the average endpoint score for general adverse events assessed by the Treatment Emergent Symptom Scale (TESS) (<a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a>; <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>; <a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a>; <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a>; <a href="./references#CD011847-bbs2-0015" title="ZhangSR , ZhangJL , LiXZ , YangYP , LangSY . The effect of MECT combined with olanzapine for refractory schizophrenia [无抽搐电休克联合奥氮平治疗难治性精神分裂症疗效观察]. People's Military Surgeon [人民军医]2012;2:141‐3. [CSzG: Ref27071] ">Zhang 2012</a>). The TESS is a valid instrument to assess adverse events, with higher scores indicating more severe adverse events. </p> <p>Seven studies reported the number of specific adverse events (<a href="./references#CD011847-bbs2-0003" title="ChenDR . Controlled study on MECT for treatment‐resistant schizophrenia [无抽搐电休克治疗难治性精神分裂症的对照分析]. 新疆医学 [Xinjiang Medical Journal]2012;9:57‐60. [CSzG: Ref32661] ">Chen 2012</a>; <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>; <a href="./references#CD011847-bbs2-0007" title="LinK , ChenXM . Clinical effect on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果刍议]. Yiayao Qianyan [医药前沿]2014;19:202‐3. ">Lin 2014</a>; <a href="./references#CD011847-bbs2-0009" title="BragaRJ , MendelowitzAJ , FinkM , SchoolerNR , BailineSH , MalurC , et al. A randomized controlled trial of ECT in clozapine‐refractory schizophrenia. Biological Psychiatry2009;65(8):212S‐3S. [CSzG: Ref19511] PetridesG . ECT augmentation in clozapine‐resistant schizophrenia: acute efficacy and maintance data. Schizophrenia Bulletin2015;41:S328. [CSzG: Ref29626] PetridesG . Electroconvulsive therapy (ECT) for medication resistant schizophrenia. Schizophrenia Research2012;136:S22. [CSzG: Ref29625] PetridesG , GoldbergT , JohnM , BragaR , MalurC , MalhotraA , et al. Electroconvulsive therapy for clozapine‐resistant schizophrenia: cognitive effects. Neuropsychopharmacology2016;41:S257. [CSzG: Ref35678] PetridesG , MalurC , BragaRJ , BailineSH , SchoolerNR , MalhotraAK , et al. Electroconvulsive therapy augmentation in clozapine‐resistant schizophrenia: a prospective, randomized study. American Journal of Psychiatry2015;172(1):52‐8. [CSzG: Ref29366] ">Petrides 2015</a>; <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a>; <a href="./references#CD011847-bbs2-0012" title="WangF , GuoDW . The effect on olanzapine combined with modified electroconvulsive therapy in refractory schizophrenia [奥氮平联合改良电休克治疗难治性精神分裂症的疗效观察]. Clinical Rational Drug Use [临床合理用药杂志]2013;24:99. [CSzG: Ref27406] ">Wang 2013</a>; <a href="./references#CD011847-bbs2-0013" title="YangKJ , LiuTB , YangHC . The effect of clozapine combining MECT for the resistant schizophrenics with agitation and aggressive behavior. Medical Journal of Chinese People's Health [中国民康医学]2005;17(9):485‐6. [CSzG: Ref12755] ">Yang 2005</a>), and two studies reported the average endpoint score for specific adverse events assessed by TESS (<a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a>; <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a>). </p> </section> </section> </section> <section id="CD011847-sec-0134"> <h4 class="title">Excluded studies</h4> <p>We excluded 49 studies (65 references) from the review for the following reasons (see <a href="./references#CD011847-sec-0344" title="">Characteristics of excluded studies</a>). </p> <p> <ol id="CD011847-list-0012"> <li> <p>Seven studies were not randomised controlled trials (<a href="./references#CD011847-bbs2-0019" title="AratoM , ErdosA , KurczM , VermesI , FeketeM . Studies on the prolactin response induced by electroconvulsive therapy in schizophrenics. Acta Psychiatrica Scandinavica1980;61(3):239‐44. [MEDLINE: 7376927] ">Arato 1980</a>; <a href="./references#CD011847-bbs2-0025" title="BhatiaMS , Balkrishna , DharNK , BohraN . Schizophrenia: electrolyte profile &amp; the effect of treatment. Indian Journal of Psychiatry1987;29(3):275‐7. ">Bhatia 1987</a>; <a href="./references#CD011847-bbs2-0029" title="ChiCTR‐OPC‐14005339 . The study of the brain network features in refractory schizophrenia. apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR‐OPC‐14005339 (first received 16 October 2014). ">ChiCTR‐OPC‐14005339</a>; <a href="./references#CD011847-bbs2-0039" title="HeathES , AdamsA , WakelingPLG . Short courses of ECT and simulated ECT in chronic schizophrenia. British Journal of Psychiatry1964;110:800‐7. ">Heath 1964</a>; <a href="./references#CD011847-bbs2-0054" title="SmithK , SurphlisWRP , GyntherMD , ShimkunasAM . ECT‐chlorpromazine and chlorpromazine compared in the treatment of schizophrenia. Journal of Nervous and Mental Disease1967;144:284‐90. ">Smith 1967</a>; <a href="./references#CD011847-bbs2-0056" title="SwobodaE , ConcaA , KonigP , WaandersR , HansenM . Maintenance electroconvulsive therapy in affective and schizoaffective disorder. Neuropsychobiology2001;43(1):23‐8. [MEDLINE: 11150895] ">Swoboda 2001</a>; <a href="./references#CD011847-bbs2-0064" title="ZhouXD , ZhangDZ , WangZT . The effect of modern ECT on hypothalamic concentration of coricotropin and thyrotropin releasing hormones in patients with schizophrenia. Medical Journal of National Defending Forces in North China2003;15(6):402‐3. ">Zhou 2003</a>). </p> </li> <li> <p>In 10 studies (with 18 references), the participants were not all diagnosed with schizophrenia or a related disorder (<a href="./references#CD011847-bbs2-0027" title="BrillNQ , CrumptonE , EidusonS , GraysonHM , HellmanLI . Predictive and concomitant variables related to improvement with actual and simulated ECT. Archives of General Psychiatry1959;1:263‐72. BrillNQ , CrumptonE , EidusonS , GraysonHM , HellmanLI , RichardsRA . An experimental study of the relative effectiveness of various components of electro‐convulsive therapy. American Journal of Psychiatry1959;115:734‐5. BrillNQ , CrumptonE , EidusonS , GraysonHM , HellmanLI , RichardsRA . Relative effectiveness of various components of electroconvulsive therapy. Archives of Neurology and Psychiatry1959;81:627‐35. BrillNQ , CrumptonE , EidusonS , GraysonHM , HellmanLI , RichardsRA , et al. Investigation of the therapeutic components and various factors associated with improvement with electroconvulsive treatment: a preliminary report. American Journal of Psychiatry1957;113(11):997‐1008. [MEDLINE: 13411281] EidusonS , BrillNG , CrumptonE . The effect of electro‐convulsive therapy on spinal fluid constituents. Journal of Mental Science1960;106:692‐8. ">Brill 1959</a>; <a href="./references#CD011847-bbs2-0030" title="d'EliaG . Comparison of ECT with unilateral and bilateral stimulation. IV. Retrograde amnesia. Acta Psychiatrica Scandinavica Supplementum1970;215:61‐75. d'EliaG . Comparison of ECT with unilateral and bilateral stimulation. V. Confusion and other side‐effects. Acta Psychiatrica Scandinavica Supplementum1970;215:76‐89. d'EliaG , PerrisC . Comparison of ECT with unilateral and bilateral stimulation: I. Seizure and post‐seizure electroencephalographic pattern. Acta Psychiatrica Scandinavica Supplementum1970;215:9‐29. ">d'Elia 1970</a>; <a href="./references#CD011847-bbs2-0034" title="GanderDR , BennettPJ , KellyDH . Hexafluorodiethyl ether (Indoklon) convulsive therapy: a pilot study. British Journal of Psychiatry1967;113(505):1413‐8. [MEDLINE: 4383928] ">Gander 1967</a>; <a href="./references#CD011847-bbs2-0036" title="GirishK , GillNS . Electroconvulsive therapy in lorazepam non‐responsive catatonia. Indian Journal of Psychiatry2003;45(1):21‐5. KunigiriG , GillNS , BGN , NaimmagaddaJ . Electroconvulsive therapy in lorazepam non‐responsive catatonia. Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24‐29; Yokohama, Japan. 2002. ">Girish 2003</a>; <a href="./references#CD011847-bbs2-0037" title="HargreavesWA , FischerA , ElashoffRM , BlackerKH . Delayed onset of impairment following electrically induced convulsions. Acta Psychiatrica Scandinavica1972;48(1):69‐77. [MEDLINE: 5027530] ">Hargreaves 1972</a>; <a href="./references#CD011847-bbs2-0042" title="KrystalAD , WeinerRD , McCallWV , ShelpFE , AriasR , SmithP . The effects of ECT stimulus dose and electrode placement on the ictal electroencephalogram: an intraindividual crossover study. Biological Psychiatry1993;34(11):759‐67. [MEDLINE: 8292679] ">Krystal 1993</a>; <a href="./references#CD011847-bbs2-0043" title="LaurellB . Comparison of electric and flurothyl convulsive therapy: confusion and other side effects. Acta Psychiatrica Scandinavica Supplementum1970;213:61‐73. LaurellB . Comparison of electric and flurothyl convulsive therapy: retrograde amnesia. Acta Psychiatrica Scandinavica Supplementum1970;213:51‐60. ">Laurell 1970</a>; <a href="./references#CD011847-bbs2-0044" title="LaurellB , PerrisC . Comparison of ECT and ICT. I. Seizure and post‐seizure electroencephalographic pattern. Acta Psychiatrica Scandinavica Supplementum1970;213:8‐21. ">Laurell 1970a</a>; <a href="./references#CD011847-bbs2-0051" title="ReichertH , BenjaminJ , KeeganD , MarjerrisonG . Bilateral and non dominant unilateral ECT: I. Therapeutic efficacy. Canadian Psychiatric Association Journal1976;21(2):69‐78. ">Reichert 1976</a>; <a href="./references#CD011847-bbs2-0059" title="UlettGA , SmithK , GleserGC . Evaluation of convulsive and subconvulsive shock therapies utilizing a control group. American Journal of Psychiatry1956;112:795‐802. ">Ulett 1956</a>). </p> </li> <li> <p>In 26 studies (with 31 references), the participants were not diagnosed with treatment‐resistant schizophrenia (<a href="./references#CD011847-bbs2-0016" title="AbrahamKR , KulharaP . The efficacy of electroconvulsive therapy in the treatment of schizophrenia. A comparative study. British Journal of Psychiatry1987;151:152‐5. [MEDLINE: 3318990] ">Abraham 1987</a>; <a href="./references#CD011847-bbs2-0017" title="AbramsR . Daily administration of unilateral ECT. American Journal of Psychiatry1967;124(3):384‐6. [MEDLINE: 6039994] ">Abrams 1967</a>; <a href="./references#CD011847-bbs2-0018" title="AgarwalAK , WinnyGC . Role of ECT phenothiazine combination in schizophrenia. Indian Journal of Psychiatry1985;27(3):233‐6. ">Agarwal 1985</a>; <a href="./references#CD011847-bbs2-0021" title="BagadiaVN , AbhyankarRR , PradhanPV , ShahLP . Re‐evaluation of ECT in schizophrenia: right temporoparietal versus bitemporal electrode placement. Convulsive Therapy1988;4:215‐20. ">Bagadia 1988</a>; <a href="./references#CD011847-bbs2-0022" title="BakerAA , GameJA , ThorpeJG . Physical treatment for schizophrenia. Journal of Mental Science1958;104:860‐4. ThorpeJG , BakerAA . The effects of physical treatment on some psychological functions. Journal of Mental Science1958;104:865‐9. ">Baker 1958</a>; <a href="./references#CD011847-bbs2-0023" title="BakerAA , BirdG , LavinNI , ThorpeJG . ECT in schizophrenia. Journal of Mental Science1960;106:1506‐11. ">Baker 1960</a>; <a href="./references#CD011847-bbs2-0024" title="BakerAA , GameJA , ThorpeJG . Some research into the treatment of schizophrenia in the mental hospital. Journal of Mental Science1960;106:203‐13. ">Baker 1960a</a>; <a href="./references#CD011847-bbs2-0026" title="BrandonS , CowleyP , McDonaldC , NevilleP , PalmerR , WellstoodES . Leicester ECT trial: results in schizophrenia. British Journal of Psychiatry1985;146:177‐83. [MEDLINE: 3884080] ">Brandon 1985</a>; <a href="./references#CD011847-bbs2-0028" title="ChatterjeeSB , MohammedE . Evaluation of unilateral electro‐convulsive therapy (a double blind study). Indian Journal of Psychiatry1980;22(2):185‐94. ">Chatterjee 1980</a>; <a href="./references#CD011847-bbs2-0031" title="DoongajiDR , JesteDV , SaojiNJ , KanePV , RavindranathS . Unilateral versus bilateral ECT in schizophrenia. British Journal of Psychiatry1973;123(572):73‐9. [MEDLINE: 4729877] ">Doongaji 1973</a>; <a href="./references#CD011847-bbs2-0032" title="ElIslamMF , AhmedSA , ErfanME . The effect of unilateral ECT on schizophrenic delusions and hallucinations. British Journal of Psychiatry1970;117(539):447‐8. [MEDLINE: 5481209] ">El Islam 1970</a>; <a href="./references#CD011847-bbs2-0033" title="GanJL , DuanHF , ChengZX , YangJM , ZhuXQ , GaoCY , et al. Neuroprotective effect of modified electroconvulsive therapy for schizophrenia: a proton magnetic resonance spectroscopy study. Journal of Nervous and Mental Disease (in press). ">Gan 2017</a>; <a href="./references#CD011847-bbs2-0035" title="GangadharB , MayurP , JanakiramaiahN , SubbakrishnaD , RaoG . Cardiovascular response during ECT: a cross‐over study across stimulus conditions. Journal of ECT2000;16(2):177‐82. ">Gangadhar 2000</a>; <a href="./references#CD011847-bbs2-0040" title="JanakiramaiahN , SubbakrishnaDK . ECT‐chlorpromazine combination compared with chlorpromazine only in schizophrenia. Indian Journal of Psychiatry1981;23:230‐3. ">Janakiramaiah 1981</a>; <a href="./references#CD011847-bbs2-0041" title="JanakiramaiahN , ChannabasavannaSM , Narashimha MurthyNS . ECT‐chlorpromazine combination versus chlorpromazine alone in acutely schizophrenic patients. Acta Psychiatrica Scandinavica1982;66(6):464‐70. [MEDLINE: 7180565] ">Janakiramaiah 1982</a>; <a href="./references#CD011847-bbs2-0045" title="MarjerrisonG , JamesJ , ReichertH . Unilateral and bilateral ECT: EEG findings. Canadian Psychiatric Association Journal1975;20(4):257‐66. [MEDLINE: 1182637] ">Marjerrison 1975</a>; <a href="./references#CD011847-bbs2-0046" title="MillerDH , ClancyJ , CummingE . A comparison between unidirectional current nonconvulsive electrical stimulation given with Reiter's machine, standard alternating current electroshock (Cerletti method), and pentothal in chronic schizophrenia. American Journal of Psychiatry1953;109:617‐20. ">Miller 1953</a>; <a href="./references#CD011847-bbs2-0047" title="NaidooD . The effects of reserpine (serpasil) on the chronic disturbed schizophrenic: a comparative study of rauwolfia alkaloids and electroconvulsive therapy. Abstracts of World Medicine1957;21(2):133. NaidooD . The effects of reserpine (serpasil) on the chronic disturbed schizophrenic: a comparative study of rauwolfia alkaloids and electroconvulsive therapy. Journal of Nervous and Mental Disease1956;123:1‐13. ">Naidoo 1956</a>; <a href="./references#CD011847-bbs2-0048" title="NataniGD , GautamS , GehlotPS . Comparison of three treatment regimes in schizophrenia. Indian Journal of Psychiatry1983;25(4):306‐11. ">Natani 1983</a>; <a href="./references#CD011847-bbs2-0050" title="RamiL , GotiJ , FerrerJ , MarcosT , SalameroM , BernardoM . Cognitive functions after only one ECT session: a controlled study. Psychiatry Research2008;158(3):389‐94. [MEDLINE: 18279973] ">Rami 2008</a>; <a href="./references#CD011847-bbs2-0052" title="SarkarP , AndradeC , KapurB , DasP , SivaramakrishnaY , HariharC , et al. An exploratory evaluation of ECT in haloperidol‐treated DSM‐IIIR schizophreniform disorder. Convulsive Therapy1994;10(4):271‐8. [MEDLINE: 7850397] ">Sarkar 1994</a>; <a href="./references#CD011847-bbs2-0053" title="SmallJG , SmallIF , SharpleyP , MooreDF . A double‐blind comparative evaluation of flurothyl and ECT. Archives of General Psychiatry1968;19(1):79‐86. [MEDLINE: 5658383] ">Small 1968</a>; <a href="./references#CD011847-bbs2-0057" title="TaylorP . ECT and schizophrenia in Great Britain. American Journal of Psychiatry1981;138(2):259‐60. [MEDLINE: 7006422] TaylorP , FlemingerJJ . ECT for schizophrenia. Lancet1980;1(8183):1380‐3. [MEDLINE: 6104172] TaylorPJ . Schizophrenia and ECT: a case for change in prescription?. Dilemmas and Difficulties in the Management of Psychiatric Patients. Oxford, UK: Oxford University Press, 1990:143‐55. ">Taylor 1980</a>; <a href="./references#CD011847-bbs2-0058" title="UkpongDI , MakanjuolaROA , MorakinyoO . A controlled trial of modified electroconvulsive therapy in schizophrenia in a Nigerian teaching hospital. West African Journal of Medicine2002;21(3):237‐40. [MEDLINE: 12744577] ">Ukpong 2002</a>; <a href="./references#CD011847-bbs2-0061" title="WesselsWH . A comparative study of the efficacy of bilateral and unilateral ECT with thioridazine in acute schizophrenia. Proceedings of the 5th World Congress of Psychiatry; 1971 Nov 28 ‐ Dec 4; Mexico City, Mexico. 1971:574. WesselsWH . A comparative study of the efficacy of bilateral and unilateral electroconvulsive therapy with thioridazine in acute schizophrenia. South African Medical Journal1972;46(26):890‐2. ">Wessels 1971</a>; <a href="./references#CD011847-bbs2-0062" title="XueCC , XieH , RuanQ , ChengY , LuoD . Electric acupuncture convulsive therapy. Convulsive Therapy1985;1(4):242‐51. ">Xue 1985</a>). </p> </li> <li> <p>The comparisons in four studies (with six references) did not meet the inclusion criteria. In one of these studies the participants were receiving concurrent pharmacological interventions and other interventions, and ECT was not being exclusively randomised (<a href="./references#CD011847-bbs2-0020" title="BagadiaVN , AbhyankarRR , DoshiJ , PradhanPV , ShahLP . A double blind controlled study of ECT vs chlorpromazine in schizophrenia. Journal of the Association of Physicians of India1983;31(10):637‐40. [MEDLINE: 6671932] BagadiaVN , AbhyankarRR , DoshiJ , PradhanPV , ShahLP . Re‐evaluation of ECT in schizophrenia. Psychopharmacology Bulletin1983;19(3):550‐5. BagadiaVN , ShahLP , PradhanPV , DoshiJ , AbhyankarRR . Evaluation of cognitive effects of ECT: preliminary observations. Indian Journal of Psychiatry1981;23(4):324‐9. ">Bagadia 1981</a>). The three studies compared different forms of ECT that were not in the protocol (<a href="./references#CD011847-bbs2-0038" title="HeQ , LiuBL , QinQL . A comparative study of side effects of non‐ versus dominance ECT on schizophrenics with EEG and ECG monitoring. Acta Academiae Medicinae Shandong2001;39(1):48‐50. ">He 2001</a>; <a href="./references#CD011847-bbs2-0049" title="NCT02159001 . Efficacy and cognitive effects of electroconvulsive therapy in clozapine‐resistant schizophrenia. clinicaltrials.gov/show/NCT02159001 (first received 4 June 2014). ">NCT02159001</a>; <a href="./references#CD011847-bbs2-0055" title="StenbackA , ViitamakiRO , KukkonenS . Personality changes in electroconvulsive treatment. Acta Psychiatrica et Neurologica Scandinavica1957;32:345‐59. ">Stenback 1957</a>). </p> </li> <li> <p>Two studies (with three references) were in languages other than English or Chinese (<a href="./references#CD011847-bbs2-0060" title="UngvariG , BitterI , CzoborP , VitraiJ , PethoeB . The role of high‐dosage neuroleptic therapy and electroconvulsive therapy in the treatment of the acute phase of schizophrenia [Zur Rolle der neuroleptischen Hochdosis‐Therapie und des Elektroschocks bei der Behandlung der akuten Phase von Schizophrenien]. Psychiatrie, Neurologie Und Medizinische Psychologie1981;33(8):458‐63. [MEDLINE: 6124987] UngvariG , PethoB . High‐dose haloperidol therapy: its effectiveness and a comparison with electroconvulsive treatment. Journal of Psychiatric Treatment and Evaluation1982;4:279‐83. ">Ungvari 1981</a>; <a href="./references#CD011847-bbs2-0063" title="ZadehMA . Comparison effects of clozapine, ECT and combination ECT and clozapine on resistance treatment of schizophrenia (double blind). Journal of Mazandaran University of Medical Sciences2006;50(15):14‐7. ">Zadeh 2006</a>). </p> </li> </ol> </p> <section id="CD011847-sec-0135"> <h5 class="title">Studies awaiting classification</h5> <p>See <a href="./references#CD011847-sec-0345" title="">Characteristics of studies awaiting classification</a>. </p> <p>There were six studies awaiting classification due to unclear diagnosis, study design, or comparison (<a href="./references#CD011847-bbs2-0065" title="ChenM . Observation and nursing of multi‐parameter monitoring electroconvulsive therapy for schizophrenia [多参数监护电休克治疗精神分裂症的疗效观察及护理]. 中国现代临床护理学杂志 [Journal of Chinese Modern Clinical Nursing]2006; Vol. 1, issue 5:433. ">Chen 2006</a>; <a href="./references#CD011847-bbs2-0066" title="Melzer‐RibeiroDL , RigonattiSP , KayoM , RibeiroRB , AvrichirB , FortesM , et al. Pilot double blind, placebo controlled and randomized study to assess electroconvulsive therapy efficacy as augmenting strategy to clozapine in super‐refractory schizophrenia. Schizophrenia Bulletin2015;41:S323‐4. NCT02049021 . Electroconvulsive therapy (ECT) in patients with super refractory schizophrenia [Pilot double blind, placebo controlled and randomized study to assess electroconvulsive therapy efficacy as augmenting strategy to clozapine in super‐refractory schizophrenia]. clinicaltrials.gov/show/NCT02049021 (first received 15 January 2014). ">Melzer 2015</a>; <a href="./references#CD011847-bbs2-0067" title="NicholasJD , JameSL , MartinR , RitaMK , JamesI , DennisWL , et al. Electrical dose and seizure threshold in bifrontal, bitemporal and right unilateral ECT ‐ relations to clinical outcome and cognitive. Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 May 4‐9; New York, USA. 1996. ">Nicholas 1996</a>; <a href="./references#CD011847-bbs2-0068" title="OlenevaE , TsukarziE , MosolovS . Combined olanzapine‐ECT therapy for resistant schizophrenia. European Neuropsychopharmacology2005;15(Suppl 2):S131. OlenevaE , TsukarziE , MosolovSN . Combined olanzapine‐ECT therapy for resistant schizophrenia. International Journal of Neuropsychopharmacology2008;11(Suppl 1):151. ">Oleneva 2005</a>; <a href="./references#CD011847-bbs2-0069" title="PeymanDAR . An investigation of the effects of group psychotherapy on chronic schizophrenic patients. Group Psychotherapy1956;9:35‐9. ">Peyman 1956</a>; <a href="./references#CD011847-bbs2-0070" title="SackeimHA . Affective and cognitive consequences of ECT. CRISP Database (https://www‐commons.cit.nih.gov/crisp/index.html. National Research Register, (accessed 19 February 2001). ">Sackeim 2000</a>). The contact information for these studies was not available. </p> </section> <section id="CD011847-sec-0136"> <h5 class="title">Ongoing studies</h5> <p>See <a href="./references#CD011847-sec-0346" title="">Characteristics of ongoing studies</a>. </p> <p>We identified three ongoing studies that began in 2000, 2008, and 2016 respectively, but had not yet been published<i>.</i> The location of these studies was the USA (<a href="./references#CD011847-bbs2-0071" title="NCT00042224 . ECT in clozapine refractory schizophrenia. www.clinicaltrials.gov/ct/show/NCT00042224 (first received 24 July 2002). ">NCT00042224</a>), Thailand (<a href="./references#CD011847-bbs2-0072" title="NCT00753051 . Treat clozapine‐resistant schizophrenia comparing between clozapine + haloperidol versus clozapine + electroconvulsive therapy (ECT). www.clinicaltrials.gov/ct/show/NCT00753051 (first received 15 September 2008). ">NCT00753051</a>), and China (<a href="./references#CD011847-bbs2-0073" title="NCT02926976 . The optimal treatment for treatment‐resistant schizophrenia. www.clinicaltrials.gov/show/NCT02926976 (first received 5 October 2016). ">NCT02926976</a>). The contact information for these studies was not available, and <a href="./references#CD011847-bbs2-0073" title="NCT02926976 . The optimal treatment for treatment‐resistant schizophrenia. www.clinicaltrials.gov/show/NCT02926976 (first received 5 October 2016). ">NCT02926976</a> had not yet started recruiting as of the writing of this review. </p> </section> </section> </section> <section id="CD011847-sec-0137"> <h3 class="title">Risk of bias in included studies</h3> <p>Details of the 'Risk of bias' assessments can be found in the 'Risk of bias' table corresponding to each study in the <a href="./references#CD011847-sec-0343" title="">Characteristics of included studies</a> tables, and in the 'Risk of bias' graph (<a href="#CD011847-fig-0002">Figure 2</a>) and summary (<a href="#CD011847-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD011847-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011847-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD011847-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011847-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011847-sec-0138"> <h4 class="title">Allocation</h4> <section id="CD011847-sec-0139"> <h5 class="title">Random sequence generation</h5> <p>All 15 included studies reported some form of randomisation. Two studies reported adequate sequence generation, which we rated as at low risk of bias. The methods used to generate the allocation sequence were random number tables (<a href="./references#CD011847-bbs2-0004" title="GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia syndrome: a double‐blind study. Indian Journal of Psychiatry2001; Vol. 43. [CSzG: Ref14832] GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia: a double‐blind study. Indian Journal of Psychiatry2003;45(1):26‐9. [CSzG: Ref14826] ">Goswami 2003</a>; <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>). The remaining 13 studies provided insufficient information to assess bias in this domain, and we classified them as at unclear risk of bias. </p> </section> <section id="CD011847-sec-0140"> <h5 class="title">Allocation concealment</h5> <p>Only <a href="./references#CD011847-bbs2-0004" title="GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia syndrome: a double‐blind study. Indian Journal of Psychiatry2001; Vol. 43. [CSzG: Ref14832] GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia: a double‐blind study. Indian Journal of Psychiatry2003;45(1):26‐9. [CSzG: Ref14826] ">Goswami 2003</a> reported adequate allocation concealment, where allocation was managed by a person who was not involved in carrying out the study. We rated this study as at low risk of bias. The remaining 14 studies provided insufficient information to assess risk of bias for this domain and were classified as at unclear risk of bias. </p> </section> </section> <section id="CD011847-sec-0141"> <h4 class="title">Blinding</h4> <section id="CD011847-sec-0142"> <h5 class="title">Blinding of participants and personnel</h5> <p>Only <a href="./references#CD011847-bbs2-0004" title="GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia syndrome: a double‐blind study. Indian Journal of Psychiatry2001; Vol. 43. [CSzG: Ref14832] GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia: a double‐blind study. Indian Journal of Psychiatry2003;45(1):26‐9. [CSzG: Ref14826] ">Goswami 2003</a> reported that both participants and personnel were double‐blinded, and that a sham‐ECT was used as a control to ensure the blinding. We rated this study as at low risk of bias. In the remaining 14 studies, participants in one group received ECT, and the other group did not. It would not have been possible to blind participants and healthcare professionals administering the treatment. We rated these studies as at high risk of performance bias. </p> </section> <section id="CD011847-sec-0143"> <h5 class="title">Blinding of outcome assessment</h5> <p>Two studies reported that the outcome assessors were blinded to the treatment, which we rated as at low risk of bias (<a href="./references#CD011847-bbs2-0002" title="ChanpattanaW . ECT in schizophrenia. Journal of the Psychiatric Association of Thailand1999;44(2):156‐70. [CSzG: Ref8163] ChanpattanaW , ChakrabhandML , KitaroonchaiW , ChoovanichvongS , PrasertsukY . Effects of twice‐ versus thrice‐weekly electroconvulsive therapy in schizophrenia. Journal of the Medical Association of Thailand1999;82(5):477‐82. ChanpattanaW , ChakrabhandML , SackeimHA , KitaroonchaiW , KongsakonR , TechakasemP , et al. Continuation ECT in treatment resistant schizophrenia: a controlled study. Journal of ECT1999;15(3):178‐92. [CSzG: Ref4913; MEDLINE: 10492856] ">Chanpattana 1999</a>; <a href="./references#CD011847-bbs2-0009" title="BragaRJ , MendelowitzAJ , FinkM , SchoolerNR , BailineSH , MalurC , et al. A randomized controlled trial of ECT in clozapine‐refractory schizophrenia. Biological Psychiatry2009;65(8):212S‐3S. [CSzG: Ref19511] PetridesG . ECT augmentation in clozapine‐resistant schizophrenia: acute efficacy and maintance data. Schizophrenia Bulletin2015;41:S328. [CSzG: Ref29626] PetridesG . Electroconvulsive therapy (ECT) for medication resistant schizophrenia. Schizophrenia Research2012;136:S22. [CSzG: Ref29625] PetridesG , GoldbergT , JohnM , BragaR , MalurC , MalhotraA , et al. Electroconvulsive therapy for clozapine‐resistant schizophrenia: cognitive effects. Neuropsychopharmacology2016;41:S257. [CSzG: Ref35678] PetridesG , MalurC , BragaRJ , BailineSH , SchoolerNR , MalhotraAK , et al. Electroconvulsive therapy augmentation in clozapine‐resistant schizophrenia: a prospective, randomized study. American Journal of Psychiatry2015;172(1):52‐8. [CSzG: Ref29366] ">Petrides 2015</a>). The remaining 13 studies provided insufficient information to assess bias in this domain and were classified as at unclear risk of detection bias. </p> </section> </section> <section id="CD011847-sec-0144"> <h4 class="title">Incomplete outcome data</h4> <p>We rated 11 studies as at low risk of bias for this domain: nine studies had no missing outcome data (<a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a>; <a href="./references#CD011847-bbs2-0003" title="ChenDR . Controlled study on MECT for treatment‐resistant schizophrenia [无抽搐电休克治疗难治性精神分裂症的对照分析]. 新疆医学 [Xinjiang Medical Journal]2012;9:57‐60. [CSzG: Ref32661] ">Chen 2012</a>; <a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a>; <a href="./references#CD011847-bbs2-0007" title="LinK , ChenXM . Clinical effect on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果刍议]. Yiayao Qianyan [医药前沿]2014;19:202‐3. ">Lin 2014</a>; <a href="./references#CD011847-bbs2-0008" title="LiuFQ , GongGQ . The effect of MECT for treatment‐resistant schizophrenic patients [精神分裂症患者无抽搐电休克的效果]. China Modern Doctor [中国现代医生]2010;48(1):29, 36. [CSzG: Ref22012] ">Liu 2010</a>; <a href="./references#CD011847-bbs2-0010" title="WangBH , ZengDZ , FanXW , HuaSG . Efficacy of modified electroconvulsive therapy in treatment‐refractory schizophrenia [无抽搐电休克对难治性精神分裂症的增效作用]. 临床精神医学杂志 [Journal of Clinical Psychiatry]2008;18(6):415‐7. [CSzG: Ref17865] ">Wang 2008</a>; <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a>; <a href="./references#CD011847-bbs2-0013" title="YangKJ , LiuTB , YangHC . The effect of clozapine combining MECT for the resistant schizophrenics with agitation and aggressive behavior. Medical Journal of Chinese People's Health [中国民康医学]2005;17(9):485‐6. [CSzG: Ref12755] ">Yang 2005</a>; <a href="./references#CD011847-bbs2-0015" title="ZhangSR , ZhangJL , LiXZ , YangYP , LangSY . The effect of MECT combined with olanzapine for refractory schizophrenia [无抽搐电休克联合奥氮平治疗难治性精神分裂症疗效观察]. People's Military Surgeon [人民军医]2012;2:141‐3. [CSzG: Ref27071] ">Zhang 2012</a>), while in the other two studies the proportion of participants who dropped was less than 10%, or the reasons for dropping were not relevant to the effect of the intervention (<a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>; <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a>). </p> <p>We rated three studies (in which the attrition rate was more than 10% but less than 20%) as at unclear risk of attrition bias. <a href="./references#CD011847-bbs2-0002" title="ChanpattanaW . ECT in schizophrenia. Journal of the Psychiatric Association of Thailand1999;44(2):156‐70. [CSzG: Ref8163] ChanpattanaW , ChakrabhandML , KitaroonchaiW , ChoovanichvongS , PrasertsukY . Effects of twice‐ versus thrice‐weekly electroconvulsive therapy in schizophrenia. Journal of the Medical Association of Thailand1999;82(5):477‐82. ChanpattanaW , ChakrabhandML , SackeimHA , KitaroonchaiW , KongsakonR , TechakasemP , et al. Continuation ECT in treatment resistant schizophrenia: a controlled study. Journal of ECT1999;15(3):178‐92. [CSzG: Ref4913; MEDLINE: 10492856] ">Chanpattana 1999</a> performed an ITT analysis, but the number of participants randomised to each group was not reported. <a href="./references#CD011847-bbs2-0004" title="GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia syndrome: a double‐blind study. Indian Journal of Psychiatry2001; Vol. 43. [CSzG: Ref14832] GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia: a double‐blind study. Indian Journal of Psychiatry2003;45(1):26‐9. [CSzG: Ref14826] ">Goswami 2003</a> did not provide a reason for the attrition and did not perform an ITT analysis. In <a href="./references#CD011847-bbs2-0009" title="BragaRJ , MendelowitzAJ , FinkM , SchoolerNR , BailineSH , MalurC , et al. A randomized controlled trial of ECT in clozapine‐refractory schizophrenia. Biological Psychiatry2009;65(8):212S‐3S. [CSzG: Ref19511] PetridesG . ECT augmentation in clozapine‐resistant schizophrenia: acute efficacy and maintance data. Schizophrenia Bulletin2015;41:S328. [CSzG: Ref29626] PetridesG . Electroconvulsive therapy (ECT) for medication resistant schizophrenia. Schizophrenia Research2012;136:S22. [CSzG: Ref29625] PetridesG , GoldbergT , JohnM , BragaR , MalurC , MalhotraA , et al. Electroconvulsive therapy for clozapine‐resistant schizophrenia: cognitive effects. Neuropsychopharmacology2016;41:S257. [CSzG: Ref35678] PetridesG , MalurC , BragaRJ , BailineSH , SchoolerNR , MalhotraAK , et al. Electroconvulsive therapy augmentation in clozapine‐resistant schizophrenia: a prospective, randomized study. American Journal of Psychiatry2015;172(1):52‐8. [CSzG: Ref29366] ">Petrides 2015</a>, the reasons for attrition varied between groups. </p> <p>We also rated the remaining study, <a href="./references#CD011847-bbs2-0012" title="WangF , GuoDW . The effect on olanzapine combined with modified electroconvulsive therapy in refractory schizophrenia [奥氮平联合改良电休克治疗难治性精神分裂症的疗效观察]. Clinical Rational Drug Use [临床合理用药杂志]2013;24:99. [CSzG: Ref27406] ">Wang 2013</a>, as at unclear risk of attrition bias. Although the attrition rate was not described, there was one additional participant in one treatment group, and two fewer participants in another treatment group according to the reported results. </p> </section> <section id="CD011847-sec-0145"> <h4 class="title">Selective reporting</h4> <p>Most of the study protocols were not available. We rated 11 studies that had appropriately reported all the outcomes stated in the methods section of the study to be at low risk of bias for this domain (<a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a>; <a href="./references#CD011847-bbs2-0002" title="ChanpattanaW . ECT in schizophrenia. Journal of the Psychiatric Association of Thailand1999;44(2):156‐70. [CSzG: Ref8163] ChanpattanaW , ChakrabhandML , KitaroonchaiW , ChoovanichvongS , PrasertsukY . Effects of twice‐ versus thrice‐weekly electroconvulsive therapy in schizophrenia. Journal of the Medical Association of Thailand1999;82(5):477‐82. ChanpattanaW , ChakrabhandML , SackeimHA , KitaroonchaiW , KongsakonR , TechakasemP , et al. Continuation ECT in treatment resistant schizophrenia: a controlled study. Journal of ECT1999;15(3):178‐92. [CSzG: Ref4913; MEDLINE: 10492856] ">Chanpattana 1999</a>; <a href="./references#CD011847-bbs2-0003" title="ChenDR . Controlled study on MECT for treatment‐resistant schizophrenia [无抽搐电休克治疗难治性精神分裂症的对照分析]. 新疆医学 [Xinjiang Medical Journal]2012;9:57‐60. [CSzG: Ref32661] ">Chen 2012</a>; <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>; <a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a>; <a href="./references#CD011847-bbs2-0007" title="LinK , ChenXM . Clinical effect on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果刍议]. Yiayao Qianyan [医药前沿]2014;19:202‐3. ">Lin 2014</a>; <a href="./references#CD011847-bbs2-0009" title="BragaRJ , MendelowitzAJ , FinkM , SchoolerNR , BailineSH , MalurC , et al. A randomized controlled trial of ECT in clozapine‐refractory schizophrenia. Biological Psychiatry2009;65(8):212S‐3S. [CSzG: Ref19511] PetridesG . ECT augmentation in clozapine‐resistant schizophrenia: acute efficacy and maintance data. Schizophrenia Bulletin2015;41:S328. [CSzG: Ref29626] PetridesG . Electroconvulsive therapy (ECT) for medication resistant schizophrenia. Schizophrenia Research2012;136:S22. [CSzG: Ref29625] PetridesG , GoldbergT , JohnM , BragaR , MalurC , MalhotraA , et al. Electroconvulsive therapy for clozapine‐resistant schizophrenia: cognitive effects. Neuropsychopharmacology2016;41:S257. [CSzG: Ref35678] PetridesG , MalurC , BragaRJ , BailineSH , SchoolerNR , MalhotraAK , et al. Electroconvulsive therapy augmentation in clozapine‐resistant schizophrenia: a prospective, randomized study. American Journal of Psychiatry2015;172(1):52‐8. [CSzG: Ref29366] ">Petrides 2015</a>; <a href="./references#CD011847-bbs2-0012" title="WangF , GuoDW . The effect on olanzapine combined with modified electroconvulsive therapy in refractory schizophrenia [奥氮平联合改良电休克治疗难治性精神分裂症的疗效观察]. Clinical Rational Drug Use [临床合理用药杂志]2013;24:99. [CSzG: Ref27406] ">Wang 2013</a>; <a href="./references#CD011847-bbs2-0013" title="YangKJ , LiuTB , YangHC . The effect of clozapine combining MECT for the resistant schizophrenics with agitation and aggressive behavior. Medical Journal of Chinese People's Health [中国民康医学]2005;17(9):485‐6. [CSzG: Ref12755] ">Yang 2005</a>; <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a>; <a href="./references#CD011847-bbs2-0015" title="ZhangSR , ZhangJL , LiXZ , YangYP , LangSY . The effect of MECT combined with olanzapine for refractory schizophrenia [无抽搐电休克联合奥氮平治疗难治性精神分裂症疗效观察]. People's Military Surgeon [人民军医]2012;2:141‐3. [CSzG: Ref27071] ">Zhang 2012</a>). </p> <p>We rated two studies as at unclear risk of bias because they did not report memory assessment in the control groups (<a href="./references#CD011847-bbs2-0010" title="WangBH , ZengDZ , FanXW , HuaSG . Efficacy of modified electroconvulsive therapy in treatment‐refractory schizophrenia [无抽搐电休克对难治性精神分裂症的增效作用]. 临床精神医学杂志 [Journal of Clinical Psychiatry]2008;18(6):415‐7. [CSzG: Ref17865] ">Wang 2008</a>; <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a>). The primary outcome (response to treatment) was not reported in the two remaining studies (<a href="./references#CD011847-bbs2-0004" title="GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia syndrome: a double‐blind study. Indian Journal of Psychiatry2001; Vol. 43. [CSzG: Ref14832] GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia: a double‐blind study. Indian Journal of Psychiatry2003;45(1):26‐9. [CSzG: Ref14826] ">Goswami 2003</a>; <a href="./references#CD011847-bbs2-0008" title="LiuFQ , GongGQ . The effect of MECT for treatment‐resistant schizophrenic patients [精神分裂症患者无抽搐电休克的效果]. China Modern Doctor [中国现代医生]2010;48(1):29, 36. [CSzG: Ref22012] ">Liu 2010</a>), therefore these studies were rated as at high risk of reporting bias. </p> </section> <section id="CD011847-sec-0146"> <h4 class="title">Other potential sources of bias</h4> <p>We did not find any other obvious bias in the included studies and therefore rated this domain as at low risk of bias. </p> </section> </section> <section id="CD011847-sec-0147"> <h3 class="title" id="CD011847-sec-0147">Effects of interventions</h3> <p>See: <a href="./full#CD011847-tbl-0001"><b>Summary of findings for the main comparison</b> ECT plus standard care versus sham‐ECT plus standard care for treatment‐resistant schizophrenia</a>; <a href="./full#CD011847-tbl-0002"><b>Summary of findings 2</b> ECT plus standard care versus antipsychotics plus standard care for treatment‐resistant schizophrenia</a>; <a href="./full#CD011847-tbl-0003"><b>Summary of findings 3</b> ECT plus standard care versus standard care for treatment‐resistant schizophrenia</a>; <a href="./full#CD011847-tbl-0004"><b>Summary of findings 4</b> ECT alone versus antipsychotics for treatment‐resistant schizophrenia</a> </p> <section id="CD011847-sec-0148"> <h4 class="title">COMPARISON 1: ECT plus standard care versus sham‐ECT plus standard care</h4> <p>For this comparison, we found only one relevant study involving 25 participants who received either ECT combined with chlorpromazine or sham‐ECT combined with chlorpromazine (<a href="./references#CD011847-bbs2-0004" title="GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia syndrome: a double‐blind study. Indian Journal of Psychiatry2001; Vol. 43. [CSzG: Ref14832] GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia: a double‐blind study. Indian Journal of Psychiatry2003;45(1):26‐9. [CSzG: Ref14826] ">Goswami 2003</a>). This was a short course of ECT performed as continuation with bilateral placement of electrodes. The participants in this study were strictly diagnosed with schizophrenia by DSM‐IV. </p> <p>See <a href="./full#CD011847-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD011847-sec-0149"> <h5 class="title">1.1 Mental state ‐ total score (BPRS, high = poor) ‐ short term</h5> <p><a href="./references#CD011847-bbs2-0004" title="GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia syndrome: a double‐blind study. Indian Journal of Psychiatry2001; Vol. 43. [CSzG: Ref14832] GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia: a double‐blind study. Indian Journal of Psychiatry2003;45(1):26‐9. [CSzG: Ref14826] ">Goswami 2003</a> reported the endpoint score of participants' mental state assessed by the BPRS at short‐term follow‐up. We found no clear difference in the BPRS score for mental state between the ECT and the sham‐ECT groups (mean difference (MD) 3.60, 95% confidence interval (CI) ‐3.69 to 10.89; participants = 25; studies = 1; very low‐quality evidence; <a href="./references#CD011847-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD011847-sec-0150"> <h5 class="title">1.2 Service use ‐ number readmitted ‐ short term</h5> <p><a href="./references#CD011847-bbs2-0004" title="GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia syndrome: a double‐blind study. Indian Journal of Psychiatry2001; Vol. 43. [CSzG: Ref14832] GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia: a double‐blind study. Indian Journal of Psychiatry2003;45(1):26‐9. [CSzG: Ref14826] ">Goswami 2003</a> reported the number of participants who were readmitted at short‐term follow‐up. There were fewer readmitted participants in the ECT group than in the sham‐ECT group (risk ratio (RR) 0.29, 95% CI 0.10 to 0.85; participants = 25; studies = 1; low‐quality evidence; <a href="./references#CD011847-fig-0005" title="">Analysis 1.2</a>). </p> <p>For this comparison, <a href="./references#CD011847-bbs2-0004" title="GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia syndrome: a double‐blind study. Indian Journal of Psychiatry2001; Vol. 43. [CSzG: Ref14832] GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia: a double‐blind study. Indian Journal of Psychiatry2003;45(1):26‐9. [CSzG: Ref14826] ">Goswami 2003</a> did not report other predefined outcomes, including response to treatment, cognitive functioning, satisfaction and acceptability of treatment, general functioning, and adverse events. </p> </section> </section> <section id="CD011847-sec-0151"> <h4 class="title">COMPARISON 2: ECT plus standard care versus antipsychotic (clozapine) plus standard care </h4> <p>For this comparison, we found only one relevant study involving 162 participants who received either modified ECT (MECT) combined with ziprasidone or clozapine combined with ziprasidone (<a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a>). The short course of ECT was performed as continuation. The electrode placement was not described in this study. The participants in this study were strictly diagnosed with schizophrenia by CCMD‐3. </p> <p>See <a href="./full#CD011847-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD011847-sec-0152"> <h5 class="title">2.1 Response to treatment ‐ clinically significant response (BPRS reducing rate ≥ 50%) ‐ medium term </h5> <p><a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a> reported that there was no clear medium‐term difference in the number of clinically significant responders between the MECT and clozapine treatment groups (RR 1.23, 95% CI 0.95 to 1.58; participants = 162; studies = 1; low‐quality evidence; <a href="./references#CD011847-fig-0006" title="">Analysis 2.1</a>). </p> </section> <section id="CD011847-sec-0153"> <h5 class="title">2.2 Mental state ‐ total score (BPRS, high = poor) ‐ short term</h5> <p><a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a> reported the endpoint score of participants' mental state assessed by the BPRS. The study found a lower short‐term total BPRS score for mental state after MECT treatment than after clozapine treatment (MD ‐5.20, 95% CI ‐7.93 to ‐2.47; participants = 162; studies = 1; very low‐quality evidence; <a href="./references#CD011847-fig-0007" title="">Analysis 2.2</a>). </p> </section> <section id="CD011847-sec-0154"> <h5 class="title">2.3 Mental state ‐ total score (BPRS, high = poor) ‐ medium term (skewed data)</h5> <p><a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a> also reported a total medium‐term BPRS score for mental state. However, as the data were skewed, a parameter test was not applicable. We have presented data in <a href="./references#CD011847-fig-0008" title="">Analysis 2.3</a>. </p> </section> <section id="CD011847-sec-0155"> <h5 class="title">2.4 Mental state ‐ specific symptom score (BPRS, high = poor) ‐ short term</h5> <p><a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a> found lower short‐term BPRS scores for specific mental symptoms in the MECT group than in the clozapine group (<a href="./references#CD011847-fig-0009" title="">Analysis 2.4</a>). </p> <section id="CD011847-sec-0156"> <h6 class="title">2.4.1 Anxiety and depression</h6> <p><a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a> found lower short‐term BPRS scores on anxiety and depression in the MECT group than in the clozapine group (MD ‐0.60, 95% CI ‐1.12 to ‐0.08; participants = 162; studies = 1). </p> </section> <section id="CD011847-sec-0157"> <h6 class="title">2.4.2 Lack of vitality</h6> <p><a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a> found lower short‐term BPRS scores on lack of vitality in the MECT group than in the clozapine group (MD ‐2.20, 95% CI ‐2.74 to ‐1.66; participants = 162; studies = 1). </p> </section> <section id="CD011847-sec-0158"> <h6 class="title">2.4.3 Thought disturbance</h6> <p><a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a> found lower short‐term BPRS scores on thought disturbance in the MECT group than in the clozapine group (MD ‐0.70, 95% CI ‐1.32 to ‐0.08; participants = 162; studies = 1). </p> </section> <section id="CD011847-sec-0159"> <h6 class="title">2.4.4 Agitation</h6> <p><a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a> found lower short‐term BPRS scores on agitation in the MECT group than in the clozapine group (MD ‐0.70, 95% CI ‐0.82 to ‐0.58; participants = 162; studies = 1). </p> </section> <section id="CD011847-sec-0160"> <h6 class="title">2.4.5 Hostile suspiciousness</h6> <p><a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a> found lower short‐term BPRS scores on hostile suspiciousness in the MECT group than in the clozapine group (MD ‐1.00, 95% CI ‐1.56 to ‐0.44; participants = 162; studies = 1). </p> </section> </section> <section id="CD011847-sec-0161"> <h5 class="title">2.5 Mental state ‐ specific symptom score (BPRS, high = poor) ‐ medium term</h5> <p><a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a> found lower medium‐term BPRS scores for specific mental symptoms in the MECT group than in the clozapine group (<a href="./references#CD011847-fig-0010" title="">Analysis 2.5</a>). </p> <section id="CD011847-sec-0162"> <h6 class="title">2.5.1 Anxiety and depression</h6> <p><a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a> found lower medium‐term BPRS scores on anxiety and depression in the MECT group than in the clozapine group (MD ‐1.50, 95% CI ‐1.73 to ‐1.27; participants = 162; studies = 1). </p> </section> <section id="CD011847-sec-0163"> <h6 class="title">2.5.2 Lack of vitality</h6> <p><a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a> found lower medium‐term BPRS scores on lack of vitality in the MECT group than in the clozapine group (MD ‐1.20, 95% CI ‐1.47 to ‐0.93; participants = 162; studies = 1). </p> </section> <section id="CD011847-sec-0164"> <h6 class="title">2.5.3 Thought disturbance</h6> <p><a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a> found lower medium‐term BPRS scores on thought disturbance in the MECT group than in the clozapine group (MD ‐1.70, 95% CI ‐2.12 to ‐1.28; participants = 162; studies = 1). </p> </section> <section id="CD011847-sec-0165"> <h6 class="title">2.5.4 Agitation</h6> <p><a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a> found lower medium‐term BPRS scores on agitation in the MECT group than in the clozapine group (MD ‐1.60, 95% CI ‐1.79 to ‐1.41; participants = 162; studies = 1). </p> </section> <section id="CD011847-sec-0166"> <h6 class="title">2.5.5 Hostile suspiciousness</h6> <p><a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a> found lower medium‐term BPRS scores on hostile suspiciousness in the MECT group than in the clozapine group (MD ‐2.80, 95% CI ‐3.14 to ‐2.46; participants = 162; studies = 1). </p> </section> </section> <section id="CD011847-sec-0167"> <h5 class="title">2.6 Adverse events ‐ total score (TESS, high = poor)</h5> <p><a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a> reported the endpoint score of adverse events assessed by TESS (<a href="./references#CD011847-fig-0011" title="">Analysis 2.6</a>). </p> <section id="CD011847-sec-0168"> <h6 class="title">2.6.1 Short term</h6> <p><a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a> found no clear short‐term difference on TESS scores between the two groups (MD ‐0.40, 95% CI ‐0.91 to 0.11; participants = 162; studies = 1). </p> </section> <section id="CD011847-sec-0169"> <h6 class="title">2.6.2 Medium term</h6> <p><a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a> found lower medium‐term TESS scores in the MECT group than in the clozapine group (MD ‐1.10, 95% CI ‐1.40 to ‐0.80; participants = 162; studies = 1). </p> <p>For this comparison, <a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a> did not report other predefined outcomes, including cognitive functioning, satisfaction and acceptability of treatment, general functioning, and service outcomes. </p> </section> </section> </section> <section id="CD011847-sec-0170"> <h4 class="title">COMPARISON 3: ECT plus standard care versus standard care</h4> <p>For this comparison, we found 12 relevant studies that compared ECT plus standard care with standard care, involving 1020 participants. </p> <p>See <a href="./full#CD011847-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD011847-sec-0171"> <h5 class="title">3.1 Response to treatment ‐ clinically significant response (as defined by each of the studies) </h5> <p>Ten studies reported useable data on this outcome (<a href="./references#CD011847-fig-0012" title="">Analysis 3.1</a>). </p> <section id="CD011847-sec-0172"> <h6 class="title">3.1.1 Short term</h6> <p><a href="./references#CD011847-bbs2-0012" title="WangF , GuoDW . The effect on olanzapine combined with modified electroconvulsive therapy in refractory schizophrenia [奥氮平联合改良电休克治疗难治性精神分裂症的疗效观察]. Clinical Rational Drug Use [临床合理用药杂志]2013;24:99. [CSzG: Ref27406] ">Wang 2013</a> reported the short‐term clinically significant responders rate. The study found that there were more responders in the ECT group than in the group that did not receive ECT (RR 1.91, 95% CI 1.09 to 3.36; participants = 72; studies = 1). </p> </section> <section id="CD011847-sec-0173"> <h6 class="title">3.1.2 Medium term</h6> <p>Nine studies reported the medium‐term clinically significant responders rate (<a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a>; <a href="./references#CD011847-bbs2-0003" title="ChenDR . Controlled study on MECT for treatment‐resistant schizophrenia [无抽搐电休克治疗难治性精神分裂症的对照分析]. 新疆医学 [Xinjiang Medical Journal]2012;9:57‐60. [CSzG: Ref32661] ">Chen 2012</a>; <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>; <a href="./references#CD011847-bbs2-0009" title="BragaRJ , MendelowitzAJ , FinkM , SchoolerNR , BailineSH , MalurC , et al. A randomized controlled trial of ECT in clozapine‐refractory schizophrenia. Biological Psychiatry2009;65(8):212S‐3S. [CSzG: Ref19511] PetridesG . ECT augmentation in clozapine‐resistant schizophrenia: acute efficacy and maintance data. Schizophrenia Bulletin2015;41:S328. [CSzG: Ref29626] PetridesG . Electroconvulsive therapy (ECT) for medication resistant schizophrenia. Schizophrenia Research2012;136:S22. [CSzG: Ref29625] PetridesG , GoldbergT , JohnM , BragaR , MalurC , MalhotraA , et al. Electroconvulsive therapy for clozapine‐resistant schizophrenia: cognitive effects. Neuropsychopharmacology2016;41:S257. [CSzG: Ref35678] PetridesG , MalurC , BragaRJ , BailineSH , SchoolerNR , MalhotraAK , et al. Electroconvulsive therapy augmentation in clozapine‐resistant schizophrenia: a prospective, randomized study. American Journal of Psychiatry2015;172(1):52‐8. [CSzG: Ref29366] ">Petrides 2015</a>; <a href="./references#CD011847-bbs2-0010" title="WangBH , ZengDZ , FanXW , HuaSG . Efficacy of modified electroconvulsive therapy in treatment‐refractory schizophrenia [无抽搐电休克对难治性精神分裂症的增效作用]. 临床精神医学杂志 [Journal of Clinical Psychiatry]2008;18(6):415‐7. [CSzG: Ref17865] ">Wang 2008</a>; <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a>; <a href="./references#CD011847-bbs2-0013" title="YangKJ , LiuTB , YangHC . The effect of clozapine combining MECT for the resistant schizophrenics with agitation and aggressive behavior. Medical Journal of Chinese People's Health [中国民康医学]2005;17(9):485‐6. [CSzG: Ref12755] ">Yang 2005</a>; <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a>; <a href="./references#CD011847-bbs2-0015" title="ZhangSR , ZhangJL , LiXZ , YangYP , LangSY . The effect of MECT combined with olanzapine for refractory schizophrenia [无抽搐电休克联合奥氮平治疗难治性精神分裂症疗效观察]. People's Military Surgeon [人民军医]2012;2:141‐3. [CSzG: Ref27071] ">Zhang 2012</a>). There were also more responders in the ECT group than in the group that did not receive ECT (RR 2.06, 95% CI 1.75 to 2.42; participants = 819; studies = 9; moderate‐quality evidence). </p> </section> </section> <section id="CD011847-sec-0174"> <h5 class="title">3.2 Cognitive functioning ‐ memory deterioration ‐ short term</h5> <p><a href="./references#CD011847-bbs2-0012" title="WangF , GuoDW . The effect on olanzapine combined with modified electroconvulsive therapy in refractory schizophrenia [奥氮平联合改良电休克治疗难治性精神分裂症的疗效观察]. Clinical Rational Drug Use [临床合理用药杂志]2013;24:99. [CSzG: Ref27406] ">Wang 2013</a> reported that there were more participants with memory deterioration in the ECT group than in the group that did not receive ECT at short‐term follow‐up (RR 27.00, 95% CI 1.67 to 437.68; participants = 72; studies = 1; very low‐quality evidence; <a href="./references#CD011847-fig-0013" title="">Analysis 3.2</a>). </p> </section> <section id="CD011847-sec-0175"> <h5 class="title">3.3 Cognitive functioning ‐ specific symptom score (WCST, high = poor, other than correct number) ‐ medium term </h5> <p><a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a> reported the medium‐term endpoint scores from sub scales of the WCST (<a href="./references#CD011847-fig-0014" title="">Analysis 3.3</a>). </p> <section id="CD011847-sec-0176"> <h6 class="title">3.3.1 Total test number</h6> <p><a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a> found that participants who received ECT had lower scores in total test number at medium‐term follow‐up (MD ‐8.74, 95% CI ‐16.88 to ‐0.60; participants = 67; studies = 1). </p> </section> <section id="CD011847-sec-0177"> <h6 class="title">3.3.2 Correct number</h6> <p><a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a> found that there were no clear differences in the correct number between the two groups at medium‐term follow‐up (MD 3.03, 95% CI ‐0.15 to 6.21; participants = 67; studies = 1). </p> </section> <section id="CD011847-sec-0178"> <h6 class="title">3.3.3 Categories completed</h6> <p><a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a> found that participants who received ECT had lower scores in categories completed at medium‐term follow‐up (MD ‐0.36, 95% CI ‐0.49 to ‐0.23; participants = 67; studies = 1). </p> </section> </section> <section id="CD011847-sec-0179"> <h5 class="title">3.4 Cognitive functioning ‐ specific symptom score (WCST, high = poor) ‐ medium term (skewed data) </h5> <p>Data reported by <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a> (n = 67) on perseveration and non‐perseveration errors were skewed; we have only presented them as 'other data' without the parameter test (<a href="./references#CD011847-fig-0015" title="">Analysis 3.4</a>). </p> </section> <section id="CD011847-sec-0180"> <h5 class="title">3.5 Cognitive functioning ‐ memory (WMS, high = good) ‐ short term</h5> <p><a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> reported the short‐term endpoint memory scores from sub scales of the WMS. There were no clear differences in specific memory symptoms between the two groups (<a href="./references#CD011847-fig-0016" title="">Analysis 3.5</a>). </p> <section id="CD011847-sec-0181"> <h6 class="title">3.5.1 Memory quotient (MQ)</h6> <p><a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> found no clear differences in MQ between the two groups (MD 0.27, 95% CI ‐3.54 to 4.08; participants = 245; studies = 1). </p> </section> <section id="CD011847-sec-0182"> <h6 class="title">3.5.2 Memorise number (1 to 100)</h6> <p><a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> found no clear differences in memorise number (1 to 100) between the two groups (MD ‐0.09, 95% CI ‐0.71 to 0.53; participants = 245; studies = 1). </p> </section> <section id="CD011847-sec-0183"> <h6 class="title">3.5.3 Memorise number (100 to 1)</h6> <p><a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> found no clear differences in memorise number (100 to 1) between the two groups (MD ‐0.30, 95% CI ‐0.98 to 0.38; participants = 245; studies = 1). </p> </section> <section id="CD011847-sec-0184"> <h6 class="title">3.5.4 Accumulation of memory</h6> <p><a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> found no clear differences in accumulation of memory between the two groups (MD ‐0.11, 95% CI ‐0.73 to 0.51; participants = 245; studies = 1). </p> </section> <section id="CD011847-sec-0185"> <h6 class="title">3.5.5 Picture memory</h6> <p><a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> found no clear differences in picture memory between the two groups (MD ‐0.41, 95% CI ‐1.01 to 0.19; participants = 245; studies = 1). </p> </section> <section id="CD011847-sec-0186"> <h6 class="title">3.5.6 Recognition memory</h6> <p><a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> found no clear differences in recognition memory between the two groups (MD ‐0.03, 95% CI ‐0.64 to 0.58; participants = 245; studies = 1). </p> </section> <section id="CD011847-sec-0187"> <h6 class="title">3.5.7 Regeneration memory</h6> <p><a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> found no clear differences in regeneration memory between the two groups (MD ‐0.04, 95% CI ‐0.78 to 0.70; participants = 245; studies = 1). </p> </section> <section id="CD011847-sec-0188"> <h6 class="title">3.5.8 Associative memory</h6> <p><a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> found no clear differences in associative memory between the two groups (MD ‐0.09, 95% CI ‐0.97 to 0.79; participants = 245; studies = 1). </p> </section> <section id="CD011847-sec-0189"> <h6 class="title">3.5.9 Haptic memory</h6> <p><a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> found no clear differences in haptic memory between the two groups (MD ‐0.07, 95% CI ‐0.53 to 0.39; participants = 245; studies = 1). </p> </section> <section id="CD011847-sec-0190"> <h6 class="title">3.5.10 Understanding memory</h6> <p><a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> found no clear differences in understanding memory between the two groups (MD 0.02, 95% CI ‐0.56 to 0.60; participants = 245; studies = 1). </p> </section> <section id="CD011847-sec-0191"> <h6 class="title">3.5.11 Memorise random number</h6> <p><a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> found no clear differences in memorise random number between the two groups (MD 0.33, 95% CI ‐0.29 to 0.95; participants = 245; studies = 1). </p> </section> </section> <section id="CD011847-sec-0192"> <h5 class="title">3.6 Cognitive functioning ‐ memory (WMS, high = good) ‐ medium term</h5> <p><a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> reported the medium‐term endpoint memory scores from sub scales of the WMS. There were no clear differences in specific memory symptoms between the two groups (<a href="./references#CD011847-fig-0017" title="">Analysis 3.6</a>). </p> <section id="CD011847-sec-0193"> <h6 class="title">3.6.1 Memory quotient (MQ)</h6> <p><a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> found no clear differences in MQ between the two groups (MD 1.75, 95% CI ‐2.24 to 5.74; participants = 245; studies = 1). </p> </section> <section id="CD011847-sec-0194"> <h6 class="title">3.6.2 Memorise number (1 to 100)</h6> <p><a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> found no clear differences in memorise number (1 to 100) between the two groups (MD ‐0.06, 95% CI ‐0.69 to 0.57; participants = 245; studies = 1). </p> </section> <section id="CD011847-sec-0195"> <h6 class="title">3.6.3 Memorise number (100 to 1)</h6> <p><a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> found no clear differences in memorise number (100 to 1) between the two groups (MD ‐0.15, 95% CI ‐0.88 to 0.58; participants = 245; studies = 1). </p> </section> <section id="CD011847-sec-0196"> <h6 class="title">3.6.4 Accumulation of memory</h6> <p><a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> found no clear differences in accumulation of memory between the two groups (MD 0.03, 95% CI ‐0.59 to 0.65; participants = 245; studies = 1). </p> </section> <section id="CD011847-sec-0197"> <h6 class="title">3.6.5 Picture memory</h6> <p><a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> found no clear differences in picture memory between the two groups (MD ‐0.41, 95% CI ‐1.01 to 0.19; participants = 245; studies = 1). </p> </section> <section id="CD011847-sec-0198"> <h6 class="title">3.6.6 Recognition memory</h6> <p><a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> found no clear differences in recognition memory between the two groups (MD 0.09, 95% CI ‐0.52 to 0.70; participants = 245; studies = 1). </p> </section> <section id="CD011847-sec-0199"> <h6 class="title">3.6.7 Regeneration memory</h6> <p><a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> found no clear differences in regeneration memory between the two groups (MD 0.11, 95% CI ‐0.64 to 0.86; participants = 245; studies = 1). </p> </section> <section id="CD011847-sec-0200"> <h6 class="title">3.6.8 Associative memory</h6> <p><a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> found no clear differences in associative memory between the two groups (MD 0.11, 95% CI ‐0.79 to 1.01; participants = 245; studies = 1). </p> </section> <section id="CD011847-sec-0201"> <h6 class="title">3.6.9 Haptic memory</h6> <p><a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> found no clear differences in haptic memory between the two groups (MD 0.10, 95% CI ‐0.38 to 0.58; participants = 245; studies = 1). </p> </section> <section id="CD011847-sec-0202"> <h6 class="title">3.6.10 Understanding memory</h6> <p><a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> found no clear differences in understanding memory between the two groups (MD ‐0.06, 95% CI ‐0.63 to 0.51; participants = 245; studies = 1). </p> </section> <section id="CD011847-sec-0203"> <h6 class="title">3.6.11 Memorise random number</h6> <p><a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> found no clear differences in memorise random number between the two groups (MD 0.24, 95% CI ‐0.37 to 0.85; participants = 245; studies = 1). </p> </section> </section> <section id="CD011847-sec-0204"> <h5 class="title">3.7 Satisfaction and acceptability of treatment ‐ leaving the study early ‐ medium term </h5> <p>Three studies reported the number of participants who left the study early at medium‐term follow‐up (<a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>; <a href="./references#CD011847-bbs2-0009" title="BragaRJ , MendelowitzAJ , FinkM , SchoolerNR , BailineSH , MalurC , et al. A randomized controlled trial of ECT in clozapine‐refractory schizophrenia. Biological Psychiatry2009;65(8):212S‐3S. [CSzG: Ref19511] PetridesG . ECT augmentation in clozapine‐resistant schizophrenia: acute efficacy and maintance data. Schizophrenia Bulletin2015;41:S328. [CSzG: Ref29626] PetridesG . Electroconvulsive therapy (ECT) for medication resistant schizophrenia. Schizophrenia Research2012;136:S22. [CSzG: Ref29625] PetridesG , GoldbergT , JohnM , BragaR , MalurC , MalhotraA , et al. Electroconvulsive therapy for clozapine‐resistant schizophrenia: cognitive effects. Neuropsychopharmacology2016;41:S257. [CSzG: Ref35678] PetridesG , MalurC , BragaRJ , BailineSH , SchoolerNR , MalhotraAK , et al. Electroconvulsive therapy augmentation in clozapine‐resistant schizophrenia: a prospective, randomized study. American Journal of Psychiatry2015;172(1):52‐8. [CSzG: Ref29366] ">Petrides 2015</a>; <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a>). There was no clear difference between the two groups (RR 1.18, 95% CI 0.38 to 3.63; participants = 354; studies = 3; very low‐quality evidence; <a href="./references#CD011847-fig-0018" title="">Analysis 3.7</a>). </p> </section> <section id="CD011847-sec-0205"> <h5 class="title">3.8 Mental state ‐ total score (BPRS, high = poor)</h5> <p>Two studies reported mental state by measuring endpoint total scores of BPRS (<a href="./references#CD011847-fig-0019" title="">Analysis 3.8</a>). </p> <section id="CD011847-sec-0206"> <h6 class="title">3.8.1 Short term</h6> <p><a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a> and <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> reported this outcome at short‐term follow‐up. We found that participants who received ECT had lower short‐term BPRS scores than those who did not receive ECT (MD ‐5.50, 95% CI ‐6.99 to ‐4.00; participants = 345; studies = 2; I<sup>2</sup> = 66%). The result had important heterogeneity, and no obvious source was identified. </p> </section> <section id="CD011847-sec-0207"> <h6 class="title">3.8.2 Medium term</h6> <p><a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a> and <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> reported this outcome at medium‐term follow‐up. We found that the participants who received ECT had lower medium‐term BPRS scores than those who did not receive ECT (MD ‐11.18, 95% CI ‐12.61 to ‐9.76; participants = 345; studies = 2; low‐quality evidence). </p> </section> </section> <section id="CD011847-sec-0208"> <h5 class="title">3.9 Mental state ‐ total score (BPRS, high = poor) ‐ medium term (skewed data)</h5> <p>We could not pool the BPRS scores in <a href="./references#CD011847-bbs2-0002" title="ChanpattanaW . ECT in schizophrenia. Journal of the Psychiatric Association of Thailand1999;44(2):156‐70. [CSzG: Ref8163] ChanpattanaW , ChakrabhandML , KitaroonchaiW , ChoovanichvongS , PrasertsukY . Effects of twice‐ versus thrice‐weekly electroconvulsive therapy in schizophrenia. Journal of the Medical Association of Thailand1999;82(5):477‐82. ChanpattanaW , ChakrabhandML , SackeimHA , KitaroonchaiW , KongsakonR , TechakasemP , et al. Continuation ECT in treatment resistant schizophrenia: a controlled study. Journal of ECT1999;15(3):178‐92. [CSzG: Ref4913; MEDLINE: 10492856] ">Chanpattana 1999</a> (n = 30) in the meta‐analysis due to skewness; we have presented these in <a href="./references#CD011847-fig-0020" title="">Analysis 3.9</a>. </p> </section> <section id="CD011847-sec-0209"> <h5 class="title">3.10 Mental state ‐ total score (MMSE, high = good) ‐ medium term</h5> <p>Two studies reported mental state by measuring endpoint total scores of MMSE at medium‐term follow‐up (<a href="./references#CD011847-bbs2-0002" title="ChanpattanaW . ECT in schizophrenia. Journal of the Psychiatric Association of Thailand1999;44(2):156‐70. [CSzG: Ref8163] ChanpattanaW , ChakrabhandML , KitaroonchaiW , ChoovanichvongS , PrasertsukY . Effects of twice‐ versus thrice‐weekly electroconvulsive therapy in schizophrenia. Journal of the Medical Association of Thailand1999;82(5):477‐82. ChanpattanaW , ChakrabhandML , SackeimHA , KitaroonchaiW , KongsakonR , TechakasemP , et al. Continuation ECT in treatment resistant schizophrenia: a controlled study. Journal of ECT1999;15(3):178‐92. [CSzG: Ref4913; MEDLINE: 10492856] ">Chanpattana 1999</a>; <a href="./references#CD011847-bbs2-0009" title="BragaRJ , MendelowitzAJ , FinkM , SchoolerNR , BailineSH , MalurC , et al. A randomized controlled trial of ECT in clozapine‐refractory schizophrenia. Biological Psychiatry2009;65(8):212S‐3S. [CSzG: Ref19511] PetridesG . ECT augmentation in clozapine‐resistant schizophrenia: acute efficacy and maintance data. Schizophrenia Bulletin2015;41:S328. [CSzG: Ref29626] PetridesG . Electroconvulsive therapy (ECT) for medication resistant schizophrenia. Schizophrenia Research2012;136:S22. [CSzG: Ref29625] PetridesG , GoldbergT , JohnM , BragaR , MalurC , MalhotraA , et al. Electroconvulsive therapy for clozapine‐resistant schizophrenia: cognitive effects. Neuropsychopharmacology2016;41:S257. [CSzG: Ref35678] PetridesG , MalurC , BragaRJ , BailineSH , SchoolerNR , MalhotraAK , et al. Electroconvulsive therapy augmentation in clozapine‐resistant schizophrenia: a prospective, randomized study. American Journal of Psychiatry2015;172(1):52‐8. [CSzG: Ref29366] ">Petrides 2015</a>). We found that the participants who received ECT had higher MMSE scores than those who did not receive ECT (MD 0.98, 95% CI 0.30 to 1.65; participants = 69; studies = 2; <a href="./references#CD011847-fig-0021" title="">Analysis 3.10</a>). </p> </section> <section id="CD011847-sec-0210"> <h5 class="title">3.11 Mental state ‐ total score (PANSS, high = poor)</h5> <p>Six studies reported mental state by measuring endpoint total scores of PANSS (<a href="./references#CD011847-fig-0022" title="">Analysis 3.11</a>). </p> <section id="CD011847-sec-0211"> <h6 class="title">3.11.1 Short term</h6> <p>Six studies reported short‐term total scores of PANSS (<a href="./references#CD011847-bbs2-0003" title="ChenDR . Controlled study on MECT for treatment‐resistant schizophrenia [无抽搐电休克治疗难治性精神分裂症的对照分析]. 新疆医学 [Xinjiang Medical Journal]2012;9:57‐60. [CSzG: Ref32661] ">Chen 2012</a>; <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>; <a href="./references#CD011847-bbs2-0010" title="WangBH , ZengDZ , FanXW , HuaSG . Efficacy of modified electroconvulsive therapy in treatment‐refractory schizophrenia [无抽搐电休克对难治性精神分裂症的增效作用]. 临床精神医学杂志 [Journal of Clinical Psychiatry]2008;18(6):415‐7. [CSzG: Ref17865] ">Wang 2008</a>; <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a>; <a href="./references#CD011847-bbs2-0013" title="YangKJ , LiuTB , YangHC . The effect of clozapine combining MECT for the resistant schizophrenics with agitation and aggressive behavior. Medical Journal of Chinese People's Health [中国民康医学]2005;17(9):485‐6. [CSzG: Ref12755] ">Yang 2005</a>; <a href="./references#CD011847-bbs2-0015" title="ZhangSR , ZhangJL , LiXZ , YangYP , LangSY . The effect of MECT combined with olanzapine for refractory schizophrenia [无抽搐电休克联合奥氮平治疗难治性精神分裂症疗效观察]. People's Military Surgeon [人民军医]2012;2:141‐3. [CSzG: Ref27071] ">Zhang 2012</a>). We found that the participants who received ECT had lower PANSS scores than those who did not receive ECT (MD ‐11.41, 95% CI ‐13.49 to ‐9.34; participants = 432; studies = 6; I<sup>2</sup> = 94%). The result had important heterogeneity. The statistical heterogeneity was reduced to I<sup>2</sup> = 0% after removing <a href="./references#CD011847-bbs2-0013" title="YangKJ , LiuTB , YangHC . The effect of clozapine combining MECT for the resistant schizophrenics with agitation and aggressive behavior. Medical Journal of Chinese People's Health [中国民康医学]2005;17(9):485‐6. [CSzG: Ref12755] ">Yang 2005</a> from the meta‐analysis (MD ‐4.96, 95% CI ‐7.48 to ‐2.44; participants = 372; studies = 5). Accordingly, the treatment effect was robust to heterogeneity amongst the studies. The participants in <a href="./references#CD011847-bbs2-0013" title="YangKJ , LiuTB , YangHC . The effect of clozapine combining MECT for the resistant schizophrenics with agitation and aggressive behavior. Medical Journal of Chinese People's Health [中国民康医学]2005;17(9):485‐6. [CSzG: Ref12755] ">Yang 2005</a> were diagnosed with treatment‐resistant schizophrenia with agitation and aggressive behaviour, which may be the source of the heterogeneity. </p> </section> <section id="CD011847-sec-0212"> <h6 class="title">3.11.2 Medium term</h6> <p>Six studies reported medium‐term total scores of PANSS (<a href="./references#CD011847-bbs2-0003" title="ChenDR . Controlled study on MECT for treatment‐resistant schizophrenia [无抽搐电休克治疗难治性精神分裂症的对照分析]. 新疆医学 [Xinjiang Medical Journal]2012;9:57‐60. [CSzG: Ref32661] ">Chen 2012</a>; <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>; <a href="./references#CD011847-bbs2-0010" title="WangBH , ZengDZ , FanXW , HuaSG . Efficacy of modified electroconvulsive therapy in treatment‐refractory schizophrenia [无抽搐电休克对难治性精神分裂症的增效作用]. 临床精神医学杂志 [Journal of Clinical Psychiatry]2008;18(6):415‐7. [CSzG: Ref17865] ">Wang 2008</a>; <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a>; <a href="./references#CD011847-bbs2-0013" title="YangKJ , LiuTB , YangHC . The effect of clozapine combining MECT for the resistant schizophrenics with agitation and aggressive behavior. Medical Journal of Chinese People's Health [中国民康医学]2005;17(9):485‐6. [CSzG: Ref12755] ">Yang 2005</a>; <a href="./references#CD011847-bbs2-0015" title="ZhangSR , ZhangJL , LiXZ , YangYP , LangSY . The effect of MECT combined with olanzapine for refractory schizophrenia [无抽搐电休克联合奥氮平治疗难治性精神分裂症疗效观察]. People's Military Surgeon [人民军医]2012;2:141‐3. [CSzG: Ref27071] ">Zhang 2012</a>). We found that the participants who received ECT had lower PANSS scores than those who did not receive ECT (MD ‐7.62, 95% CI ‐9.49 to ‐5.74; participants = 432; studies = 6). </p> </section> </section> <section id="CD011847-sec-0213"> <h5 class="title">3.12 Mental state ‐ specific symptom score (BPRS, high = poor) ‐ short term</h5> <p>Three studies reported short‐term BPRS sub scale scores for specific mental symptoms. We found that the participants who received ECT had lower BPRS scores for specific symptoms compared with those who did not receive ECT (<a href="./references#CD011847-fig-0023" title="">Analysis 3.12</a>). </p> <section id="CD011847-sec-0214"> <h6 class="title">3.12.1 Anxiety and depression</h6> <p><a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a> and <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> reported data on anxiety and depression. We found that the participants who received ECT had lower BPRS scores for anxiety and depression compared with those who did not receive ECT (MD ‐0.97, 95% CI ‐1.28 to ‐0.65; participants = 345; studies = 2; I<sup>2</sup> = 77%). The result had important heterogeneity, and no obvious source was identified. </p> </section> <section id="CD011847-sec-0215"> <h6 class="title">3.12.2 Lack of vitality</h6> <p><a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a> and <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> reported data on lack of vitality. We found that the participants who received ECT had lower BPRS scores for lack of vitality compared with those who did not receive ECT (MD ‐2.40, 95% CI ‐2.71 to ‐2.09; participants = 345; studies = 2; I<sup>2</sup> = 77%). The result had important heterogeneity, and no obvious source was identified. </p> </section> <section id="CD011847-sec-0216"> <h6 class="title">3.12.3 Thought disturbance</h6> <p><a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a> and <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> reported data on thought disturbance. We found that the participants who received ECT had lower BPRS scores for thought disturbance compared with those who did not receive ECT (MD ‐0.71, 95% CI ‐1.06 to ‐0.35; participants = 345; studies = 2). </p> </section> <section id="CD011847-sec-0217"> <h6 class="title">3.12.4 Agitation</h6> <p><a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a> and <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> reported data on agitation. We found that the participants who received ECT had lower BPRS scores for agitation compared with those who did not receive ECT (MD ‐1.23, 95% CI ‐1.51 to ‐0.95; participants = 345; studies = 2). </p> </section> <section id="CD011847-sec-0218"> <h6 class="title">3.12.5 Hostile suspiciousness</h6> <p><a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a> and <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> reported data on hostile suspiciousness. We found that the participants who received ECT had lower BPRS scores for hostile suspiciousness compared with those who did not receive ECT (MD ‐0.57, 95% CI ‐0.91 to ‐0.24; participants = 345; studies = 2). </p> </section> <section id="CD011847-sec-0219"> <h6 class="title">3.12.6 Psychosis</h6> <p><a href="./references#CD011847-bbs2-0009" title="BragaRJ , MendelowitzAJ , FinkM , SchoolerNR , BailineSH , MalurC , et al. A randomized controlled trial of ECT in clozapine‐refractory schizophrenia. Biological Psychiatry2009;65(8):212S‐3S. [CSzG: Ref19511] PetridesG . ECT augmentation in clozapine‐resistant schizophrenia: acute efficacy and maintance data. Schizophrenia Bulletin2015;41:S328. [CSzG: Ref29626] PetridesG . Electroconvulsive therapy (ECT) for medication resistant schizophrenia. Schizophrenia Research2012;136:S22. [CSzG: Ref29625] PetridesG , GoldbergT , JohnM , BragaR , MalurC , MalhotraA , et al. Electroconvulsive therapy for clozapine‐resistant schizophrenia: cognitive effects. Neuropsychopharmacology2016;41:S257. [CSzG: Ref35678] PetridesG , MalurC , BragaRJ , BailineSH , SchoolerNR , MalhotraAK , et al. Electroconvulsive therapy augmentation in clozapine‐resistant schizophrenia: a prospective, randomized study. American Journal of Psychiatry2015;172(1):52‐8. [CSzG: Ref29366] ">Petrides 2015</a> reported data on psychosis. We found that the participants who received ECT had lower BPRS scores for psychosis compared with those who did not receive ECT (MD ‐5.24, 95% CI ‐5.89 to ‐4.59; participants = 39; studies = 1). </p> </section> </section> <section id="CD011847-sec-0220"> <h5 class="title">3.13 Mental state ‐ specific symptom score (BPRS, high = poor) ‐ medium term</h5> <p>Four studies reported medium‐term BPRS sub scale scores for specific mental symptoms. We found that the participants who received ECT had lower BPRS scores for specific symptoms compared with those who did not receive ECT (<a href="./references#CD011847-fig-0024" title="">Analysis 3.13</a>). </p> <section id="CD011847-sec-0221"> <h6 class="title">3.13.1 Anxiety and depression</h6> <p>Three studies reported data on anxiety and depression (<a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a>; <a href="./references#CD011847-bbs2-0007" title="LinK , ChenXM . Clinical effect on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果刍议]. Yiayao Qianyan [医药前沿]2014;19:202‐3. ">Lin 2014</a>; <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a>). We found that the participants who received ECT had lower BPRS scores for anxiety and depression compared with those who did not receive ECT (MD ‐1.50, 95% CI ‐1.72 to ‐1.29; participants = 423; studies = 3; I<sup>2</sup> = 76%). The result had important heterogeneity, and no obvious source was identified. However, the treatment effect was robust to heterogeneity amongst the studies. The statistical heterogeneity was reduced to I<sup>2</sup> = 0% after removing <a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a> from the meta‐analysis (MD ‐1.61, 95% CI ‐1.84 to ‐1.39; participants = 323; studies = 2). </p> </section> <section id="CD011847-sec-0222"> <h6 class="title">3.13.2 Lack of vitality</h6> <p>Three studies reported data on lack of vitality (<a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a>; <a href="./references#CD011847-bbs2-0007" title="LinK , ChenXM . Clinical effect on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果刍议]. Yiayao Qianyan [医药前沿]2014;19:202‐3. ">Lin 2014</a>; <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a>). We found that the participants who received ECT had lower BPRS scores for lack of vitality compared with those who did not receive ECT (MD ‐1.80, 95% CI ‐2.02 to ‐1.58; participants = 423; studies = 3; I<sup>2</sup> = 87%). The result had important heterogeneity, and no obvious source was identified. However, the treatment effect was robust to heterogeneity amongst the studies. The statistical heterogeneity was reduced to I<sup>2</sup> = 0% after removing <a href="./references#CD011847-bbs2-0007" title="LinK , ChenXM . Clinical effect on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果刍议]. Yiayao Qianyan [医药前沿]2014;19:202‐3. ">Lin 2014</a> from the meta‐analysis (MD ‐2.14, 95% CI ‐2.42 to ‐1.86; participants = 345; studies = 2). </p> </section> <section id="CD011847-sec-0223"> <h6 class="title">3.13.3 Thought disturbance</h6> <p>Three studies reported data on thought disturbance (<a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a>; <a href="./references#CD011847-bbs2-0007" title="LinK , ChenXM . Clinical effect on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果刍议]. Yiayao Qianyan [医药前沿]2014;19:202‐3. ">Lin 2014</a>; <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a>). We found that the participants who received ECT had lower BPRS scores for thought disturbance compared with those who did not receive ECT (MD ‐2.69, 95% CI ‐2.95 to ‐2.43; participants = 423; studies = 3; I<sup>2</sup> = 85%). The statistical heterogeneity was reduced to I<sup>2</sup> = 0% after removing <a href="./references#CD011847-bbs2-0007" title="LinK , ChenXM . Clinical effect on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果刍议]. Yiayao Qianyan [医药前沿]2014;19:202‐3. ">Lin 2014</a> from the meta‐analysis (MD ‐2.94, 95% CI ‐3.23 to ‐2.64; participants = 345; studies = 2). </p> </section> <section id="CD011847-sec-0224"> <h6 class="title">3.13.4 Agitation</h6> <p>Three studies reported data on agitation (<a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a>; <a href="./references#CD011847-bbs2-0007" title="LinK , ChenXM . Clinical effect on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果刍议]. Yiayao Qianyan [医药前沿]2014;19:202‐3. ">Lin 2014</a>; <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a>). We found that the participants who received ECT had lower BPRS scores for agitation compared with those who did not receive ECT (MD ‐1.73, 95% CI ‐1.91 to ‐1.54; participants = 423; studies = 3). </p> </section> <section id="CD011847-sec-0225"> <h6 class="title">3.13.5 Hostile suspiciousness</h6> <p>Three studies reported data on hostile suspiciousness (<a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a>; <a href="./references#CD011847-bbs2-0007" title="LinK , ChenXM . Clinical effect on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果刍议]. Yiayao Qianyan [医药前沿]2014;19:202‐3. ">Lin 2014</a>; <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a>). We found that the participants who received ECT had lower BPRS scores for hostile suspiciousness compared with those who did not receive ECT (MD ‐2.77, 95% CI ‐3.00 to ‐2.54; participants = 423; studies = 3). </p> </section> <section id="CD011847-sec-0226"> <h6 class="title">3.13.6 Psychosis</h6> <p><a href="./references#CD011847-bbs2-0009" title="BragaRJ , MendelowitzAJ , FinkM , SchoolerNR , BailineSH , MalurC , et al. A randomized controlled trial of ECT in clozapine‐refractory schizophrenia. Biological Psychiatry2009;65(8):212S‐3S. [CSzG: Ref19511] PetridesG . ECT augmentation in clozapine‐resistant schizophrenia: acute efficacy and maintance data. Schizophrenia Bulletin2015;41:S328. [CSzG: Ref29626] PetridesG . Electroconvulsive therapy (ECT) for medication resistant schizophrenia. Schizophrenia Research2012;136:S22. [CSzG: Ref29625] PetridesG , GoldbergT , JohnM , BragaR , MalurC , MalhotraA , et al. Electroconvulsive therapy for clozapine‐resistant schizophrenia: cognitive effects. Neuropsychopharmacology2016;41:S257. [CSzG: Ref35678] PetridesG , MalurC , BragaRJ , BailineSH , SchoolerNR , MalhotraAK , et al. Electroconvulsive therapy augmentation in clozapine‐resistant schizophrenia: a prospective, randomized study. American Journal of Psychiatry2015;172(1):52‐8. [CSzG: Ref29366] ">Petrides 2015</a> reported data on psychosis. We found that the participants who received ECT had lower BPRS scores for psychosis compared with those who did not receive ECT (MD ‐6.07, 95% CI ‐6.72 to ‐5.42; participants = 39; studies = 1). </p> </section> </section> <section id="CD011847-sec-0227"> <h5 class="title">3.14 Mental state ‐ specific symptom score (PANSS, high = poor) ‐ short term</h5> <p>Six studies reported useable short‐term PANSS sub scale scores for specific mental symptoms (<a href="./references#CD011847-fig-0025" title="">Analysis 3.14</a>). </p> <section id="CD011847-sec-0228"> <h6 class="title">3.14.1 Positive symptom</h6> <p>Three studies reported data on positive symptom (<a href="./references#CD011847-bbs2-0003" title="ChenDR . Controlled study on MECT for treatment‐resistant schizophrenia [无抽搐电休克治疗难治性精神分裂症的对照分析]. 新疆医学 [Xinjiang Medical Journal]2012;9:57‐60. [CSzG: Ref32661] ">Chen 2012</a>; <a href="./references#CD011847-bbs2-0010" title="WangBH , ZengDZ , FanXW , HuaSG . Efficacy of modified electroconvulsive therapy in treatment‐refractory schizophrenia [无抽搐电休克对难治性精神分裂症的增效作用]. 临床精神医学杂志 [Journal of Clinical Psychiatry]2008;18(6):415‐7. [CSzG: Ref17865] ">Wang 2008</a>; <a href="./references#CD011847-bbs2-0015" title="ZhangSR , ZhangJL , LiXZ , YangYP , LangSY . The effect of MECT combined with olanzapine for refractory schizophrenia [无抽搐电休克联合奥氮平治疗难治性精神分裂症疗效观察]. People's Military Surgeon [人民军医]2012;2:141‐3. [CSzG: Ref27071] ">Zhang 2012</a>). We found no clear differences in short‐term PANSS scores for positive symptom between the two groups (MD ‐1.56, 95% CI ‐3.12 to 0.00; participants = 231; studies = 3). </p> </section> <section id="CD011847-sec-0229"> <h6 class="title">3.14.2 Negative symptom</h6> <p>Five studies reported data on negative symptom (<a href="./references#CD011847-bbs2-0003" title="ChenDR . Controlled study on MECT for treatment‐resistant schizophrenia [无抽搐电休克治疗难治性精神分裂症的对照分析]. 新疆医学 [Xinjiang Medical Journal]2012;9:57‐60. [CSzG: Ref32661] ">Chen 2012</a>; <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>; <a href="./references#CD011847-bbs2-0010" title="WangBH , ZengDZ , FanXW , HuaSG . Efficacy of modified electroconvulsive therapy in treatment‐refractory schizophrenia [无抽搐电休克对难治性精神分裂症的增效作用]. 临床精神医学杂志 [Journal of Clinical Psychiatry]2008;18(6):415‐7. [CSzG: Ref17865] ">Wang 2008</a>; <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a>; <a href="./references#CD011847-bbs2-0015" title="ZhangSR , ZhangJL , LiXZ , YangYP , LangSY . The effect of MECT combined with olanzapine for refractory schizophrenia [无抽搐电休克联合奥氮平治疗难治性精神分裂症疗效观察]. People's Military Surgeon [人民军医]2012;2:141‐3. [CSzG: Ref27071] ">Zhang 2012</a>). We found no clear differences in short‐term PANSS scores for negative symptom between the two groups (MD ‐1.03, 95% CI ‐2.42 to 0.35; participants = 372; studies = 5). </p> </section> <section id="CD011847-sec-0230"> <h6 class="title">3.14.3 General psychopathology</h6> <p>Three studies reported data on general psychopathology (<a href="./references#CD011847-bbs2-0010" title="WangBH , ZengDZ , FanXW , HuaSG . Efficacy of modified electroconvulsive therapy in treatment‐refractory schizophrenia [无抽搐电休克对难治性精神分裂症的增效作用]. 临床精神医学杂志 [Journal of Clinical Psychiatry]2008;18(6):415‐7. [CSzG: Ref17865] ">Wang 2008</a>; <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a>; <a href="./references#CD011847-bbs2-0015" title="ZhangSR , ZhangJL , LiXZ , YangYP , LangSY . The effect of MECT combined with olanzapine for refractory schizophrenia [无抽搐电休克联合奥氮平治疗难治性精神分裂症疗效观察]. People's Military Surgeon [人民军医]2012;2:141‐3. [CSzG: Ref27071] ">Zhang 2012</a>). We found no clear differences in short‐term PANSS scores for general psychopathology between the two groups (MD ‐1.59, 95% CI ‐3.83 to 0.66; participants = 234; studies = 3). </p> </section> <section id="CD011847-sec-0231"> <h6 class="title">3.14.4 Excitement</h6> <p><a href="./references#CD011847-bbs2-0013" title="YangKJ , LiuTB , YangHC . The effect of clozapine combining MECT for the resistant schizophrenics with agitation and aggressive behavior. Medical Journal of Chinese People's Health [中国民康医学]2005;17(9):485‐6. [CSzG: Ref12755] ">Yang 2005</a> reported that participants with agitation and aggressive behaviour who received ECT had lower short‐term PANSS scores for excitement than those who did not receive ECT (MD ‐5.79, 95% CI ‐7.34 to ‐4.24; participants = 60; studies = 1). </p> </section> <section id="CD011847-sec-0232"> <h6 class="title">3.14.5 Hostility</h6> <p><a href="./references#CD011847-bbs2-0013" title="YangKJ , LiuTB , YangHC . The effect of clozapine combining MECT for the resistant schizophrenics with agitation and aggressive behavior. Medical Journal of Chinese People's Health [中国民康医学]2005;17(9):485‐6. [CSzG: Ref12755] ">Yang 2005</a> reported that participants with agitation and aggressive behaviour who received ECT had lower short‐term PANSS scores for hostility than those who did not receive ECT (MD ‐2.48, 95% CI ‐3.93 to ‐1.03; participants = 60; studies = 1). </p> </section> </section> <section id="CD011847-sec-0233"> <h5 class="title">3.15 Mental state ‐ specific symptom score (PANSS, high = poor) ‐ short term (skewed data) </h5> <p>Data reported by other studies for positive symptom and general psychopathology at short‐term follow‐up were skewed and are presented as 'other data' (<a href="./references#CD011847-fig-0026" title="">Analysis 3.15</a>) (<a href="./references#CD011847-bbs2-0003" title="ChenDR . Controlled study on MECT for treatment‐resistant schizophrenia [无抽搐电休克治疗难治性精神分裂症的对照分析]. 新疆医学 [Xinjiang Medical Journal]2012;9:57‐60. [CSzG: Ref32661] ">Chen 2012</a>; <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>; <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a>). </p> </section> <section id="CD011847-sec-0234"> <h5 class="title">3.16 Mental state ‐ specific symptom score (PANSS, high = poor) ‐ medium term</h5> <p>Five studies reported useable medium‐term PANSS sub scale scores for specific mental symptoms (<a href="./references#CD011847-fig-0027" title="">Analysis 3.16</a>). </p> <section id="CD011847-sec-0235"> <h6 class="title">3.16.1 Negative symptom</h6> <p>Three studies reported data on negative symptom (<a href="./references#CD011847-bbs2-0003" title="ChenDR . Controlled study on MECT for treatment‐resistant schizophrenia [无抽搐电休克治疗难治性精神分裂症的对照分析]. 新疆医学 [Xinjiang Medical Journal]2012;9:57‐60. [CSzG: Ref32661] ">Chen 2012</a>; <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a>; <a href="./references#CD011847-bbs2-0015" title="ZhangSR , ZhangJL , LiXZ , YangYP , LangSY . The effect of MECT combined with olanzapine for refractory schizophrenia [无抽搐电休克联合奥氮平治疗难治性精神分裂症疗效观察]. People's Military Surgeon [人民军医]2012;2:141‐3. [CSzG: Ref27071] ">Zhang 2012</a>). We found no clear differences in medium‐term PANSS scores for negative symptom between the two groups (MD 0.58, 95% CI ‐1.47 to 2.62; participants = 229; studies = 3). </p> </section> <section id="CD011847-sec-0236"> <h6 class="title">3.16.2 General psychopathology</h6> <p>Two studies reported data on general psychopathology (<a href="./references#CD011847-bbs2-0010" title="WangBH , ZengDZ , FanXW , HuaSG . Efficacy of modified electroconvulsive therapy in treatment‐refractory schizophrenia [无抽搐电休克对难治性精神分裂症的增效作用]. 临床精神医学杂志 [Journal of Clinical Psychiatry]2008;18(6):415‐7. [CSzG: Ref17865] ">Wang 2008</a>; <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a>). We found that participants who received ECT had lower medium‐term PANSS scores for general psychopathology than those who did not receive ECT (MD ‐2.93, 95% CI ‐5.32 to ‐0.54; participants = 150; studies = 2). </p> </section> <section id="CD011847-sec-0237"> <h6 class="title">3.16.3 Excitement</h6> <p><a href="./references#CD011847-bbs2-0013" title="YangKJ , LiuTB , YangHC . The effect of clozapine combining MECT for the resistant schizophrenics with agitation and aggressive behavior. Medical Journal of Chinese People's Health [中国民康医学]2005;17(9):485‐6. [CSzG: Ref12755] ">Yang 2005</a> reported that participants with agitation and aggressive behaviour who received ECT had lower medium‐term PANSS scores for excitement than those who did not receive ECT (MD ‐2.31, 95% CI ‐3.44 to ‐1.18; participants = 60; studies = 1). </p> </section> <section id="CD011847-sec-0238"> <h6 class="title">3.16.4 Hostility</h6> <p><a href="./references#CD011847-bbs2-0013" title="YangKJ , LiuTB , YangHC . The effect of clozapine combining MECT for the resistant schizophrenics with agitation and aggressive behavior. Medical Journal of Chinese People's Health [中国民康医学]2005;17(9):485‐6. [CSzG: Ref12755] ">Yang 2005</a> reported that participants with agitation and aggressive behaviour who received ECT had lower medium‐term PANSS scores for hostility than those who did not receive ECT (MD ‐2.81, 95% CI ‐4.05 to ‐1.57; participants = 60; studies = 1). </p> </section> </section> <section id="CD011847-sec-0239"> <h5 class="title">3.17 Mental state ‐ specific symptom score (PANSS, high = poor) ‐ medium term (skewed data) </h5> <p>Five studies also reported the medium‐term PANSS scores for positive symptoms (<a href="./references#CD011847-bbs2-0003" title="ChenDR . Controlled study on MECT for treatment‐resistant schizophrenia [无抽搐电休克治疗难治性精神分裂症的对照分析]. 新疆医学 [Xinjiang Medical Journal]2012;9:57‐60. [CSzG: Ref32661] ">Chen 2012</a>; <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>; <a href="./references#CD011847-bbs2-0010" title="WangBH , ZengDZ , FanXW , HuaSG . Efficacy of modified electroconvulsive therapy in treatment‐refractory schizophrenia [无抽搐电休克对难治性精神分裂症的增效作用]. 临床精神医学杂志 [Journal of Clinical Psychiatry]2008;18(6):415‐7. [CSzG: Ref17865] ">Wang 2008</a>; <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a>; <a href="./references#CD011847-bbs2-0015" title="ZhangSR , ZhangJL , LiXZ , YangYP , LangSY . The effect of MECT combined with olanzapine for refractory schizophrenia [无抽搐电休克联合奥氮平治疗难治性精神分裂症疗效观察]. People's Military Surgeon [人民军医]2012;2:141‐3. [CSzG: Ref27071] ">Zhang 2012</a>); however, as the data were skewed, we have presented them as 'other data' in <a href="./references#CD011847-fig-0028" title="">Analysis 3.17</a>. </p> </section> <section id="CD011847-sec-0240"> <h5 class="title">3.18 Mental state ‐ specific symptom score (SAPS, high = poor) ‐ short term</h5> <p>Only one study reported the SAPS scores for positive symptoms at short‐term follow‐up (<a href="./references#CD011847-fig-0029" title="">Analysis 3.18</a>) (<a href="./references#CD011847-bbs2-0008" title="LiuFQ , GongGQ . The effect of MECT for treatment‐resistant schizophrenic patients [精神分裂症患者无抽搐电休克的效果]. China Modern Doctor [中国现代医生]2010;48(1):29, 36. [CSzG: Ref22012] ">Liu 2010</a>). </p> <section id="CD011847-sec-0241"> <h6 class="title">3.18.1 Hallucinations</h6> <p><a href="./references#CD011847-bbs2-0008" title="LiuFQ , GongGQ . The effect of MECT for treatment‐resistant schizophrenic patients [精神分裂症患者无抽搐电休克的效果]. China Modern Doctor [中国现代医生]2010;48(1):29, 36. [CSzG: Ref22012] ">Liu 2010</a> reported that participants who received ECT had lower short‐term SAPS scores for hallucinations than those who did not receive ECT (MD ‐1.50, 95% CI ‐1.71 to ‐1.29; participants = 72; studies = 1). </p> </section> <section id="CD011847-sec-0242"> <h6 class="title">3.18.2 Delusions</h6> <p><a href="./references#CD011847-bbs2-0008" title="LiuFQ , GongGQ . The effect of MECT for treatment‐resistant schizophrenic patients [精神分裂症患者无抽搐电休克的效果]. China Modern Doctor [中国现代医生]2010;48(1):29, 36. [CSzG: Ref22012] ">Liu 2010</a> reported that participants who received ECT had lower short‐term SAPS scores for delusions than those who did not receive ECT (MD ‐2.81, 95% CI ‐3.10 to ‐2.52; participants = 72; studies = 1). </p> </section> <section id="CD011847-sec-0243"> <h6 class="title">3.18.3 Bizarre behaviour</h6> <p><a href="./references#CD011847-bbs2-0008" title="LiuFQ , GongGQ . The effect of MECT for treatment‐resistant schizophrenic patients [精神分裂症患者无抽搐电休克的效果]. China Modern Doctor [中国现代医生]2010;48(1):29, 36. [CSzG: Ref22012] ">Liu 2010</a> reported that there was no clear difference in short‐term SAPS scores for bizarre behaviour between the two groups (MD ‐0.10, 95% CI ‐0.21 to 0.01; participants = 72; studies = 1). </p> </section> <section id="CD011847-sec-0244"> <h6 class="title">3.18.4 Positive formal thought disorder</h6> <p><a href="./references#CD011847-bbs2-0008" title="LiuFQ , GongGQ . The effect of MECT for treatment‐resistant schizophrenic patients [精神分裂症患者无抽搐电休克的效果]. China Modern Doctor [中国现代医生]2010;48(1):29, 36. [CSzG: Ref22012] ">Liu 2010</a> reported that participants who received ECT had lower short‐term SAPS scores for positive formal thought disorder than those who did not receive ECT (MD ‐2.20, 95% CI ‐2.50 to ‐1.90; participants = 72; studies = 1). </p> </section> </section> <section id="CD011847-sec-0245"> <h5 class="title">3.19 Mental state ‐ specific symptom score (SANS, high = poor) ‐ short term</h5> <p>Only one study reported the SANS scores for negative symptoms at short‐term follow‐up (<a href="./references#CD011847-fig-0030" title="">Analysis 3.19</a>) (<a href="./references#CD011847-bbs2-0008" title="LiuFQ , GongGQ . The effect of MECT for treatment‐resistant schizophrenic patients [精神分裂症患者无抽搐电休克的效果]. China Modern Doctor [中国现代医生]2010;48(1):29, 36. [CSzG: Ref22012] ">Liu 2010</a>). </p> <section id="CD011847-sec-0246"> <h6 class="title">3.19.1 Affective flattening or blunting</h6> <p><a href="./references#CD011847-bbs2-0008" title="LiuFQ , GongGQ . The effect of MECT for treatment‐resistant schizophrenic patients [精神分裂症患者无抽搐电休克的效果]. China Modern Doctor [中国现代医生]2010;48(1):29, 36. [CSzG: Ref22012] ">Liu 2010</a> reported that participants who received ECT had lower short‐term SANS scores for affective flattening or blunting than those who did not receive ECT (MD ‐4.70, 95% CI ‐5.03 to ‐4.37; participants = 72; studies = 1). </p> </section> <section id="CD011847-sec-0247"> <h6 class="title">3.19.2 Alogia</h6> <p><a href="./references#CD011847-bbs2-0008" title="LiuFQ , GongGQ . The effect of MECT for treatment‐resistant schizophrenic patients [精神分裂症患者无抽搐电休克的效果]. China Modern Doctor [中国现代医生]2010;48(1):29, 36. [CSzG: Ref22012] ">Liu 2010</a> reported that there was no clear difference in short‐term SANS scores for alogia between the two groups (MD ‐0.20, 95% CI ‐0.43 to 0.03; participants = 72; studies = 1). </p> </section> <section id="CD011847-sec-0248"> <h6 class="title">3.19.3 Avolition</h6> <p><a href="./references#CD011847-bbs2-0008" title="LiuFQ , GongGQ . The effect of MECT for treatment‐resistant schizophrenic patients [精神分裂症患者无抽搐电休克的效果]. China Modern Doctor [中国现代医生]2010;48(1):29, 36. [CSzG: Ref22012] ">Liu 2010</a> reported that there was no clear difference in short‐term SANS scores for avolition between the two groups (MD ‐0.20, 95% CI ‐0.40 to 0.00; participants = 72; studies = 1). </p> </section> <section id="CD011847-sec-0249"> <h6 class="title">3.19.4 Anhedonia</h6> <p><a href="./references#CD011847-bbs2-0008" title="LiuFQ , GongGQ . The effect of MECT for treatment‐resistant schizophrenic patients [精神分裂症患者无抽搐电休克的效果]. China Modern Doctor [中国现代医生]2010;48(1):29, 36. [CSzG: Ref22012] ">Liu 2010</a> reported that participants who received ECT had lower short‐term SANS scores for anhedonia than those who did not receive ECT (MD ‐0.30, 95% CI ‐0.44 to ‐0.16; participants = 72; studies = 1). </p> </section> <section id="CD011847-sec-0250"> <h6 class="title">3.19.5 Attention</h6> <p><a href="./references#CD011847-bbs2-0008" title="LiuFQ , GongGQ . The effect of MECT for treatment‐resistant schizophrenic patients [精神分裂症患者无抽搐电休克的效果]. China Modern Doctor [中国现代医生]2010;48(1):29, 36. [CSzG: Ref22012] ">Liu 2010</a> reported that participants who received ECT had lower short‐term SANS scores for attention than those who did not receive ECT (MD ‐0.90, 95% CI ‐0.97 to ‐0.83; participants = 72; studies = 1). </p> </section> </section> <section id="CD011847-sec-0251"> <h5 class="title">3.20 General functioning ‐ total score (GAF, high = good)</h5> <p>Two studies reported general functioning by measuring endpoint total scores of GAF (<a href="./references#CD011847-fig-0031" title="">Analysis 3.20</a>). </p> <section id="CD011847-sec-0252"> <h6 class="title">3.20.1 Short term</h6> <p><a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a> (n = 67) reported the endpoint total score of general functioning assessed by GAF. There was no clear difference in short‐term GAF scores between the two groups (MD 4.32, 95% CI ‐0.20 to 8.84; participants = 67; studies = 1). </p> </section> <section id="CD011847-sec-0253"> <h6 class="title">3.20.2 Medium term</h6> <p>Two studies reported the endpoint total score for this outcome assessed by GAF (<a href="./references#CD011847-bbs2-0002" title="ChanpattanaW . ECT in schizophrenia. Journal of the Psychiatric Association of Thailand1999;44(2):156‐70. [CSzG: Ref8163] ChanpattanaW , ChakrabhandML , KitaroonchaiW , ChoovanichvongS , PrasertsukY . Effects of twice‐ versus thrice‐weekly electroconvulsive therapy in schizophrenia. Journal of the Medical Association of Thailand1999;82(5):477‐82. ChanpattanaW , ChakrabhandML , SackeimHA , KitaroonchaiW , KongsakonR , TechakasemP , et al. Continuation ECT in treatment resistant schizophrenia: a controlled study. Journal of ECT1999;15(3):178‐92. [CSzG: Ref4913; MEDLINE: 10492856] ">Chanpattana 1999</a>; <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>). We found that participants who received ECT had higher medium‐term GAF scores than those who did not receive ECT (MD 10.66, 95% CI 6.98 to 14.34; participants = 97; studies = 2; I<sup>2</sup> = 80%; very low‐quality evidence). The result had important heterogeneity. <a href="./references#CD011847-bbs2-0002" title="ChanpattanaW . ECT in schizophrenia. Journal of the Psychiatric Association of Thailand1999;44(2):156‐70. [CSzG: Ref8163] ChanpattanaW , ChakrabhandML , KitaroonchaiW , ChoovanichvongS , PrasertsukY . Effects of twice‐ versus thrice‐weekly electroconvulsive therapy in schizophrenia. Journal of the Medical Association of Thailand1999;82(5):477‐82. ChanpattanaW , ChakrabhandML , SackeimHA , KitaroonchaiW , KongsakonR , TechakasemP , et al. Continuation ECT in treatment resistant schizophrenia: a controlled study. Journal of ECT1999;15(3):178‐92. [CSzG: Ref4913; MEDLINE: 10492856] ">Chanpattana 1999</a> used a long course of ECT (MD 20.47, 95% CI 11.21 to 29.73; participants = 30; studies = 1), while <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a> used a short course (MD 8.82, 95% CI 4.81 to 12.83; participants = 67; studies = 1). Accordingly, the treatment effect was robust to heterogeneity between the studies. </p> </section> </section> <section id="CD011847-sec-0254"> <h5 class="title">3.21 Adverse events ‐ general ‐ medium term</h5> <p>Only one study reported the number of participants who had any adverse event at medium‐term follow‐up (<a href="./references#CD011847-bbs2-0015" title="ZhangSR , ZhangJL , LiXZ , YangYP , LangSY . The effect of MECT combined with olanzapine for refractory schizophrenia [无抽搐电休克联合奥氮平治疗难治性精神分裂症疗效观察]. People's Military Surgeon [人民军医]2012;2:141‐3. [CSzG: Ref27071] ">Zhang 2012</a>). This study found no clear difference in the incidence of adverse events between the two groups (RR 1.33, 95% CI 0.86 to 2.06; participants = 84; studies = 1; <a href="./references#CD011847-fig-0032" title="">Analysis 3.21</a>). </p> </section> <section id="CD011847-sec-0255"> <h5 class="title">3.22 Adverse events ‐ total score (TESS, high = poor)</h5> <p>Four studies reported useable data for this outcome (<a href="./references#CD011847-fig-0033" title="">Analysis 3.22</a>). </p> <section id="CD011847-sec-0256"> <h6 class="title">3.22.1 Short term</h6> <p>Three studies reported the short‐term endpoint scores of adverse events assessed by TESS (<a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a>; <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>; <a href="./references#CD011847-bbs2-0015" title="ZhangSR , ZhangJL , LiXZ , YangYP , LangSY . The effect of MECT combined with olanzapine for refractory schizophrenia [无抽搐电休克联合奥氮平治疗难治性精神分裂症疗效观察]. People's Military Surgeon [人民军医]2012;2:141‐3. [CSzG: Ref27071] ">Zhang 2012</a>). There was no clear difference in the TESS total score between the two groups (MD ‐0.19, 95% CI ‐0.96 to 0.57; participants = 251; studies = 3). </p> </section> <section id="CD011847-sec-0257"> <h6 class="title">3.22.2 Medium term</h6> <p>Four studies reported the medium‐term endpoint scores of adverse events assessed by TESS (<a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a>; <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>; <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a>; <a href="./references#CD011847-bbs2-0015" title="ZhangSR , ZhangJL , LiXZ , YangYP , LangSY . The effect of MECT combined with olanzapine for refractory schizophrenia [无抽搐电休克联合奥氮平治疗难治性精神分裂症疗效观察]. People's Military Surgeon [人民军医]2012;2:141‐3. [CSzG: Ref27071] ">Zhang 2012</a>). We found that participants who received ECT had lower TESS total scores than those who did not receive ECT (MD ‐0.63, 95% CI ‐1.01 to ‐0.25; participants = 496; studies = 4). </p> </section> </section> <section id="CD011847-sec-0258"> <h5 class="title">3.23 Adverse events ‐ specific symptom ‐ short term</h5> <p>Only one study reported the number of participants who had adverse events at short‐term follow‐up (<a href="./references#CD011847-bbs2-0012" title="WangF , GuoDW . The effect on olanzapine combined with modified electroconvulsive therapy in refractory schizophrenia [奥氮平联合改良电休克治疗难治性精神分裂症的疗效观察]. Clinical Rational Drug Use [临床合理用药杂志]2013;24:99. [CSzG: Ref27406] ">Wang 2013</a>). There were no clear differences in the incidence of specific symptoms between the two groups (<a href="./references#CD011847-fig-0034" title="">Analysis 3.23</a>). </p> <section id="CD011847-sec-0259"> <h6 class="title">3.23.1 Abnormal electrocardiogram</h6> <p>There were no clear differences in the incidence of abnormal electrocardiogram between the two groups (RR 0.85, 95% CI 0.44 to 1.63; participants = 72; studies = 1). </p> </section> <section id="CD011847-sec-0260"> <h6 class="title">3.23.2 Abnormal liver function</h6> <p>There were no clear differences in the incidence of abnormal liver function between the two groups (RR 0.67, 95% CI 0.12 to 3.75; participants = 72; studies = 1). </p> </section> <section id="CD011847-sec-0261"> <h6 class="title">3.23.3 Constipation</h6> <p>There were no clear differences in the incidence of constipation between the two groups (RR 0.75, 95% CI 0.36 to 1.56; participants = 72; studies = 1). </p> </section> <section id="CD011847-sec-0262"> <h6 class="title">3.23.4 Headache</h6> <p>There were no clear differences in the incidence of headache between the two groups (RR 7.00, 95% CI 0.37 to 130.82; participants = 72; studies = 1). </p> </section> <section id="CD011847-sec-0263"> <h6 class="title">3.23.5 Lethargy</h6> <p>There were no clear differences in the incidence of lethargy between the two groups (RR 0.80, 95% CI 0.44 to 1.46; participants = 72; studies = 1). </p> </section> <section id="CD011847-sec-0264"> <h6 class="title">3.23.6 Nausea or vomiting</h6> <p>There were no clear differences in the incidence of nausea or vomiting between the two groups (RR 2.00, 95% CI 0.19 to 21.09; participants = 72; studies = 1). </p> </section> <section id="CD011847-sec-0265"> <h6 class="title">3.23.7 Salivation</h6> <p>There were no clear differences in the incidence of salivation between the two groups (RR 0.73, 95% CI 0.33 to 1.59; participants = 72; studies = 1). </p> </section> <section id="CD011847-sec-0266"> <h6 class="title">3.23.8 Weight gain</h6> <p>There were no clear differences in the incidence of weight gain between the two groups (RR 0.40, 95% CI 0.14 to 1.16; participants = 72; studies = 1). </p> </section> </section> <section id="CD011847-sec-0267"> <h5 class="title">3.24 Adverse events ‐ specific symptom ‐ medium term</h5> <p>Six studies reported the number of participants who had specific adverse events at medium‐term follow‐up (<a href="./references#CD011847-fig-0035" title="">Analysis 3.24</a>). </p> <section id="CD011847-sec-0268"> <h6 class="title">3.24.1 Abnormal electrocardiogram</h6> <p>Four studies reported this outcome (<a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a>; <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>; <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a>; <a href="./references#CD011847-bbs2-0013" title="YangKJ , LiuTB , YangHC . The effect of clozapine combining MECT for the resistant schizophrenics with agitation and aggressive behavior. Medical Journal of Chinese People's Health [中国民康医学]2005;17(9):485‐6. [CSzG: Ref12755] ">Yang 2005</a>). There was no clear difference between the two groups (RR 0.92, 95% CI 0.67 to 1.26; participants = 274; studies = 4). </p> </section> <section id="CD011847-sec-0269"> <h6 class="title">3.24.2 Abnormal electroencephalogram</h6> <p><a href="./references#CD011847-bbs2-0013" title="YangKJ , LiuTB , YangHC . The effect of clozapine combining MECT for the resistant schizophrenics with agitation and aggressive behavior. Medical Journal of Chinese People's Health [中国民康医学]2005;17(9):485‐6. [CSzG: Ref12755] ">Yang 2005</a> reported this outcome. There was no clear difference between the two groups (RR 1.04, 95% CI 0.82 to 1.32; participants = 60; studies = 1). </p> </section> <section id="CD011847-sec-0270"> <h6 class="title">3.24.3 Abnormal liver function</h6> <p>Three studies reported this outcome (<a href="./references#CD011847-bbs2-0003" title="ChenDR . Controlled study on MECT for treatment‐resistant schizophrenia [无抽搐电休克治疗难治性精神分裂症的对照分析]. 新疆医学 [Xinjiang Medical Journal]2012;9:57‐60. [CSzG: Ref32661] ">Chen 2012</a>; <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a>; <a href="./references#CD011847-bbs2-0013" title="YangKJ , LiuTB , YangHC . The effect of clozapine combining MECT for the resistant schizophrenics with agitation and aggressive behavior. Medical Journal of Chinese People's Health [中国民康医学]2005;17(9):485‐6. [CSzG: Ref12755] ">Yang 2005</a>). There was no clear difference between the two groups (RR 0.72, 95% CI 0.30 to 1.71; participants = 205; studies = 3). </p> </section> <section id="CD011847-sec-0271"> <h6 class="title">3.24.4 Blurred vision</h6> <p><a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a> reported this outcome. There was no clear difference between the two groups (RR 1.03, 95% CI 0.28 to 3.79; participants = 69; studies = 1). </p> </section> <section id="CD011847-sec-0272"> <h6 class="title">3.24.5 Breathing discomfort</h6> <p><a href="./references#CD011847-bbs2-0007" title="LinK , ChenXM . Clinical effect on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果刍议]. Yiayao Qianyan [医药前沿]2014;19:202‐3. ">Lin 2014</a> reported that fewer participants who received ECT experienced breathing discomfort compared with those who did not receive ECT (RR 0.08, 95% CI 0.01 to 0.61; participants = 78; studies = 1). </p> </section> <section id="CD011847-sec-0273"> <h6 class="title">3.24.6 Cathisophobia</h6> <p><a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a> reported this outcome. There was no clear difference between the two groups (RR 0.80, 95% CI 0.34 to 1.91; participants = 69; studies = 1). </p> </section> <section id="CD011847-sec-0274"> <h6 class="title">3.24.7 Constipation</h6> <p>Two studies reported that fewer participants who received ECT experienced constipation compared with those who did not receive ECT (RR 0.76, 95% CI 0.61 to 0.95; participants = 145; studies = 2; I<sup>2</sup> = 83%) (<a href="./references#CD011847-bbs2-0003" title="ChenDR . Controlled study on MECT for treatment‐resistant schizophrenia [无抽搐电休克治疗难治性精神分裂症的对照分析]. 新疆医学 [Xinjiang Medical Journal]2012;9:57‐60. [CSzG: Ref32661] ">Chen 2012</a>; <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a>). The results had important heterogeneity, and no obvious source was identified. <a href="./references#CD011847-bbs2-0003" title="ChenDR . Controlled study on MECT for treatment‐resistant schizophrenia [无抽搐电休克治疗难治性精神分裂症的对照分析]. 新疆医学 [Xinjiang Medical Journal]2012;9:57‐60. [CSzG: Ref32661] ">Chen 2012</a> reported that fewer participants in the ECT group had constipation (RR 0.56, 95% CI 0.37 to 0.83; participants = 71; studies = 1), while <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a> reported that there was no clear difference between the two groups (RR 0.97, 95% CI 0.75 to 1.24; participants = 74; studies = 1). </p> </section> <section id="CD011847-sec-0275"> <h6 class="title">3.24.8 Decreased activity</h6> <p><a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a> reported this outcome. There was no clear difference between the two groups (RR 0.56, 95% CI 0.23 to 1.35; participants = 69; studies = 1). </p> </section> <section id="CD011847-sec-0276"> <h6 class="title">3.24.9 Dizziness</h6> <p><a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a> reported this outcome. There was no clear difference between the two groups (RR 1.72, 95% CI 0.70 to 4.20; participants = 69; studies = 1). </p> </section> <section id="CD011847-sec-0277"> <h6 class="title">3.24.10 Dry mouth</h6> <p><a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a> reported this outcome. There was no clear difference between the two groups (RR 1.03, 95% CI 0.33 to 3.24; participants = 69; studies = 1). </p> </section> <section id="CD011847-sec-0278"> <h6 class="title">3.24.11 Headache</h6> <p>Two studies reported that more participants who received ECT experienced headache compared with those who did not receive ECT (RR 5.47, 95% CI 1.47 to 20.39; participants = 147; studies = 2; I<sup>2</sup> = 55%) (<a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>; <a href="./references#CD011847-bbs2-0007" title="LinK , ChenXM . Clinical effect on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果刍议]. Yiayao Qianyan [医药前沿]2014;19:202‐3. ">Lin 2014</a>). The result had important heterogeneity, and no obvious source was identified. <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a> reported that more participants in the ECT group had headaches (RR 19.54, 95% CI 1.18 to 323.15; participants = 69; studies = 1), while <a href="./references#CD011847-bbs2-0007" title="LinK , ChenXM . Clinical effect on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果刍议]. Yiayao Qianyan [医药前沿]2014;19:202‐3. ">Lin 2014</a> reported that there was no clear difference between the two groups (RR 2.00, 95% CI 0.39 to 10.29; participants = 78; studies = 1). </p> </section> <section id="CD011847-sec-0279"> <h6 class="title">3.24.12 Indigestion</h6> <p><a href="./references#CD011847-bbs2-0007" title="LinK , ChenXM . Clinical effect on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果刍议]. Yiayao Qianyan [医药前沿]2014;19:202‐3. ">Lin 2014</a> reported this outcome. There was no clear difference between the two groups (RR 0.50, 95% CI 0.16 to 1.53; participants = 78; studies = 1). </p> </section> <section id="CD011847-sec-0280"> <h6 class="title">3.24.13 Insomnia</h6> <p><a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a> reported this outcome. There was no clear difference between the two groups (RR 0.05, 95% CI 0.00 to 0.80; participants = 69; studies = 1). </p> </section> <section id="CD011847-sec-0281"> <h6 class="title">3.24.14 Lethargy</h6> <p>Three studies reported this outcome (<a href="./references#CD011847-bbs2-0003" title="ChenDR . Controlled study on MECT for treatment‐resistant schizophrenia [无抽搐电休克治疗难治性精神分裂症的对照分析]. 新疆医学 [Xinjiang Medical Journal]2012;9:57‐60. [CSzG: Ref32661] ">Chen 2012</a>; <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>; <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a>). There was no clear difference between the two groups (RR 0.86, 95% CI 0.70 to 1.05; participants = 214; studies = 3; I<sup>2</sup> = 73%). The result had important heterogeneity, and no obvious source was identified. </p> </section> <section id="CD011847-sec-0282"> <h6 class="title">3.24.15 Leucopenia</h6> <p>Two studies reported this outcome (<a href="./references#CD011847-bbs2-0003" title="ChenDR . Controlled study on MECT for treatment‐resistant schizophrenia [无抽搐电休克治疗难治性精神分裂症的对照分析]. 新疆医学 [Xinjiang Medical Journal]2012;9:57‐60. [CSzG: Ref32661] ">Chen 2012</a>; <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a>). There was no clear difference between the two groups (RR 0.73, 95% CI 0.18 to 3.03; participants = 145; studies = 2). </p> </section> <section id="CD011847-sec-0283"> <h6 class="title">3.24.16 Muscle rigidity</h6> <p><a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a> reported this outcome. There was no clear difference between the two groups (RR 0.77, 95% CI 0.37 to 1.59; participants = 69; studies = 1). </p> </section> <section id="CD011847-sec-0284"> <h6 class="title">3.24.17 Nausea or vomiting</h6> <p>Two studies reported this outcome (<a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>; <a href="./references#CD011847-bbs2-0007" title="LinK , ChenXM . Clinical effect on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果刍议]. Yiayao Qianyan [医药前沿]2014;19:202‐3. ">Lin 2014</a>). There was no clear difference between the two groups (RR 0.79, 95% CI 0.31 to 2.02; participants = 147; studies = 2; I<sup>2</sup> = 60%). The result had important heterogeneity, and no obvious source was identified. </p> </section> <section id="CD011847-sec-0285"> <h6 class="title">3.24.18 Recurrence of pre‐existing involuntary 'jerky' movements</h6> <p><a href="./references#CD011847-bbs2-0009" title="BragaRJ , MendelowitzAJ , FinkM , SchoolerNR , BailineSH , MalurC , et al. A randomized controlled trial of ECT in clozapine‐refractory schizophrenia. Biological Psychiatry2009;65(8):212S‐3S. [CSzG: Ref19511] PetridesG . ECT augmentation in clozapine‐resistant schizophrenia: acute efficacy and maintance data. Schizophrenia Bulletin2015;41:S328. [CSzG: Ref29626] PetridesG . Electroconvulsive therapy (ECT) for medication resistant schizophrenia. Schizophrenia Research2012;136:S22. [CSzG: Ref29625] PetridesG , GoldbergT , JohnM , BragaR , MalurC , MalhotraA , et al. Electroconvulsive therapy for clozapine‐resistant schizophrenia: cognitive effects. Neuropsychopharmacology2016;41:S257. [CSzG: Ref35678] PetridesG , MalurC , BragaRJ , BailineSH , SchoolerNR , MalhotraAK , et al. Electroconvulsive therapy augmentation in clozapine‐resistant schizophrenia: a prospective, randomized study. American Journal of Psychiatry2015;172(1):52‐8. [CSzG: Ref29366] ">Petrides 2015</a> reported this outcome. There was no clear difference between the two groups (RR 2.86, 95% CI 0.12 to 66.11; participants = 39; studies = 1). </p> </section> <section id="CD011847-sec-0286"> <h6 class="title">3.24.19 Salivation</h6> <p>Two studies reported this outcome (<a href="./references#CD011847-bbs2-0003" title="ChenDR . Controlled study on MECT for treatment‐resistant schizophrenia [无抽搐电休克治疗难治性精神分裂症的对照分析]. 新疆医学 [Xinjiang Medical Journal]2012;9:57‐60. [CSzG: Ref32661] ">Chen 2012</a>; <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a>). There was no clear difference between the two groups (RR 0.80, 95% CI 0.57 to 1.14; participants = 145; studies = 2). </p> </section> <section id="CD011847-sec-0287"> <h6 class="title">3.24.20 Tremor</h6> <p><a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a> reported this outcome. There was no clear difference between the two groups (RR 0.72, 95% CI 0.31 to 1.67; participants = 69; studies = 1). </p> </section> <section id="CD011847-sec-0288"> <h6 class="title">3.24.21 Weight gain</h6> <p>Three studies reported this outcome (<a href="./references#CD011847-bbs2-0003" title="ChenDR . Controlled study on MECT for treatment‐resistant schizophrenia [无抽搐电休克治疗难治性精神分裂症的对照分析]. 新疆医学 [Xinjiang Medical Journal]2012;9:57‐60. [CSzG: Ref32661] ">Chen 2012</a>; <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>; <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a>). There was no clear difference between the two groups (RR 0.72, 95% CI 0.46 to 1.13; participants = 214; studies = 3). </p> </section> <section id="CD011847-sec-0289"> <h6 class="title">3.24.22 Others</h6> <p>Two studies reported there was no clear difference in other adverse events between the two groups (RR 0.99, 95% CI 0.44 to 2.23; participants = 145; studies = 2) (<a href="./references#CD011847-bbs2-0003" title="ChenDR . Controlled study on MECT for treatment‐resistant schizophrenia [无抽搐电休克治疗难治性精神分裂症的对照分析]. 新疆医学 [Xinjiang Medical Journal]2012;9:57‐60. [CSzG: Ref32661] ">Chen 2012</a>; <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a>). </p> </section> </section> <section id="CD011847-sec-0290"> <h5 class="title">3.25 Adverse events ‐ specific symptom score (TESS, high = poor) ‐ short term (skewed data) </h5> <p><a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a> (n = 100) reported the TESS scores for specific symptoms, including abnormal laboratory values, behavioural toxicity, symptoms of the cardiovascular system, symptoms of the nervous system, symptoms of a vegetative nervous system, and others. Because of skewed data, we did not perform parameter tests, and only presented this information as 'other data' (<a href="./references#CD011847-fig-0036" title="">Analysis 3.25</a>). </p> </section> <section id="CD011847-sec-0291"> <h5 class="title">3.26 Adverse events ‐ specific symptom score (TESS, high = poor) ‐ medium term</h5> <p>Only one study reported this outcome at medium‐term follow‐up (<a href="./references#CD011847-fig-0037" title="">Analysis 3.26</a>) (<a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a>). </p> <section id="CD011847-sec-0292"> <h6 class="title">3.26.1 Abnormal laboratory values</h6> <p><a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> reported this outcome. There was no clear difference between the two groups (MD ‐0.01, 95% CI ‐0.08 to 0.06; participants = 245; studies = 1). </p> </section> <section id="CD011847-sec-0293"> <h6 class="title">3.26.2 Behavioural toxicity</h6> <p><a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> reported that participants who received ECT had lower TESS scores for behavioural toxicity compared with those who did not receive ECT (MD ‐0.31, 95% CI ‐0.38 to ‐0.24; participants = 245; studies = 1). </p> </section> <section id="CD011847-sec-0294"> <h6 class="title">3.26.3 Symptoms of cardiovascular system</h6> <p><a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> reported that participants who received ECT had lower TESS scores for symptoms of the cardiovascular system compared with those who did not receive ECT (MD ‐0.50, 95% CI ‐0.58 to ‐0.42; participants = 245; studies = 1). </p> </section> <section id="CD011847-sec-0295"> <h6 class="title">3.26.4 Symptoms of nervous system</h6> <p><a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> reported this outcome. There was no clear difference between the two groups (MD ‐0.02, 95% CI ‐0.08 to 0.04; participants = 245; studies = 1). </p> </section> <section id="CD011847-sec-0296"> <h6 class="title">3.26.5 Symptoms of vegetative nervous system</h6> <p><a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> reported this outcome. There was no clear difference between the two groups (MD 0.03, 95% CI ‐0.05 to 0.11; participants = 245; studies = 1). </p> </section> <section id="CD011847-sec-0297"> <h6 class="title">3.26.6 Others</h6> <p><a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a> reported there was no clear difference in other adverse events between the two groups (MD ‐0.02, 95% CI ‐0.17 to 0.13; participants = 245; studies = 1). </p> </section> </section> <section id="CD011847-sec-0298"> <h5 class="title">3.27 Adverse events ‐ specific symptom score (TESS, high = poor) ‐ medium term (skewed data) </h5> <p>As data reported in <a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a> (n = 100) were skewed, we did not perform parameter tests, and only presented this information in <a href="./references#CD011847-fig-0038" title="">Analysis 3.27</a>. </p> <p>Service outcomes were not reported for this comparison.</p> </section> </section> <section id="CD011847-sec-0299"> <h4 class="title">COMPARISON 4: ECT alone versus antipsychotic alone (flupenthixol)</h4> <p>For this comparison, we found only one relevant study involving 30 participants receiving either ECT alone or flupenthixol (<a href="./references#CD011847-bbs2-0002" title="ChanpattanaW . ECT in schizophrenia. Journal of the Psychiatric Association of Thailand1999;44(2):156‐70. [CSzG: Ref8163] ChanpattanaW , ChakrabhandML , KitaroonchaiW , ChoovanichvongS , PrasertsukY . Effects of twice‐ versus thrice‐weekly electroconvulsive therapy in schizophrenia. Journal of the Medical Association of Thailand1999;82(5):477‐82. ChanpattanaW , ChakrabhandML , SackeimHA , KitaroonchaiW , KongsakonR , TechakasemP , et al. Continuation ECT in treatment resistant schizophrenia: a controlled study. Journal of ECT1999;15(3):178‐92. [CSzG: Ref4913; MEDLINE: 10492856] ">Chanpattana 1999</a>). This study evaluated the effects of a long course of ECT performed as continuation with bilateral electrode placement. The participants in this study were strictly diagnosed with schizophrenia by DSM‐IV. </p> <p>See <a href="./full#CD011847-tbl-0004">summary of findings Table 4</a>. </p> <section id="CD011847-sec-0300"> <h5 class="title">4.1 Mental state ‐ total score (BPRS, high = poor) ‐ medium term</h5> <p><a href="./references#CD011847-bbs2-0002" title="ChanpattanaW . ECT in schizophrenia. Journal of the Psychiatric Association of Thailand1999;44(2):156‐70. [CSzG: Ref8163] ChanpattanaW , ChakrabhandML , KitaroonchaiW , ChoovanichvongS , PrasertsukY . Effects of twice‐ versus thrice‐weekly electroconvulsive therapy in schizophrenia. Journal of the Medical Association of Thailand1999;82(5):477‐82. ChanpattanaW , ChakrabhandML , SackeimHA , KitaroonchaiW , KongsakonR , TechakasemP , et al. Continuation ECT in treatment resistant schizophrenia: a controlled study. Journal of ECT1999;15(3):178‐92. [CSzG: Ref4913; MEDLINE: 10492856] ">Chanpattana 1999</a> reported the medium‐term endpoint total scores of mental state assessed by the BPRS. The study found no clear differences in BPRS scores between the two groups (MD ‐0.93, 95% CI ‐6.95 to 5.09; participants = 30; studies = 1; very low‐quality evidence; <a href="./references#CD011847-fig-0039" title="">Analysis 4.1</a>). </p> </section> <section id="CD011847-sec-0301"> <h5 class="title">4.2 Mental state ‐ total score (MMSE, high = good) ‐ medium term</h5> <p><a href="./references#CD011847-bbs2-0002" title="ChanpattanaW . ECT in schizophrenia. Journal of the Psychiatric Association of Thailand1999;44(2):156‐70. [CSzG: Ref8163] ChanpattanaW , ChakrabhandML , KitaroonchaiW , ChoovanichvongS , PrasertsukY . Effects of twice‐ versus thrice‐weekly electroconvulsive therapy in schizophrenia. Journal of the Medical Association of Thailand1999;82(5):477‐82. ChanpattanaW , ChakrabhandML , SackeimHA , KitaroonchaiW , KongsakonR , TechakasemP , et al. Continuation ECT in treatment resistant schizophrenia: a controlled study. Journal of ECT1999;15(3):178‐92. [CSzG: Ref4913; MEDLINE: 10492856] ">Chanpattana 1999</a> reported the medium‐term endpoint total scores of mental state assessed by the BPRS. The study found no clear differences in MMSE scores between the two groups (MD ‐0.20, 95% CI ‐3.70 to 3.30; participants = 30; studies = 1; <a href="./references#CD011847-fig-0040" title="">Analysis 4.2</a>). </p> </section> <section id="CD011847-sec-0302"> <h5 class="title">4.3 General functioning ‐ total score (GAF, high = good) ‐ medium term</h5> <p><a href="./references#CD011847-bbs2-0002" title="ChanpattanaW . ECT in schizophrenia. Journal of the Psychiatric Association of Thailand1999;44(2):156‐70. [CSzG: Ref8163] ChanpattanaW , ChakrabhandML , KitaroonchaiW , ChoovanichvongS , PrasertsukY . Effects of twice‐ versus thrice‐weekly electroconvulsive therapy in schizophrenia. Journal of the Medical Association of Thailand1999;82(5):477‐82. ChanpattanaW , ChakrabhandML , SackeimHA , KitaroonchaiW , KongsakonR , TechakasemP , et al. Continuation ECT in treatment resistant schizophrenia: a controlled study. Journal of ECT1999;15(3):178‐92. [CSzG: Ref4913; MEDLINE: 10492856] ">Chanpattana 1999</a> reported the medium‐term endpoint total score for general functioning assessed by GAF. The study found no clear differences in GAF scores between the two groups (MD ‐0.66, 95% CI ‐3.60 to 2.28; participants = 30; studies = 1; very low‐quality evidence; <a href="./references#CD011847-fig-0041" title="">Analysis 4.3</a>). </p> <p>For this comparison, <a href="./references#CD011847-bbs2-0002" title="ChanpattanaW . ECT in schizophrenia. Journal of the Psychiatric Association of Thailand1999;44(2):156‐70. [CSzG: Ref8163] ChanpattanaW , ChakrabhandML , KitaroonchaiW , ChoovanichvongS , PrasertsukY . Effects of twice‐ versus thrice‐weekly electroconvulsive therapy in schizophrenia. Journal of the Medical Association of Thailand1999;82(5):477‐82. ChanpattanaW , ChakrabhandML , SackeimHA , KitaroonchaiW , KongsakonR , TechakasemP , et al. Continuation ECT in treatment resistant schizophrenia: a controlled study. Journal of ECT1999;15(3):178‐92. [CSzG: Ref4913; MEDLINE: 10492856] ">Chanpattana 1999</a> did not report other predefined outcomes including response to treatment, cognitive functioning, satisfaction and acceptability of treatment, service outcomes, and adverse events. </p> </section> </section> <section id="CD011847-sec-0303"> <h4 class="title">5 SUBGROUP: ECT plus standard care versus standard care (TEST FOR DIFFERENCE BETWEEN SHORT/LONG COURSE OF ECT) </h4> <section id="CD011847-sec-0304"> <h5 class="title">5.1 Response to treatment ‐ clinically significant response (as defined by each of the studies) ‐ medium term </h5> <p>We performed subgroup analysis on this primary outcome according to different treatment duration of ECT (<a href="./references#CD011847-fig-0042" title="">Analysis 5.1</a>). </p> <section id="CD011847-sec-0305"> <h6 class="title">5.1.1 Short course of ECT</h6> <p>Six studies used a short course of ECT (<a href="./references#CD011847-bbs2-0001" title="CaiXY , LiangJL , SuY . A comparison study of MECT combining clozapine in the treatment of treatment‐resistant schizophrenia [无抽搐电休克合并氯氮平治疗难治性精神分裂症的对照研究]. 中国民康医学 [Medical Journal of Chinese People's Health]2008;20(13):1423‐4. [CSzG: Ref17951] ">Cai 2008</a>; <a href="./references#CD011847-bbs2-0003" title="ChenDR . Controlled study on MECT for treatment‐resistant schizophrenia [无抽搐电休克治疗难治性精神分裂症的对照分析]. 新疆医学 [Xinjiang Medical Journal]2012;9:57‐60. [CSzG: Ref32661] ">Chen 2012</a>; <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>; <a href="./references#CD011847-bbs2-0010" title="WangBH , ZengDZ , FanXW , HuaSG . Efficacy of modified electroconvulsive therapy in treatment‐refractory schizophrenia [无抽搐电休克对难治性精神分裂症的增效作用]. 临床精神医学杂志 [Journal of Clinical Psychiatry]2008;18(6):415‐7. [CSzG: Ref17865] ">Wang 2008</a>; <a href="./references#CD011847-bbs2-0011" title="WangZH , LingYX , XiaZ . The role of modified ECT treatment of refractory schizophrenia [改良电抽搐治疗难治性精神分裂症的作用]. Journal of Clinical Psychological Medicine [临床精神医学杂志]2011;21(4):252‐4. [CSzG: Ref23979] ">Wang 2011</a>; <a href="./references#CD011847-bbs2-0013" title="YangKJ , LiuTB , YangHC . The effect of clozapine combining MECT for the resistant schizophrenics with agitation and aggressive behavior. Medical Journal of Chinese People's Health [中国民康医学]2005;17(9):485‐6. [CSzG: Ref12755] ">Yang 2005</a>). There were more responders in the group that received a short course of ECT than in the group that did not receive ECT (RR 2.23, 95% CI 1.78 to 2.80; participants = 450; studies = 6). </p> </section> <section id="CD011847-sec-0306"> <h6 class="title">5.1.2 Long course of ECT</h6> <p>Three studies used a long course of ECT (<a href="./references#CD011847-bbs2-0009" title="BragaRJ , MendelowitzAJ , FinkM , SchoolerNR , BailineSH , MalurC , et al. A randomized controlled trial of ECT in clozapine‐refractory schizophrenia. Biological Psychiatry2009;65(8):212S‐3S. [CSzG: Ref19511] PetridesG . ECT augmentation in clozapine‐resistant schizophrenia: acute efficacy and maintance data. Schizophrenia Bulletin2015;41:S328. [CSzG: Ref29626] PetridesG . Electroconvulsive therapy (ECT) for medication resistant schizophrenia. Schizophrenia Research2012;136:S22. [CSzG: Ref29625] PetridesG , GoldbergT , JohnM , BragaR , MalurC , MalhotraA , et al. Electroconvulsive therapy for clozapine‐resistant schizophrenia: cognitive effects. Neuropsychopharmacology2016;41:S257. [CSzG: Ref35678] PetridesG , MalurC , BragaRJ , BailineSH , SchoolerNR , MalhotraAK , et al. Electroconvulsive therapy augmentation in clozapine‐resistant schizophrenia: a prospective, randomized study. American Journal of Psychiatry2015;172(1):52‐8. [CSzG: Ref29366] ">Petrides 2015</a>; <a href="./references#CD011847-bbs2-0014" title="ZhangYJ , LiuQ , HuY , ZhouLG . Effects of modified electroconvulsive therapy combined with clozapine in patients with treatment‐refractory schizophrenia [无抽搐电痉挛治疗合并氯氮平治疗难治性精神分裂症及其对记忆力的影响]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(6):440‐4. [CSzG: Ref22996] ">Zhang 2010</a>; <a href="./references#CD011847-bbs2-0015" title="ZhangSR , ZhangJL , LiXZ , YangYP , LangSY . The effect of MECT combined with olanzapine for refractory schizophrenia [无抽搐电休克联合奥氮平治疗难治性精神分裂症疗效观察]. People's Military Surgeon [人民军医]2012;2:141‐3. [CSzG: Ref27071] ">Zhang 2012</a>). There were more responders in the group that received a long course of ECT than in the group that did not receive ECT (RR 1.87, 95% CI 1.49 to 2.36; participants = 369; studies = 3). </p> <p>We tested for subgroup differences between short and long course of ECT. There was no evidence of different effects of ECT between the two groups at medium‐term follow‐up (Chi<sup>2</sup> = 1.12, df = 1 (P = 0.29), I<sup>2</sup> = 10.7%). </p> <p>The subgroup analyses on other predefined factors, comparisons, and outcomes were not applicable due to insufficient data. </p> </section> </section> </section> <section id="CD011847-sec-0307"> <h4 class="title">SENSITIVITY ANALYSIS: ECT plus standard care versus standard care</h4> <section id="CD011847-sec-0308"> <h5 class="title">1. Implication of randomisation</h5> <p>The sensitivity analysis was not applicable because all the included studies had a random component in the sequence generation process. </p> </section> <section id="CD011847-sec-0309"> <h5 class="title">2. Assumptions for lost binary data</h5> <p>This sensitivity analysis was only applicable for one primary outcome (medium‐term response to treatment). Results were consistent between the incorporation of lost data with and without an ITT analysis (<a href="./references#CD011847-fig-0043" title="">Analysis 6.1</a>). </p> </section> <section id="CD011847-sec-0310"> <h5 class="title">3. Risk of bias</h5> <p>The sensitivity analysis was not applicable because all the included studies were rated as at high risk of bias in at least one domain. </p> </section> <section id="CD011847-sec-0311"> <h5 class="title">4. Imputed values</h5> <p>The sensitivity analysis was not applicable because all the included studies were without imputed values. </p> </section> <section id="CD011847-sec-0312"> <h5 class="title">5. Fixed‐effect versus random‐effects model</h5> <p>This sensitivity analysis was only applicable for one primary outcome (medium‐term response to treatment). The results were consistent between fixed‐effect and random‐effects models (<a href="./references#CD011847-fig-0044" title="">Analysis 7.1</a>). </p> </section> <section id="CD011847-sec-0313"> <h5 class="title">6. Diagnostic criteria</h5> <p>The sensitivity analysis was not applicable because all participants in the included studies had strictly diagnosed schizophrenia by international standards. </p> <p>The sensitivity analyses on other comparisons were not applicable due to insufficient data. </p> </section> </section> <section id="CD011847-sec-0314"> <h4 class="title">Assessment of reporting biases</h4> <p>None of the comparisons included more than 10 studies reporting the same outcome, so we did not produce a funnel plot to assess reporting biases. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011847-sec-0315" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011847-sec-0315">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011847-sec-0436">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011847-sec-0315"></div> <section id="CD011847-sec-0316"> <h3 class="title" id="CD011847-sec-0316">Summary of main results</h3> <section id="CD011847-sec-0317"> <h4 class="title">COMPARISON 1: ECT plus standard care versus sham‐ECT plus standard care</h4> <p>For the comparison of ECT versus sham‐ECT for treatment‐resistant schizophrenia, we identified one study with a high risk of bias and a very small sample size (n = 25) (<a href="./full#CD011847-tbl-0001">summary of findings Table for the main comparison</a>). Very low‐ to low‐quality evidence showed no clear short‐term difference between groups in mental state and that there were fewer readmitted participants in the ECT group (three participants) than in the sham‐ECT group (seven participants). No evidence was available on cognitive functioning or other predefined secondary outcomes. </p> </section> <section id="CD011847-sec-0318"> <h4 class="title">COMPARISON 2: ECT plus standard care versus antipsychotics (clozapine) plus standard care </h4> <p>For the comparison of ECT versus antipsychotics (clozapine), there was no clear difference in the medium‐term response to treatment based on low‐quality evidence. Furthermore, very low‐quality evidence was obtained from a study with a high risk of bias and a small sample size (n = 162) (<a href="./full#CD011847-tbl-0002">summary of findings Table 2</a>). This study showed that ECT may be associated with both short‐ and medium‐term improvement in patients' mental state (assessed by BPRS score). There were no clear differences in the incidence of adverse events between the groups, although participants who received ECT had lower medium‐term TESS scores than participants who received clozapine. No evidence was available for cognitive functioning, satisfaction and acceptability of treatment, general functioning, and service outcomes. </p> </section> <section id="CD011847-sec-0319"> <h4 class="title">COMPARISON 3: ECT plus standard care versus standard care</h4> <p>For the comparison of ECT versus standard care, data indicated that there more participants with a clinically important response to treatment in the ECT than in the standard care group. The quality of this evidence was moderate for the medium‐term outcome (<a href="./full#CD011847-tbl-0003">summary of findings Table 3</a>). Data showed that ECT may be associated with an improvement in patients' general mental state and some specific mental symptoms (such as anxiety and depression, lack of vitality, thought disturbance, agitation, hostile suspiciousness, psychosis, excitement, and hostility) regardless of whether short‐ or medium‐term endpoints were considered. Electroconvulsive therapy was also associated with medium‐term improvement in general functioning, but this evidence was obtained from limited data (<a href="./references#CD011847-bbs2-0002" title="ChanpattanaW . ECT in schizophrenia. Journal of the Psychiatric Association of Thailand1999;44(2):156‐70. [CSzG: Ref8163] ChanpattanaW , ChakrabhandML , KitaroonchaiW , ChoovanichvongS , PrasertsukY . Effects of twice‐ versus thrice‐weekly electroconvulsive therapy in schizophrenia. Journal of the Medical Association of Thailand1999;82(5):477‐82. ChanpattanaW , ChakrabhandML , SackeimHA , KitaroonchaiW , KongsakonR , TechakasemP , et al. Continuation ECT in treatment resistant schizophrenia: a controlled study. Journal of ECT1999;15(3):178‐92. [CSzG: Ref4913; MEDLINE: 10492856] ">Chanpattana 1999</a>, n = 30; <a href="./references#CD011847-bbs2-0005" title="JiangXQ , YangKR , ZhouB , JinP , ZhengLF , GaoXF , et al. Study on efficacy of modified electroconvulsive therapy (MECT) together with risperidone in treatment‐resistant schizophrenia (TRS) [利培酮合并无抽搐电休克治疗难治性精神分裂症的临床研究]. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]2009;35(2):79‐83. [CSzG: Ref22088] ">Jiang 2009</a>, n = 67) at high risk of bias. For total adverse events, data showed lower medium‐term TESS scores in the ECT group than in the non‐ECT group. ECT increased the risk of memory deterioration, but no differences were observed for the risk of breathing discomfort and insomnia. There was no clear differences between groups for other outcomes including satisfaction and acceptability of treatment (leaving the study early), and most of the other adverse events. No evidence was available on cognitive functioning and service outcomes. </p> </section> <section id="CD011847-sec-0320"> <h4 class="title">COMPARISON 4: ECT alone versus antipsychotics (flupenthixol) alone</h4> <p>For the comparison of ECT alone versus antipsychotics (flupenthixol) alone, we identified one study at high risk of bias with a very small sample size (n = 30) (<a href="./full#CD011847-tbl-0004">summary of findings Table 4</a>). Very low‐quality evidence showed no clear differences in mental state and general functioning between groups. No evidence was available for our primary outcomes or the remaining secondary outcomes. </p> <p>The other comparisons predefined in the protocol were not available in this review.</p> </section> </section> <section id="CD011847-sec-0321"> <h3 class="title" id="CD011847-sec-0321">Overall completeness and applicability of evidence</h3> <p>Overall, the evidence is incomplete related to several aspects including participants, interventions, and outcomes. All included participants were between 18 and 46 years old (on average), with strictly diagnosed schizophrenia by international standards (ICD‐10, DSM‐IV, CCMD‐2‐R, and CCMD‐3), and were well‐defined as treatment‐resistant in each included study. Most participants (1161/1285, 90.6%) were recruited from China, hence limiting the applicability of the findings for an illness that affects people worldwide. </p> <p>In terms of interventions, all included studies used ECT plus standard care, with only one arm in one study ECT as sole intervention. Except for the comparison with placebo (no treatment), the comparators of sham‐ECT, antipsychotics, or non‐pharmacological forms of treatment were limited. Evidence for comparing different modalities of ECT (including electrode placement, duration of course, frequency of treatment) was also lacking. </p> <p>Evidence for clinically important change in cognitive functioning (one of our primary outcomes) was not available; only data for memory deterioration were reported. There was a lack of data for most of our secondary outcomes, which is reflected in the 'Summary of findings' tables, namely acceptability of treatment (leaving the study early), mental state (clinically important change in general mental state), general functioning (clinically important change in general functioning), service outcomes (hospitalisation), and death. This may further limit the applicability of our findings. </p> </section> <section id="CD011847-sec-0322"> <h3 class="title" id="CD011847-sec-0322">Quality of the evidence</h3> <p>Overall, the quality of the evidence was very low to moderate, downgraded due to study limitations such as high risk of performance bias or imprecision. All the included studies except <a href="./references#CD011847-bbs2-0004" title="GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia syndrome: a double‐blind study. Indian Journal of Psychiatry2001; Vol. 43. [CSzG: Ref14832] GoswamiU , KumarU , SinghB . Efficacy of electroconvulsive therapy in treatment resistant schizophrenia: a double‐blind study. Indian Journal of Psychiatry2003;45(1):26‐9. [CSzG: Ref14826] ">Goswami 2003</a> had a high risk of performance bias due to insufficient reporting of blinding of participants and personnel. Most studies did not clearly describe the method of random sequence generation and allocation concealment, and provided insufficient information on blinding of outcome assessment. Four studies that reported on attrition (less than 20%) had an unclear risk of attrition bias. Two studies that did not report the primary outcome appropriately had a high risk of reporting bias. For the moderate‐quality evidence on response to treatment, we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but the possibility exists that it is substantially different. For the very low‐ and low‐quality evidence, we have very little or limited confidence in the effect estimate. </p> <p>The other two main limitations of the body of evidence were indirectness and imprecision. Imprecision was due mainly to small sample size, low event rate, or wide confidence interval. Indirectness is relatively more prevalent in subjectively measured outcomes such as mental state and functioning, as usually numerical scales are employed as an indirect index. </p> </section> <section id="CD011847-sec-0323"> <h3 class="title" id="CD011847-sec-0323">Potential biases in the review process</h3> <p>We developed comprehensive search strategies and performed the search with no limitations on language, date, document type, or publication status. However, we only included published data, so there is a possibility of publication bias. Nonetheless, two review authors independently screened studies and extracted data, therefore it is less likely that this process could have introduced bias. </p> </section> <section id="CD011847-sec-0324"> <h3 class="title" id="CD011847-sec-0324">Agreements and disagreements with other studies or reviews</h3> <p>This is an update of a previous Cochrane Review that was originally published in 2005 (<a href="./references#CD011847-bbs1-0006" title="">Other published versions of this review</a>). The previous review did not look specifically at the evidence for ECT in people with treatment‐resistant schizophrenia. This updated review assessed the current evidence for ECT specifically for the group of people whose illness has been designated as resistant to treatment, therefore we excluded studies included in the previous version of the review that did not state that the participants were diagnosed as treatment‐resistant (<a href="./references#CD011847-bbs1-0006" title="">Other published versions of this review</a>). There is another systematic review assessing the efficacy and safety of ECT in combination with antipsychotics (except for clozapine) versus the same antipsychotic monotherapy for treatment‐resistant schizophrenia (<a href="./references#CD011847-bbs2-0133" title="ZhengW , CaoXL , UngvariGS , XiangYQ , GuoT , LiuZR , et al. Electroconvulsive therapy added to non‐clozapine antipsychotic medication for treatment resistant schizophrenia: meta‐analysis of randomized controlled trials. PLOS ONE2016;11(6):e0156510. ">Zheng 2016</a>). <a href="./references#CD011847-bbs2-0133" title="ZhengW , CaoXL , UngvariGS , XiangYQ , GuoT , LiuZR , et al. Electroconvulsive therapy added to non‐clozapine antipsychotic medication for treatment resistant schizophrenia: meta‐analysis of randomized controlled trials. PLOS ONE2016;11(6):e0156510. ">Zheng 2016</a> found that ECT was superior to antipsychotic monotherapy in terms of clinical response, symptomatic improvement, and specific mental symptoms based on the PANSS score. The present review did not predefine the exact same outcomes as <a href="./references#CD011847-bbs2-0133" title="ZhengW , CaoXL , UngvariGS , XiangYQ , GuoT , LiuZR , et al. Electroconvulsive therapy added to non‐clozapine antipsychotic medication for treatment resistant schizophrenia: meta‐analysis of randomized controlled trials. PLOS ONE2016;11(6):e0156510. ">Zheng 2016</a>, but reached a similar conclusion. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011847-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011847-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/full#CD011847-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011847-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/full#CD011847-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011847-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/full#CD011847-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ECT plus standard care versus sham‐ECT plus standard care, Outcome 1 Mental state ‐ total score (BPRS, high = poor) ‐ short term." data-id="CD011847-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 ECT plus standard care versus sham‐ECT plus standard care, Outcome 1 Mental state ‐ total score (BPRS, high = poor) ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ECT plus standard care versus sham‐ECT plus standard care, Outcome 2 Service use ‐ number readmitted ‐ short term." data-id="CD011847-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 ECT plus standard care versus sham‐ECT plus standard care, Outcome 2 Service use ‐ number readmitted ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 ECT plus standard care versus antipsychotics plus standard care, Outcome 1 Response to treatment ‐ clinically important response (BPRS reducing rate ≥ 50%) ‐ medium term." data-id="CD011847-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 ECT plus standard care versus antipsychotics plus standard care, Outcome 1 Response to treatment ‐ clinically important response (BPRS reducing rate ≥ 50%) ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 ECT plus standard care versus antipsychotics plus standard care, Outcome 2 Mental state ‐ total score (BPRS, high = poor) ‐ short term." data-id="CD011847-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 ECT plus standard care versus antipsychotics plus standard care, Outcome 2 Mental state ‐ total score (BPRS, high = poor) ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0008"> <p> <div class="table" id="CD011847-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jiang 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MECT + ziprasidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jiang 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine + ziprasidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 ECT plus standard care versus antipsychotics plus standard care, Outcome 3 Mental state ‐ total score (BPRS, high = poor) ‐ medium term (skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0008">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011847-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 ECT plus standard care versus antipsychotics plus standard care, Outcome 4 Mental state ‐ specific symptom score (BPRS, high = poor) ‐ short term." data-id="CD011847-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 ECT plus standard care versus antipsychotics plus standard care, Outcome 4 Mental state ‐ specific symptom score (BPRS, high = poor) ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 ECT plus standard care versus antipsychotics plus standard care, Outcome 5 Mental state ‐ specific symptom score (BPRS, high = poor) ‐ medium term." data-id="CD011847-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 ECT plus standard care versus antipsychotics plus standard care, Outcome 5 Mental state ‐ specific symptom score (BPRS, high = poor) ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 ECT plus standard care versus antipsychotics plus standard care, Outcome 6 Adverse events ‐ total score (TESS, high = poor)." data-id="CD011847-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 ECT plus standard care versus antipsychotics plus standard care, Outcome 6 Adverse events ‐ total score (TESS, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ECT plus standard care versus standard care, Outcome 1 Response to treatment ‐ clinically important response (as defined by each study)." data-id="CD011847-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 ECT plus standard care versus standard care, Outcome 1 Response to treatment ‐ clinically important response (as defined by each study). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ECT plus standard care versus standard care, Outcome 2 Cognitive functioning ‐ memory deterioration ‐ short term." data-id="CD011847-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 ECT plus standard care versus standard care, Outcome 2 Cognitive functioning ‐ memory deterioration ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ECT plus standard care versus standard care, Outcome 3 Cognitive functioning ‐ specific symptom score (WCST, high = poor, other than correct number) ‐ medium term." data-id="CD011847-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 ECT plus standard care versus standard care, Outcome 3 Cognitive functioning ‐ specific symptom score (WCST, high = poor, other than correct number) ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0015"> <p> <div class="table" id="CD011847-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Perseveration errors</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jiang 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MECT + risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jiang 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27.94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Non‐perseveration errors</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jiang 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MECT + risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jiang 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 ECT plus standard care versus standard care, Outcome 4 Cognitive functioning ‐ specific symptom score (WCST, high = poor) ‐ medium term (skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0015">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011847-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ECT plus standard care versus standard care, Outcome 5 Cognitive functioning ‐ memory (WMS, high = good) ‐ short term." data-id="CD011847-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 ECT plus standard care versus standard care, Outcome 5 Cognitive functioning ‐ memory (WMS, high = good) ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ECT plus standard care versus standard care, Outcome 6 Cognitive functioning ‐ memory (WMS, high = good) ‐ medium term." data-id="CD011847-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 ECT plus standard care versus standard care, Outcome 6 Cognitive functioning ‐ memory (WMS, high = good) ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ECT plus standard care versus standard care, Outcome 7 Satisfaction and acceptability of treatment ‐ leaving the study early ‐ medium term." data-id="CD011847-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 ECT plus standard care versus standard care, Outcome 7 Satisfaction and acceptability of treatment ‐ leaving the study early ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ECT plus standard care versus standard care, Outcome 8 Mental state ‐ total score (BPRS, high = poor)." data-id="CD011847-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 ECT plus standard care versus standard care, Outcome 8 Mental state ‐ total score (BPRS, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0020"> <p> <div class="table" id="CD011847-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chanpattana 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ECT + flupenthixol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chanpattana 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flupenthixol alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 ECT plus standard care versus standard care, Outcome 9 Mental state ‐ total score (BPRS, high = poor) ‐ medium term (skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0020">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011847-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ECT plus standard care versus standard care, Outcome 10 Mental state ‐ total score (MMSE, high = good) ‐ medium term." data-id="CD011847-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 ECT plus standard care versus standard care, Outcome 10 Mental state ‐ total score (MMSE, high = good) ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ECT plus standard care versus standard care, Outcome 11 Mental state ‐ total score (PANSS, high = poor)." data-id="CD011847-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 ECT plus standard care versus standard care, Outcome 11 Mental state ‐ total score (PANSS, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ECT plus standard care versus standard care, Outcome 12 Mental state ‐ specific symptom score (BPRS, high = poor) ‐ short term." data-id="CD011847-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 ECT plus standard care versus standard care, Outcome 12 Mental state ‐ specific symptom score (BPRS, high = poor) ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ECT plus standard care versus standard care, Outcome 13 Mental state ‐ specific symptom score (BPRS, high = poor) ‐ medium term." data-id="CD011847-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 ECT plus standard care versus standard care, Outcome 13 Mental state ‐ specific symptom score (BPRS, high = poor) ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-003-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-003-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ECT plus standard care versus standard care, Outcome 14 Mental state ‐ specific symptom score (PANSS, high = poor) ‐ short term." data-id="CD011847-fig-0025" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 ECT plus standard care versus standard care, Outcome 14 Mental state ‐ specific symptom score (PANSS, high = poor) ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0026"> <p> <div class="table" id="CD011847-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Positive symptom</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jiang 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MECT + risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jiang 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MECT + clozapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>General psychopathology</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MECT + clozapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jiang 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MECT + risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jiang 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3 ECT plus standard care versus standard care, Outcome 15 Mental state ‐ specific symptom score (PANSS, high = poor) ‐ short term (skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0026">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011847-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-003-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-003-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ECT plus standard care versus standard care, Outcome 16 Mental state ‐ specific symptom score (PANSS, high = poor) ‐ medium term." data-id="CD011847-fig-0027" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.16</div> <div class="figure-caption"> <p>Comparison 3 ECT plus standard care versus standard care, Outcome 16 Mental state ‐ specific symptom score (PANSS, high = poor) ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0028"> <p> <div class="table" id="CD011847-tblf-0005"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Positive symptom</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MECT + clozapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jiang 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MECT + risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jiang 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MECT + clozapine and risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>clozapine and risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MECT + clozapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhang 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MECT + olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhang 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Negative symptom</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jiang 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MECT + risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jiang 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MECT + clozapine and risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>clozapine and risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>General psychopathology</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MECT + clozapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jiang 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MECT + risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jiang 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27.96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhang 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MECT + olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhang 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.17</div> <div class="figure-caption"> <p>Comparison 3 ECT plus standard care versus standard care, Outcome 17 Mental state ‐ specific symptom score (PANSS, high = poor) ‐ medium term (skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0028">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011847-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-003-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-003-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ECT plus standard care versus standard care, Outcome 18 Mental state ‐ specific symptom score (SAPS, high = poor) ‐ short term." data-id="CD011847-fig-0029" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.18</div> <div class="figure-caption"> <p>Comparison 3 ECT plus standard care versus standard care, Outcome 18 Mental state ‐ specific symptom score (SAPS, high = poor) ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-003-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-003-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ECT plus standard care versus standard care, Outcome 19 Mental state ‐ specific symptom score (SANS, high = poor) ‐ short term." data-id="CD011847-fig-0030" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.19</div> <div class="figure-caption"> <p>Comparison 3 ECT plus standard care versus standard care, Outcome 19 Mental state ‐ specific symptom score (SANS, high = poor) ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-003-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-003-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ECT plus standard care versus standard care, Outcome 20 General functioning ‐ total score (GAF, high = good)." data-id="CD011847-fig-0031" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.20</div> <div class="figure-caption"> <p>Comparison 3 ECT plus standard care versus standard care, Outcome 20 General functioning ‐ total score (GAF, high = good). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-003-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-003-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ECT plus standard care versus standard care, Outcome 21 Adverse events ‐ general ‐ medium term." data-id="CD011847-fig-0032" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.21</div> <div class="figure-caption"> <p>Comparison 3 ECT plus standard care versus standard care, Outcome 21 Adverse events ‐ general ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-003-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-003-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ECT plus standard care versus standard care, Outcome 22 Adverse events ‐ total score (TESS, high = poor)." data-id="CD011847-fig-0033" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.22</div> <div class="figure-caption"> <p>Comparison 3 ECT plus standard care versus standard care, Outcome 22 Adverse events ‐ total score (TESS, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-003-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-003-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ECT plus standard care versus standard care, Outcome 23 Adverse events ‐ specific symptom ‐ short term." data-id="CD011847-fig-0034" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.23</div> <div class="figure-caption"> <p>Comparison 3 ECT plus standard care versus standard care, Outcome 23 Adverse events ‐ specific symptom ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-003-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-003-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ECT plus standard care versus standard care, Outcome 24 Adverse events ‐ specific symptom ‐ medium term." data-id="CD011847-fig-0035" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.24</div> <div class="figure-caption"> <p>Comparison 3 ECT plus standard care versus standard care, Outcome 24 Adverse events ‐ specific symptom ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0036"> <p> <div class="table" id="CD011847-tblf-0006"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Abnormal laboratory values</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cai 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MECT + clozapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cai 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.935</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Behavioural toxicity</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cai 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MECT + clozapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.377</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cai 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.528</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Symptoms of cardiovascular system</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cai 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MECT + clozapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cai 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Symptoms of nervous system</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cai 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MECT + clozapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.857</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cai 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.055</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Symptoms of vegetative nervous system</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cai 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MECT + clozapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.735</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cai 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Others</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cai 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MECT + clozapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cai 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.625</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.25</div> <div class="figure-caption"> <p>Comparison 3 ECT plus standard care versus standard care, Outcome 25 Adverse events ‐ specific symptom score (TESS, high = poor) ‐ short term (skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0036">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011847-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-003-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-003-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ECT plus standard care versus standard care, Outcome 26 Adverse events ‐ specific symptom score (TESS, high = poor) ‐ medium term." data-id="CD011847-fig-0037" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.26</div> <div class="figure-caption"> <p>Comparison 3 ECT plus standard care versus standard care, Outcome 26 Adverse events ‐ specific symptom score (TESS, high = poor) ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-003-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0038"> <p> <div class="table" id="CD011847-tblf-0007"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Abnormal laboratory values</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cai 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MECT + clozapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.679</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cai 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Behavioral toxicity</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cai 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MECT + clozapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.402</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cai 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Symptoms of cardiovascular system</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cai 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MECT + clozapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.041</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cai 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Symptoms of nervous system</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cai 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MECT + clozapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cai 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.505</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Symptoms of vegetative nervous system</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cai 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MECT + clozapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cai 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.077</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Others</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cai 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MECT + clozapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cai 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.616</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.27</div> <div class="figure-caption"> <p>Comparison 3 ECT plus standard care versus standard care, Outcome 27 Adverse events ‐ specific symptom score (TESS, high = poor) ‐ medium term (skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0038">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011847-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 ECT alone versus antipsychotic alone (flupenthixol), Outcome 1 Mental state ‐ total score (BPRS, high = poor) ‐ medium term." data-id="CD011847-fig-0039" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 ECT alone versus antipsychotic alone (flupenthixol), Outcome 1 Mental state ‐ total score (BPRS, high = poor) ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 ECT alone versus antipsychotic alone (flupenthixol), Outcome 2 Mental state ‐ total score (MMSE, high = good) ‐ medium term." data-id="CD011847-fig-0040" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 ECT alone versus antipsychotic alone (flupenthixol), Outcome 2 Mental state ‐ total score (MMSE, high = good) ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 ECT alone versus antipsychotic alone (flupenthixol), Outcome 3 General functioning ‐ total score (GAF, high = good) ‐ medium term." data-id="CD011847-fig-0041" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 ECT alone versus antipsychotic alone (flupenthixol), Outcome 3 General functioning ‐ total score (GAF, high = good) ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 SUBGROUP: ECT plus standard care versus standard care (TEST FOR DIFFERENCE BETWEEN SHORT/LONG COURSE OF ECT), Outcome 1 Response to treatment ‐ clinically significant response (as defined by each study) ‐ medium term." data-id="CD011847-fig-0042" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 SUBGROUP: ECT plus standard care versus standard care (TEST FOR DIFFERENCE BETWEEN SHORT/LONG COURSE OF ECT), Outcome 1 Response to treatment ‐ clinically significant response (as defined by each study) ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 SENSITIVITY ANALYSIS: ECT plus standard care versus standard care (ASSUMPTIONS FOR LOST BINARY DATA), Outcome 1 Response to treatment ‐ clinically significant response (as defined by each study) ‐ medium term." data-id="CD011847-fig-0043" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 SENSITIVITY ANALYSIS: ECT plus standard care versus standard care (ASSUMPTIONS FOR LOST BINARY DATA), Outcome 1 Response to treatment ‐ clinically significant response (as defined by each study) ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011847-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/urn:x-wiley:14651858:media:CD011847:CD011847-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_t/tCD011847-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 SENSITIVITY ANALYSIS: ECT plus standard care versus standard care (FIXED‐EFFECT AND RANDOM‐EFFECTS MODEL), Outcome 1 Response to treatment ‐ clinically significant response (as defined by each study) ‐ medium term." data-id="CD011847-fig-0044" src="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 SENSITIVITY ANALYSIS: ECT plus standard care versus standard care (FIXED‐EFFECT AND RANDOM‐EFFECTS MODEL), Outcome 1 Response to treatment ‐ clinically significant response (as defined by each study) ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/media/CDSR/CD011847/image_n/nCD011847-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011847-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">ECT plus standard care versus sham‐ECT plus standard care for treatment‐resistant schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>ECT plus standard care versus sham‐ECT plus standard care for treatment‐resistant schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with treatment‐resistant schizophrenia<br/> <b>Settings:</b> hospital<br/> <b>Intervention:</b> ECT plus standard care </p> <p><b>Comparison:</b> sham‐ECT plus standard care </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with sham‐ECT</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ECT (add‐on)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response to treatment</b> </p> <p>Clinically important response to treatment as defined by each study</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive functioning</b> </p> <p>Clinically important change in cognitive functioning as defined by each study</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction and acceptability of treatment</b> ‐ leaving the study early </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state (short term)</b> ‐ total scores (BPRS, high = poor) </p> <p>Follow‐up: 4 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state ‐ average scores (BPRS, high = poor, short term) was <b>40.4</b>. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 3.60 higher</b> (3.69 lower to 10.89 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for predefined outcome 'clinically important change' not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>General functioning</b><br/> Clinically important change in general functioning as defined by each study </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Service use (short term)</b> ‐ hospitalisation (number readmitted) </p> <p>Follow‐up: 4 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.29</b> </p> <p>(0.10 to 0.85)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>25</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>700 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>203 per 1000</b> </p> <p>(70 to 595)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse event/effect(s) ‐</b> death </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>BPRS:</b> Brief Psychiatric Rating Scale; <b>CI:</b> confidence interval; <b>ECT:</b> electroconvulsive therapy; <b>MD:</b> mean difference; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to indirectness: scores from scale were employed as a surrogate index of the intended outcome.<br/> <sup>2</sup>Downgraded by two levels due to imprecision: very small sample size. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">ECT plus standard care versus sham‐ECT plus standard care for treatment‐resistant schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/full#CD011847-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011847-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">ECT plus standard care versus antipsychotics plus standard care for treatment‐resistant schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>ECT plus standard care versus antipsychotics plus standard care for treatment‐resistant schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with treatment‐resistant schizophrenia<br/> <b>Settings:</b> hospital<br/> <b>Intervention:</b> ECT plus ziprasidone </p> <p><b>Comparison:</b> clozapine plus ziprasidone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with antipsychotics (clozapine)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ECT (add‐on)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Response to treatment (medium term)</b><br/> Clinically important response to treatment as defined by each study<br/> Follow‐up: 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.23</b> <br/> (0.95 to 1.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>162<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>543 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>668 per 1000</b><br/> (516 to 858) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive functioning</b> </p> <p>Clinically important change in cognitive functioning as defined by each study</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction and acceptability of treatment</b> ‐ leaving the study early </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state (short term)</b> ‐ total scores (BPRS, high = poor) </p> <p>Follow‐up: 4 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state ‐ average scores (BPRS, high = poor, short term) was <b>44.7</b>. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 5.20 lower</b> (7.93 to 2.47 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for predefined outcome 'clinically important change' not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>General functioning</b><br/> Clinically important change in general functioning as defined by each study </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service use</b> ‐ hospitalisation </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse event/effect(s)</b> ‐ death </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>BPRS:</b> Brief Psychiatric Rating Scale; <b>CI:</b> confidence interval; <b>ECT:</b> electroconvulsive therapy; <b>MD:</b> mean difference; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to risk of bias: <a href="./references#CD011847-bbs2-0006" title="JiangZW . Clinical analysis on MECT combined with ziprasidone in treatment of patients with refractory schizophrenia [无抽搐电休克联合齐拉西酮治疗难治性精神分裂症临床效果分析]. Journal of Clinical and Experimental Medicine [临床和实验医学杂志]2013;17:1394‐5. [CSzG: Ref27359] ">Jiang 2013</a> had high risk of bias for blinding of participants and personnel.<br/> <sup>2</sup>Downgraded by one level due to indirectness: scores from scale were employed as a surrogate index of the intended outcome.<br/> <sup>3</sup>Downgraded by one level due to imprecision: small sample size and wide confidence interval. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">ECT plus standard care versus antipsychotics plus standard care for treatment‐resistant schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/full#CD011847-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011847-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">ECT plus standard care versus standard care for treatment‐resistant schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>ECT plus standard care versus standard care for treatment‐resistant schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with treatment‐resistant schizophrenia<br/> <b>Settings:</b> hospital<br/> <b>Intervention:</b> ECT plus standard care </p> <p><b>Comparison:</b> standard care </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo (no treatment)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ECT (add‐on)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response to treatment (medium term)</b> </p> <p>Clinically important response to treatment as defined by each study<br/> Follow‐up: 8 to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>308 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>635 per 1000</b><br/> (539 to 746) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.06</b> <br/> (1.75 to 2.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>819<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive functioning (short term)</b> ‐ memory deterioration </p> <p>Follow‐up: 3 to 4 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> <p>(1 to 219)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 27</b> </p> <p>(1.67 to 437.68)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for predefined outcome 'clinically important change' not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction and acceptability of treatment (medium term)</b> ‐ leaving the study early<br/> Follow‐up: 8 to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>27 per 1000</b><br/> (9 to 82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.18</b> <br/> (0.38 to 3.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>354<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state (medium term)</b> ‐ total scores (BPRS, high = poor) </p> <p>Follow‐up: 8 to 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state ‐ average scores (BPRS, high = poor, medium term) was <b>33.4</b>. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 11.18 lower</b> (12.61 to 9.76 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>345<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for predefined outcome 'clinically important change' not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>General functioning (medium term)</b> ‐ average scores (GAF, high = good) </p> <p>Follow‐up: 12 weeks to 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state ‐ average scores (GAF, high = good, medium term) was <b>47.3</b>. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 10.66 higher</b> (6.98 to 14.34 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for predefined outcome 'clinically important change' not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service use</b> ‐ hospitalisation </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse event/effect(s)</b> ‐ death </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>BPRS:</b> Brief Psychiatric Rating Scale; <b>CI:</b> confidence interval; <b>ECT:</b> electroconvulsive therapy; <b>GAF:</b> Global Assessment of Functioning; <b>MD:</b> mean difference; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to risk of bias: high risk of bias with blinding of participants and personnel.<br/> <sup>2</sup>Downgraded by one level due to indirectness: scores from scale were employed as a surrogate index of the intended outcome.<br/> <sup>3</sup>Downgraded by one level due to heterogeneity.<br/> <sup>4</sup>Downgraded by two levels due to imprecision: low event rate.<br/> <sup>5</sup>Downgraded by one level due to imprecision: small sample size. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">ECT plus standard care versus standard care for treatment‐resistant schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/full#CD011847-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011847-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">ECT alone versus antipsychotics for treatment‐resistant schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>ECT alone versus antipsychotics for treatment‐resistant schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with treatment‐resistant schizophrenia<br/> <b>Settings:</b> hospital<br/> <b>Intervention:</b> ECT </p> <p><b>Comparison:</b> Flupenthixol </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with antipsychotics (flupenthixol)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ECT (alone)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response to treatment</b> </p> <p>Clinically significant response to treatment as defined by each study</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive functioning</b> </p> <p>Clinically important change in cognitive functioning as defined by each study</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction and acceptability of treatment</b> ‐ leaving the study early </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state (medium term)</b> ‐ total scores (BPRS, high = poor) </p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state ‐ average scores (BPRS, high = poor, medium term) was <b>44.3</b>. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.93 lower</b> (6.95 lower to 5.09 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for predefined outcome 'clinically important change' not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>General functioning (medium term)</b> ‐ average scores (GAF, high = good) </p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean general functioning ‐ average scores (GAF, high = good, medium term) was <b>30.1</b>. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.66 lower</b> (3.6 lower to 2.28 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for predefined outcome 'clinically important change' not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service use</b> ‐ hospitalisation </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse event/effect(s)</b> ‐ death </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, so there is no evidence to support or refute benefits of the intervention. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>BPRS:</b> Brief Psychiatric Rating Scale; <b>CI:</b> confidence interval; <b>ECT:</b> electroconvulsive therapy; <b>GAF:</b> Global Assessment of Functioning; <b>MD:</b> mean difference; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to risk of bias: <a href="./references#CD011847-bbs2-0002" title="ChanpattanaW . ECT in schizophrenia. Journal of the Psychiatric Association of Thailand1999;44(2):156‐70. [CSzG: Ref8163] ChanpattanaW , ChakrabhandML , KitaroonchaiW , ChoovanichvongS , PrasertsukY . Effects of twice‐ versus thrice‐weekly electroconvulsive therapy in schizophrenia. Journal of the Medical Association of Thailand1999;82(5):477‐82. ChanpattanaW , ChakrabhandML , SackeimHA , KitaroonchaiW , KongsakonR , TechakasemP , et al. Continuation ECT in treatment resistant schizophrenia: a controlled study. Journal of ECT1999;15(3):178‐92. [CSzG: Ref4913; MEDLINE: 10492856] ">Chanpattana 1999</a> had high risk of bias for blinding of participants and personnel.<br/> <sup>2</sup>Downgraded by one level due to indirectness: scores from scale were employed as a surrogate index of the intended outcome.<br/> <sup>3</sup>Downgraded by two levels due to imprecision: small sample size and wide confidence interval. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">ECT alone versus antipsychotics for treatment‐resistant schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/full#CD011847-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011847-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">ECT plus standard care versus sham‐ECT plus standard care</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mental state ‐ total score (BPRS, high = poor) ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.60 [‐3.69, 10.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Service use ‐ number readmitted ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.10, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">ECT plus standard care versus sham‐ECT plus standard care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011847-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">ECT plus standard care versus antipsychotics plus standard care</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Response to treatment ‐ clinically important response (BPRS reducing rate ≥ 50%) ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.95, 1.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mental state ‐ total score (BPRS, high = poor) ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.20 [‐7.93, ‐2.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental state ‐ total score (BPRS, high = poor) ‐ medium term (skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state ‐ specific symptom score (BPRS, high = poor) ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Anxiety and depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐1.12, ‐0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Lack of vitality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.20 [‐2.74, ‐1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Thought disturbance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐1.32, ‐0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐0.82, ‐0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Hostile suspiciousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐1.56, ‐0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mental state ‐ specific symptom score (BPRS, high = poor) ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Anxiety and depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.50 [‐1.73, ‐1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Lack of vitality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.20 [‐1.47, ‐0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Thought disturbance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.70 [‐2.12, ‐1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.60 [‐1.79, ‐1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Hostile suspiciousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.80 [‐3.14, ‐2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events ‐ total score (TESS, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐0.91, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.1 [‐1.40, ‐0.80]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">ECT plus standard care versus antipsychotics plus standard care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011847-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">ECT plus standard care versus standard care</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Response to treatment ‐ clinically important response (as defined by each study) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [1.09, 3.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>819</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [1.75, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cognitive functioning ‐ memory deterioration ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>27.0 [1.67, 437.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cognitive functioning ‐ specific symptom score (WCST, high = poor, other than correct number) ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Total test number</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.74 [‐16.88, ‐0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Correct number</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.03 [‐0.15, 6.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Categories completed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.36 [‐0.49, ‐0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Cognitive functioning ‐ specific symptom score (WCST, high = poor) ‐ medium term (skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Perseveration errors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Non‐perseveration errors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Cognitive functioning ‐ memory (WMS, high = good) ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Memory quotient (MQ)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [‐3.54, 4.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Memorise number (1 to 100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.71, 0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Memorise number (100 to 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.98, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Accumulation of memory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.73, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Picture memory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.41 [‐1.01, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 Recognition memory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.64, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7 Regeneration memory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.78, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8 Associative memory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.97, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9 Haptic memory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.53, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.10 Understanding memory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.56, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.11 Memorise number (random)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [‐0.29, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Cognitive functioning ‐ memory (WMS, high = good) ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Memory quotient (MQ)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [‐2.24, 5.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Memorise number (1 to 100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.69, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Memorise number (100 to 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.15 [‐0.88, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Accumulation of memory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.59, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Picture memory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.41 [‐1.01, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 Recognition memory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐0.52, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7 Regeneration memory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.64, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.8 Associative memory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.79, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.9 Haptic memory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.38, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.10 Understanding memory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.63, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.11 Memorise number (random)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [‐0.37, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Satisfaction and acceptability of treatment ‐ leaving the study early ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.38, 3.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mental state ‐ total score (BPRS, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.50 [‐6.99, ‐4.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.18 [‐12.61, ‐9.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Mental state ‐ total score (BPRS, high = poor) ‐ medium term (skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Mental state ‐ total score (MMSE, high = good) ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.30, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Mental state ‐ total score (PANSS, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.41 [‐13.49, ‐9.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.62 [‐9.49, ‐5.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Mental state ‐ specific symptom score (BPRS, high = poor) ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Anxiety and depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.97 [‐1.28, ‐0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Lack of vitality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.40 [‐2.71, ‐2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Thought disturbance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.71 [‐1.06, ‐0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 Agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.23 [‐1.51, ‐0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5 Hostile suspiciousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.57 [‐0.91, ‐0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.6 Psychosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.24 [‐5.89, ‐4.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Mental state ‐ specific symptom score (BPRS, high = poor) ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Anxiety and depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>423</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.50 [‐1.72, ‐1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Lack of vitality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>423</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.80 [‐2.02, ‐1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 Thought disturbance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>423</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.69 [‐2.95, ‐2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 Agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>423</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.73 [‐1.91, ‐1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.5 Hostile suspiciousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>423</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.77 [‐3.00, ‐2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.6 Psychosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.07 [‐6.72, ‐5.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Mental state ‐ specific symptom score (PANSS, high = poor) ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Positive symptom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.56 [‐3.12, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Negative symptom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.03 [‐2.42, 0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 General psychopathology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.59 [‐3.83, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4 Excitement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.79 [‐7.34, ‐4.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.5 Hostility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.48 [‐3.93, ‐1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Mental state ‐ specific symptom score (PANSS, high = poor) ‐ short term (skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Positive symptom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 General psychopathology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Mental state ‐ specific symptom score (PANSS, high = poor) ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Negative symptom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [‐1.47, 2.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 General psychopathology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.93 [‐5.32, ‐0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 Excitement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.31 [‐3.44, ‐1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4 Hostility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.81 [‐4.05, ‐1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Mental state ‐ specific symptom score (PANSS, high = poor) ‐ medium term (skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Positive symptom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Negative symptom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 General psychopathology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Mental state ‐ specific symptom score (SAPS, high = poor) ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Hallucinations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.5 [‐1.71, ‐1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Delusions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.81 [‐3.10, ‐2.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 Bizarre behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.21, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4 Positive formal thought disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.2 [‐2.50, ‐1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Mental state ‐ specific symptom score (SANS, high = poor) ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Affective flattening or blunting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.70 [‐5.03, ‐4.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 Alogia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.43, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3 Avolition</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.40, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.4 Anhedonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.44, ‐0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.5 Attention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐0.97, ‐0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 General functioning ‐ total score (GAF, high = good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 Short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.32 [‐0.20, 8.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 Medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.66 [6.98, 14.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Adverse events ‐ general ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.86, 2.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Adverse events ‐ total score (TESS, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 Short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.96, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 Medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>496</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.63 [‐1.01, ‐0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Adverse events ‐ specific symptom ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 Abnormal electrocardiogram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.44, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 Abnormal liver function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.12, 3.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.3 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.36, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.4 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.0 [0.37, 130.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.5 Lethargy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.8 [0.44, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.6 Nausea or vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.19, 21.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.7 Salivation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.33, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.8 Weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.4 [0.14, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Adverse events ‐ specific symptom ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 Abnormal electrocardiogram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.67, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 Abnormal electroencephalogram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.82, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.3 Abnormal liver function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.30, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.4 Blurred vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.28, 3.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.5 Breathing discomfort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.01, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.6 Cathisophobia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.34, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.7 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.61, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.8 Decreased activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.23, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.9 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [0.70, 4.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.10 Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.33, 3.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.11 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.47 [1.47, 20.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.12 Indigestion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.16, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.13 Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.00, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.14 Lethargy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.70, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.15 Leucopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.18, 3.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.16 Muscle rigidity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.37, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.17 Nausea or vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.31, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.18 Recurrence of pre‐existing involuntary 'jerky' movements</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.86 [0.12, 66.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.19 Salivation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.57, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.20 Tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.31, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.21 Weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.46, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.22 Others</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.44, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Adverse events ‐ specific symptom score (TESS, high = poor) ‐ short term (skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 Abnormal laboratory values</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2 Behavioural toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.3 Symptoms of cardiovascular system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.4 Symptoms of nervous system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.5 Symptoms of vegetative nervous system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.6 Others</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Adverse events ‐ specific symptom score (TESS, high = poor) ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 Abnormal laboratory values</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.08, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2 Behavioural toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐0.38, ‐0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.3 Symptoms of cardiovascular system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.5 [‐0.58, ‐0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.4 Symptoms of nervous system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.08, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.5 Symptoms of vegetative nervous system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.05, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.6 Others</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.17, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Adverse events ‐ specific symptom score (TESS, high = poor) ‐ medium term (skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 Abnormal laboratory values</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.2 Behavioral toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.3 Symptoms of cardiovascular system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.4 Symptoms of nervous system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.5 Symptoms of vegetative nervous system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.6 Others</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">ECT plus standard care versus standard care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011847-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">ECT alone versus antipsychotic alone (flupenthixol)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mental state ‐ total score (BPRS, high = poor) ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.93 [‐6.95, 5.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mental state ‐ total score (MMSE, high = good) ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐3.70, 3.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 General functioning ‐ total score (GAF, high = good) ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.66 [‐3.60, 2.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">ECT alone versus antipsychotic alone (flupenthixol)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011847-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">SUBGROUP: ECT plus standard care versus standard care (TEST FOR DIFFERENCE BETWEEN SHORT/LONG COURSE OF ECT)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Response to treatment ‐ clinically significant response (as defined by each study) ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Short course of ECT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>450</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.23 [1.78, 2.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Long course of ECT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [1.49, 2.36]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">SUBGROUP: ECT plus standard care versus standard care (TEST FOR DIFFERENCE BETWEEN SHORT/LONG COURSE OF ECT)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011847-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">SENSITIVITY ANALYSIS: ECT plus standard care versus standard care (ASSUMPTIONS FOR LOST BINARY DATA)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Response to treatment ‐ clinically significant response (as defined by each study) ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 With assumption</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>819</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [1.75, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Without assumption</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>816</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [1.75, 2.42]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">SENSITIVITY ANALYSIS: ECT plus standard care versus standard care (ASSUMPTIONS FOR LOST BINARY DATA)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011847-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">SENSITIVITY ANALYSIS: ECT plus standard care versus standard care (FIXED‐EFFECT AND RANDOM‐EFFECTS MODEL)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Response to treatment ‐ clinically significant response (as defined by each study) ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Fixed‐effect model</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>819</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [1.75, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Random‐effects model</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>819</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [1.75, 2.42]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">SENSITIVITY ANALYSIS: ECT plus standard care versus standard care (FIXED‐EFFECT AND RANDOM‐EFFECTS MODEL)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011847.pub2/references#CD011847-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011847.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011847-note-0007">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011847-note-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011847-note-0006">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD011847-note-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD011847-note-0004">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD011847-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD011847-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011847-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011847\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011847\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011847\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011847\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011847\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011847\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011847\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011847\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011847\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011847\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011847\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011847\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011847\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011847\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011847\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011847\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011847\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011847\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mV7VuqgF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011847.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011847.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011847.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011847.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011847.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729035444"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011847.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729035447"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011847.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ed30e9ad4f56f',t:'MTc0MDcyOTAzNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 